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2 Summary/Zusammenfassung
2.1 Summary
The glycosylphosphatidylinositol (GPI) anchor is a lipid moiety attached to over 150 human pro-
teins and plays a crucial role in cell surface display at the plasma membrane. The transamidase
complex, consisting of the subunits PIGK/S/T/U and GPAA1, is localised to the endoplasmic retic-
ulum (ER) and is responsible for attachment of the GPI-anchor to receiving proteins. Previously,
interactions between the transamidase complex subunit GPAA1 and a sphingolipid have been
shown. The aim of this thesis was to establish an experimental setup to analyse protein lipid in-
teractions of the transamidase complex.
These interactions were assessed via in-gel fluorescence and western blot quantification through
click chemistry with bifunctional sphingolipids combined with transient expression of transam-
idase subunits. Thin layer chromatography was used to verify the metabolic status of exogen-
ously added photoactivatable and clickable sphingosine (pacSph) at given time points. Results
confirmed the previous reported interaction of GPAA1. The validity of this outcome was lim-
ited to GPAA1 only due to uncertainty with regards to the transient expression, such as affecting
the stoichiometry of the transamidase complex and mislocalisation of the transiently overex-
pressed GPAA1. To circumvent these limitations, CRISPR/Cas9-based gene editingwas performed
to insert a C-terminal tag in the genomic region of GPAA1. This allowed to establish a cellu-
lar model to study sphingolipid and cholesterol interactions with the endogenous transamidase
complex. Gene edited tagging of GPAA1 did not interfere with synthesis and trafficking of GPI-
anchor proteins to the cell surface. The analysis of the composition of the transamidase complex
in this cell line by co-immunoprecipitation showed only PIGK/T/S to interact with GPAA1, but
not PIGU. When styrene maleic anhydride (SMA) co-polymer was used to extract the transam-
idase complex and its native lipid environment, even PIGU was detected, suggesting that PIGU
might be only loosely attached to the transamidase complex. Furthermore, first studies on mass
spectrometric analysis of lipids extracted from an SMA-immunoprecipitation suggested that this
approach allows to determine lipids in direct proximity of the transamaidase complex. Finally,
GPAA1-pacSphmetabolite interaction could be inhibited through the ceramide synthase inhibitor
FB1, while the glucosylceramide synthase inhibitor PPMP did not interfere with the interaction.
This suggested that ceramide or a metabolite upstream of this lipid is the interaction partner of
GPAA1.
In summary, the established cellular model verified previously published results in an endogen-
ous setting. For the future, this model lays the foundation for quantitative determination of the
lipid environment of the transamidase complex. Furthermore, this system might also provide
structural information via single particle cryo-electron microscopy of affinity purified GPAA1
complexes.
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2.2 Zusammenfassung
Der Glycosylphosphatidylinositol (GPI)-Anker ist eine Lipidmodifikation, welche an über 150 ver-
schiedenen menschlichen Proteinen gefunden wurde und eine wichtige Rolle in der Lokalisation
von Oberflächenproteinen an der Plasmamembran spielt. Der Transamidasekomplex, bestehend
aus den Untereinheiten PIGK/S/T/U und GPAA1, befindet sich im Endoplasmatischen Retiku-
lum (ER) und ist verantwortlich für das Anfügen des GPI-Ankers an entsprechende Proteine. Das
Ziel dieser Arbeit war die Entwicklung und Etablierung eines Versuchsaufbaues zur Analyse von
Protein-Lipid-Interaktionen des heteropentameren Transamidasekomplexes.
Basierend auf photoaktivier- und kreuzvernetzbaren Sphingolipiden und transienter Expression
von Transamidasekomplexuntereinheiten wurde ein Protokoll zur Untersuchung der Sphingol-
ipidinteraktionen des Komplexes etabliert. Dünnschichtchromatographie wurde eingesetzt um
die Verstoffwechselung des exogen hinzugefügten bifunktionalen Sphingosins (pacSph) zu ver-
folgen. Die Ergebnisse bestätigten bereits vorhandene Ergebnisse zur Sphingolipid-Interaktion
von GPAA1. Durch die transiente Expression wurden jedoch eine Beeinflussung der Stöchiomet-
rie des Transamidasekomplexes und Fehllokalisation von GPAA1 beobachtet, welche die Aus-
sagekraft der Ergebnisse mindert. Um diese Limitierungen zu überkommen, wurde eine CRIS-
PR/Cas9 Geneditierung im genomischen Lokus von GPAA1 mit dem Ziel der Insertion eines C-
terminalen Tags durchgeführt. Dies führte zur Generierung einer Zelllinie, welche geeignet ist
Interaktionen von Sphingolipiden und Cholesterin mit dem Transamidasekomplex zu studieren.
Nach Geneditierung wurde keine Beeinflussung der Synthese oder des Transportes von GPI-
Anker-Proteinen an die Zelloberfläche festgestellt. Bei der Analyse der Komposition des Trans-
amidasekomplexes durch Co-Immunpräzipitation mit GPAA1 konnten nur PIGK/T/S nachgew-
iesen werden, während PIGU nicht detektierbar war. PIGU konnte jedoch nachgewiesen werden,
wennmit Styrol-Maleinsäureanhydrid (SMA)-Copolymer der Transamidasekompex in seiner nat-
iven Lipidumgebung extrahiert wurde. Dies deutet auf eine eher transiente Assoziation von PIGU
mit dem Transamidasekomplex hin. Weiterhin konnten bei einer massenspektrometrischen
Analyse einer SMA-Immunpräzipitation Lipide detektiert werden, welches die Möglichkeit der
quantitativen Analyse der nativen Lipidumgebung des Transamidasekomplexes anhand dieser
Versuchsanordnung aufzeigt. Schlussendlich konnte die GPAA1-pacSph Interaktion durch die
pharmakologische Hemmung der Ceramid-Synthase gestört werden, während ein Inhibierung
der Glucosylceramid-Synthase keine Auswirkungen hatte. Dies ist ein Indiz dafür, dass Ceramid
oder ein im Biosyntheseweg dem Ceramid nachgeschalteter Metabolit den Interaktionspartner
von GPAA1 stellt.
Zusammenfassend konnten in dieser Arbeit mit demneu etablierten Zellmodel bereits über einen
alternativen Ansatz gewonnene Daten bestätigt werden. Darüber hinaus wurden die Grundlagen
geschaffen, um in zukünftigen Experimenten die native Lipidumgebung zu untersuchen. Weiter-
hin dienen diese Vorarbeiten als Anknüpfungspunkt für weiterführende Experimente zur struk-
turelle Analyse des GPAA1-Komplexes durch Einzelpartikel-Kryo-Elektronenmikroskopie.
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3 Introduction
3.1 Lipids and protein-lipid interactions
Membrane lipids are functionally characterised as compartmentalisation factors in cells, creat-
ing distinct cellular microenvironments and to serve as a matrix for membrane proteins[1]. To
create distinct subcellular compartments, lipid bilayers are formed. Essential for the formation
of this bilayer are amphipathic lipids, namely glycerophospholipids (GPLs), sphingolipids (SP)
and sterols (ST), such as cholesterol (Chol), that contain a hydrophilic head group and a hydro-
phobic/lipophilic tail[2]. Containing a glucose-3-phosphate backbone esterified at the C-1 and C-2
position with fatty acids and varying groups at the phosphate, such as choline (PC), ethanolam-
ine (PE), serine (PS), inositol (PI) or hydrogen (PA), GPLs form the major component of biological
membranes[3]. The de novo synthesis of SPs (see figure 1) starts from a condensation reaction
using serine and palmitoyl to form 3-ketodihydrosphingosine, which is sequentially reduced to
dihydrosphingosine and acylated to form the ceramide precursor dihydroceramide[4]. Ceramide,
the common hydrophobic core of all SPs is based on a sphingosine core, in mammalian mem-
branes mainly a C18 amino alcohol containing a trans-double bond between C-4 and C-5, linked
via an amide bond to a fatty acid[5]. The addition of different hydrophilic head groups results in
sphingomyelins, cerebrosides or higher glycosphingolipids such as gangliosides[3]. The salvage
pathway of long chain sphingoid bases leads to the re-generation of sphingolipids and has been
estimated to contribute from 50% to 90% of sphingolipid biosynthesis and suggests a crucial role
for sphingolipid breakdown in sphingolipid biosynthesis/turnover as well as in cellular signal
transduction[6]. Manifold variations in the head groups, fatty acid chain length as well as satura-
tion with and orientation of double bonds in GPLs and SPs give rise to an incredible high amount
of possible combinations of lipid species. Analysis of the major structural membrane lipids (GPL,
SP, ST), revealed an unequal distribution in different cellular membranes[7]. On top of this, some
cellular organelles maintain an asymmetric lipid distribution between the cytosolic and luminal
side of their membranes[8]. Interestingly, even though continuous vesicular transport from and
to membranes takes place, the lipid distribution is stable and not altered over time[7]. As there
are different lipid profiles for different subcellular membranes, variations between different cell
types of one organism as well as different taxa should be no surprise[7].
Due to recent advances in technology, analysis of cellular lipidomes emerged as a feasible task and
continuously provides new insights into the function of over thousands of different lipids in euk-
aryotic cells. Currently, the LIPIDMAPS structure database counts 21118manually curated lipids,
as well as 21953 computational derived hypothesised lipids (time stamp: 29.08.2018)[9; 10]. This
high complexity leads to the question of what is the rationale behind the need of the human body
for such a huge amount of different lipid species within membranes. Identifications of protein
amino acid sequences correlatingwith structural features of lipids or lipid classes lead to the term
protein-lipid interactionmotifs. For example, motifs are described for leaflet specific cholesterol
interactions with the CARC (L/VX1 5YX1 5K/R) motif facing to the outer leaflet and the inverted
CRAC (K/RX1 5Y/FX1 5L/V) motif facing the inner leaflet[11]. Recent reports indicate regulat-
ory roles of individual lipid species by identifying specific protein-lipid interactions. For example
the ganglioside GM3has been shown to negatively regulate the autophosphorylation of the kinase
domains of the epidermal growth factor receptor (EGFR)[12]. Another example is the necessity of
cardiolipin for the supercomplex formation between the respiratory chain complexes III and IV in
mitochondria[13; 14]. The study of the interaction between sphingomyelin species 18 (SM18) and
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the transmembrane domain of the COPI machinery protein p24 revealed a conserved signature
sequence (VXXTLXXIY) in a number ofmammalian transmembrane proteins[15; 16]. UniProt ana-
lysis using this sphingolipid-binding motif resulted in a list containing 615 novel candidates for
sphingolipid-protein interactions[16]. Two of these proteins are the endoplasmic reticulum (ER)
localised transmembrane proteins glycosylphosphatidylinositol anchor (GPI) attachment 1 pro-
tein (GPAA1) and GPI inositol-deacylase (PGAP1). GPAA1, being part of the transamidase complex
(PIGK/S/T/U and GPAA1), plays a crucial role in the transfers of the GPI-anchor to the C-terminus
of the receiving protein. Before GPI anchored proteins (GPI-APs) are sorted into ER exit sites, the
GPI anchor undergoes multiple steps of post-attachment modifications and part of this matura-
tion process is PGAP1 (see section 3.2.1). The remodelled GPI-APs are then efficiently recognised
by members of the p24 protein family, packaged into COPII-derived vesicles for ER export[17].
Figure 1: Simplified schematic drawing of the sphingolipid biosynthetic pathway Sphingolipids are
either synthesised de novo, or products of the catabolic pathway, consisting out of the salvage pathway and
the recycling of exogenous ceramides[6]. To study specific protein-sphingolipid interactions, a knock-out
of the sphingosine-1-phosphate lyase (red cross) prevents sphingosine derivatives to be channeled into
the sphingolipid-to-glycerolipid metabolic pathway[18].
3.2 The glycosylphosphatidylinositol (GPI)-anchor
Eukaryotic organisms producemanymembrane proteins that are anchored to the outer cellmem-
brane by GPI-anchor[19]. The GPI-anchor is a glycolipid consisting of PI, glucosamine (GlcN),
mannose (Man), and ethanolaminephosphate (EtNP) and acts as a lipid anchor for various plasma-
membrane proteins[5] (see figure 2A). GPI-anchored proteins play important roles, for example in
host self-defence or intracellular signal transduction. Besides, some of them function as receptors
for viruses and toxins[20; 21]. The GPI-anchor is widely distributed with over 150 different human
proteins, conserved in various eukaryotes, essential for development in higher animals as well as
for growth of yeasts and protozoan parasites[22; 23; 24]. Malfunctions of the GPI-anchor biosyn-
thesis (see section 3.2.1) and consequently the missing representation of GPI-anchored proteins
at the surface of the plasma membrane has major implications on human health and is known to
be involved in many diseases [19; 22; 25; 26]. Especially the transamidase complex members (see
section 3.2.3) of the biosynthetic pathway of the GPI anchor are linked to different cancers[27; 28].
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3.2.1 Biosynthesis of the GPI-Anchor
The synthesis of the GPI-anchor until its attachment to a protein containing a GPI-attachment
sequence occurs in different steps in the ER. This procedure is described in the following and
schematically depicted in figure 2B. In the first step N-acetylglucosaminyl-phosphatidylinositol
(GlcNAc-PI) is generated by attachment of N-Acetylglucosamine (GlcNAc) to phosphatidylin-
ositol (PI), thus generating GlcNAc-PI. This step is catalysed by an enzyme complex consist-
ing of at least seven components, PIGA, PIGC, PIGH, PIGP, GPI1, DPM2 and PIGY[29]. After-
wards, the N-acetyl group is removed by PIGL (de-N-acetylation[30]) to generate glucosaminyl-
PI (GlcN-PI)[31]. After completion, GlcN-PI flips from the cytosolic side of the ER to the lu-
minal side where the ER-associated multi-transmembrane acyl transferase PIGW adds an acyl
chain (e.g. palmitate or myristate ) to the second position of the inositol ring (GlcN-aPI)[31].
Mannose-P-dolichol (MPD) is transported into the ER by the cytosolic located enzyme com-
plex DPM1/2/3d. Required for this process is SL15, also known as Mannose-P-dolichol utiliz-
ation defect 1 protein (MPDU1), which is needed for all known classes of monosaccharide-P-
dolichol-dependent glycosyltransferase reactions in mammals[32] and is predicted to be involved
in vesicle formation and in protein trafficking[33]. After availability of mannose in the ER lu-
men, the glycosylphosphatidylinositol mannosyltransferase complex 1 (GPI-MT-1), consisting
out of PIGM and its stabilising cofactor PIGX, transfers one mannose group to the fourth posi-
tion of the glucosaminyl group, thus forming Mana4GlcNa6(acyl-2)myo-inositol-phospholipid
(ManGlcN-aPI)[34]. PIGV (GPI-MT-2) transfers then a second mannose group to position 6 of
the previous primary mannose group, resulting in the formation of Mana6Mana4GlcNa6(acyl-
2)myo-inositol-phospholipid (ManManGlcN-aPI)[35]. Afterwards, an ethanolamine phosphate
group (EtNP) is added to position 2 of the first mannose group by PIGN, an ethanolam-
ine phosphate transferase (EtNPT-1)[36], thus generating Mana6(EtNP-2)Mana4GlcNa6(acyl-
2)myo-inositol-phospholipid (Man(EtNP)ManGlcN-aPI). PIGB (GPI-MT-3) adds the third mannose
group at position 2 of the second one, resulting in Mana2Mana6(EtNP-2)Mana4GlcNa6(acyl-
2)myo-inositol-phospholipid (ManMan(EtNP)ManGlcN-aPI)[37]. PIGO, together with the cata-
lytic subunit PIGF forms the ethanolamine phosphate transferase-2 (EtNP-T2), which binds EtNP
to position 6 of the third mannose (EtNP-6Mana2Mana6(EtNP-2)Mana4GlcNa6(acyl-2)myo-
inositol-phospholipid, short EtNPManMan(EtNP)ManGlcN-aPI)[38]. By switching partners, PIGF
forms together with GPI7 the ethanolamine phosphate transferase-3 (EtNP-T3), which binds
an EtNP on position 6 of the second mannose and therefore forms the last stage of the GPI-
anchor (EtNP-6Mana2(EtNP-6)Mana6(EtNP-2)Mana4GlcNa6(acyl-2)myo-inositol-phospholipid
(EtNPMan(EtNP)Man(EtNP)ManGlcN-aPI), before transferred to a protein containing the neces-
sary GPI-attachment sequence[39]. It has been shown that certain GPI proteins contain a fourth
mannose group which is linked as a side branch towards the GPI core at the third mannose and
is transferred by PIGZ in humans[40].
3.2.2 GPI-anchor attachment signal
Proteins marked for GPI modification (see figure 2C) contain two signal peptides, an N-terminal
one for import into the ER as well as a C-terminal one for the attachment of the GPI-anchor which
consists out of the following structural domains[5]. At the GPI attachment side w , amino acids
with short side chains are present, namely glycine, alanine, serine, asparagine, aspartic acid or
cysteine[41]. Similar tow , short side chained amino acids (glycine, alanine, serine) are also found
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in the positions named w+1 and w+2, which describes the first and second amino acid of the
cleaved signalling peptide[41]. An unstructured linker of approximately 10 amino acids precedes
w [42]. w+2 is followed by a hydrophilic spacer sequence with six or more residues (w+3) and is
concluded by a 15-20 amino acid long hydrophobic sequence at the C-terminal end (w+4), which
is long enough to span the ER membrane[41; 42].
3.2.3 Attachment of the GPI-anchor by the mammalian transamidase complex
Responsible for the transfer of the GPI-anchor to the C-terminus of the receiving protein is the
transamidase complex[41; 43] (see table 1). This complex, located in the ER membrane and facing
the luminal side, consist out of the catalytic subunit PIGK (also known as GPI8), the subcompon-
ents PIGS/T/U and GPAA1[41; 44]. Even though the players are known, there are still unsolved
questions about the structure and the spatial arrangement of the transamidase complex. While
the 3D structure of PIGK is determined[42] (at least in yeast), and for PIGT[45] and GPAA1[46] pre-
dicted, relatively less is known about PIGS and PIGU. A disulfide-link between PIGT (Cys182) and
PIGK (Cys92) is crucial for the complex activity and it is predicted that the unspecific cleavage
activity of PIGK, belonging to the C13 cysteine peptidase family, is being regulated by its covalent
bound partner PIGT[44; 46; 47]. GPI transamidase complex forms a carbonyl intermediate with
the GPI-attachment sequence protein, cleavage between the w and w+1 residues takes place, and
nucleophilic attack by GPI on the activated carbonyl yields a GPI-anchored protein[48; 49; 50].
Table 1: Subunits of the mammalian transamidase complex
Gene name1 NCBI Gene ID2 UniProt ID3 Protein name
GPAA1 8733 O43292 GPI anchor attachment 1 protein
PIGK 10026 Q92643 phosphatidylinositol glycan anchor biosynthesis class K
PIGS 94005 Q96S52 phosphatidylinositol glycan anchor biosynthesis class S
PIGT 51604 Q969N2 phosphatidylinositol glycan anchor biosynthesis class T
PIGU 128869 Q9H490 phosphatidylinositol glycan anchor biosynthesis class U
1HUGO: human gene nomenclature committee (http://www.genenames.org); 2 https://www.ncbi.
nlm.nih.gov/gene; 3 https://www.uniprot.org/
GPAA1 contains an approximately 300 amino acid long luminal side preceded by a transmem-
brane domain, which is closed up by the cytoplasmic located N-terminus, and followed by six
transmembrane domains until the luminal located C-terminal end is reached[51; 52]. The luminal
loop matches with a 290 amino acid stretch that identifies this domain as a M28 family metallo-
peptide and thus indicates that GPAA1 is the complex subunit that catalyses the formation of
the peptide bond between the w site and the EtNP group of the GPI anchor[44; 46]. Being a
metallo proteinase it is suggested that suitable binding sites for zinc residues are located at
Asp153, ASP188, Glu226 and Tyr328[46]. Other members of the M28 family of metalloproteases
are known to function as aminopeptidases, carboxylpeptidases, cyclisation of N-terminal
glutamine and it cannot be excluded that GPAA1 might have some exopeptidase activity[46].
Interestingly, GPAA1 does not contain any ER localisation information, whereas PIGT and
PIGK do[52]. It is to be noted, that the ER quality control mechanisms that targets terminally
misfolded proteins for ER-associated degradation (ERAD), is not the main degradation pathway
for misfolded glycophosphatidylinositol-anchored proteins, who are disposed of mainly via the
vacuole/lysosome pathway and indicate that the GPI-anchor sterically obstructs ERAD[53].
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Figure 2: The mammalian GPI-anchor synthesis in the ER A) The typical chemical structure of the
GPI lipid anchor and its linkage via the w-site to the substrate protein for the transamidase reaction are
schematically illustrated. Heterogeneity in GPI anchors is derived from various substitutions of this core
structure and is represented as R groups. Adapted and modified from[5; 46]. B) The synthesis of the GPI
starts on the cytoplasmic side of the ER by attachment of N-acetylglucosamine to phosphatidylinositol (1),
followed by de-N-acetylation to generate glucosaminyl-PI (2). The intermediate gets transported to the
lumenal side of the ER membrane (3), followed by attachment of an acyl chain (4), which can be palmitate
or myristate. Successive additions of mannose, derived frommannose-P-dolichol from the cytoplasm (5a),
and ethanolamine phosphate groups to the glucosaminyl group (5-9) prepare for the attachment of the GPI-
anchor to its respective protein. The attachment is facilitated by the transamidase complex (TA). Adapted
and modified from[41]. C) Schematic drawing of a hypothetical GPI-anchor protein with its N-terminal ER
localisation signal and the C-terminal attachments sequence, with the GPI-attachment sitew . Adapted and
modified from[5].
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3.2.4 Post-attachment remodelling of the GPI-anchor and transport to the plasma mem-
brane
The first post-attachment remodelling (figure 3) step of the GPI-anchor is performed by PGAP1,
which removes the acyl chain attached by PIGW[17]. PGAP5 removes in the second step the EtNP
group from the second mannose[54]. These two GPI remodeling reactions in the ER are critical
for the sorting of GPI-APs to ER-exit sites (ERES), as the remodeled GPI-anchor acts as an ER exit
signal and is efficiently recognised by the p24 protein family complex that concentrates GPI-APs
into COPII-derived vesicles[17; 54].
Figure 3: Post-attachment remodelling of the GPI-anchor After the transamidase complex (TA) trans-
fers the protein with a GPI-attachment signal to a GPI-anchor, multiple post-attachment remodelling steps
are performed. The acyl chain from the inositol ring (11) and the ethanolamine phosphate group from
second mannose are removed (12). Followed by sorting of the GPI-anchored protein into ER exit sites by
binding to the p24g2subunit (13a), transport to the Golgi and pH dependent disassembly of the p24 com-
plex (13b) and recycling of the transport machinery (13c). Finally, the unsaturated fatty acid is removed
(14) and replaced through attachment of a saturated fatty acid (15). At last, GPI-anchor proteins are trans-
ported to their final destination via the the Golgi apparatus. Figure adapted and modified from[17].
The transport from ER to Golgi depends on the activity of the GTP-binding protein SAR1a and
the transport velocity of not mature GPI-anchors is significantly reduced[54; 55; 56]. The lower
pH in the Golgi, when compared to the pH in the ER, induces a dissociation of the p24 protein
complex and the GPI-anchored protein[17]. The third step of the post-attachment remodelling
is performed in the Golgi by PGAP3, which performs fatty acid remodelling and removes an un-
saturated acid at the sn2 position in the GPI lipid[57]. The free spot at the sn2 position is then
taken by an saturated fatty acid, attached via PGAP2[57; 58]. This fatty acid remodeling of GPI-
anchored proteins was suggested to be required for raft association[57]. Once thesemodifications
are completed, the mature GPI-anchor protein is transported to the plasma membrane via the
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Golgi apparatus[17]. A specific role play GPI-APs in human erythrocytes, such as CD55 (decay-
accelerating factor), CD59 and acetylcholine esterase, which maintain unsaturated fatty acids at
the sn2 position and a palmitoyl chain linked to the 2-position of the inositol ring[41]. At the
plasma membrane, GPI-anchored proteins have been shown to reside in cholesterol-dependent
nanoscale assemblies of sphingolipids and GPI-anchored proteins[2; 59]. It has been suggested
that transbilayer interactions between outer-leaflet long-acyl-chain-containing lipids and inner-
leaflet phosphatidylserine are pivotal in generating actin-dependent nanoclusters of membrane
lipid-anchored proteins, such as GPI-anchored proteins[60].
3.3 Methods to study protein lipid interactions
3.3.1 Methods for solubilisation of proteins with transmembrane domains
Proteins containing one or more transmembrane domains (TMD) interact with lipids in their
near micro-environment. Ways to study proteins with TMDs involves some difficulties, as the
TMDs consist of amino acids characterised by their mostly hydrophobic nature and tend to lose
their specific tertiary structure as soon as the stabilising lipid environment is removed. Tradi-
tional ways employ solublisation of proteins via detergents micelles (figure 4A) or via amphi-
pols (figure 4B)[61; 62]. These are so called non-bilayer systems, as they disrupt the local lipid
micro-environment during the solublisation process[63]. Generally, the detergent induced solu-
bilisation occurs in three stages (see figure 4B)[64]. The lipid bilayer usually remains intact but
selective extraction of some membrane proteins might take place at molar detergent to mem-
brane lipid ratios of 0.1-1:1[65]. Solubilisation of the membrane and generation of mixed micelles
(phospholipid–detergent, detergent–protein, and lipid–detergent–proteinmicelle) occurs at a ra-
tio of to 2:1[65]. At a ratio of 10:1, all native membrane lipid-protein interactions are effectively
exchanged for detergent-protein interactions[65]. The solubilisation efficacy and functionality
of extracted proteins might vary greatly, depending on the type of detergent (cationic, anionic,
zwitterionic) and selected lysis parameter (e.g. duration, temperature, lysis buffer composition).
One example are detergent resistant membranes, which contain proteins surrounded by a stiff
membrane section that mostly consists of sphingolipid/cholesterol [66; 67].
So called bilayer systems approach the solublisation of proteins by preserving a stabilising lipid
environment or reconstitute extracted proteins with synthetic lipids[63]. Onemethod of this type
is the bicelle, which is a discoidal structure obtained by mixing phospholipids (often short-chain
phospholipids) with detergents in a defined ratio (figure 4C)[63; 68]. Recent techniques to study
proteins containing TMDs are based on the extraction of proteins with their surrounding micro-
environment. This can be achieved by employing the artificially engineered membrane scaffold
protein (MSP, figure 4D) or the styrene-maleic acid (SMA) copolymer (figure 4E)[69; 70; 71; 72].
Especially SMA has shown profound implications on TMD protein research, due to its compat-
ibility with cryo-electron microscopy, mass spectrometry (e.g. analysis of lipids in the micro-
environment) and its ease of use [62; 73; 74; 75]. The mechanism of SMA derives from its pH-
dependent change of tertiary structure, which results in formation of a scaffold around themem-
brane protein that is trapped with the annular membrane lipids[62; 76]. These SMA lipid particles
(SMALP) can differ in size (e.g. from 10 nm up to 35 nm) and the actual size of the SMALP de-
pends solely on the weight ratio of SMA to lipid (e.g. 1.25-4:1)[62; 72; 77; 78; 79]. SMA copolymers
are available in different styrene/maleic acid ratios and chain lengths, thus possessing differ-
ent charge densities, hydrophobicities, and solubilisation properties[80]. It has been shown that
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nanodiscs prepared using this polymer are very dynamic structures with rapid exchange of the
different components and there is a controversy about a potential preference of lipids included
into SMALPs, but for now it is assumed that SMA does not differentiate[62; 81; 82].
In summary, different methods for solubilisation of proteins with TMD exist, but the best condi-
tions for solubilisation and subsequent analytics are to be determined for each protein anew.
Figure 4: Membrane-mimetic systems for membrane protein stabilisation. A) A Protein in detergent
(red) micelle. AI) At low detergent:membrane lipid molar ratios (e.g. 0.1-1:1), the detergent (light blue)
integrates at low quantities into the lipid bilayer. AII) With increasing ratios (2:1), partial solubilisation
and formation of micelles containing protein complexes starts. AIII) If the ratio increases further (e.g.
10:1), all native lipid-protein interactions are exchanged and detergent-protein micells are formed. B)
Protein stabilised by amphipol (orange). C) Protein in bicelle (detergent in red, lipids in green). D) Protein
in nanodisc stabilised bymembrane scaffold protein (MSP in purple, lipids in green). E) Protein in nanodisc
stabilised by SMA. The addition of the styrene-maleic acid (SMA) copolymer (brown) to native membranes
(gray) that contain proteins (red) at elevated pH results in the formation of SMA lipid particles (SMALP)
that form a scaffold around the membrane protein trapped with the annular phospholipids. Figure and
figure legend adapted and modified from[62; 63; 64; 65].
3.3.2 Bioorthogonal tagging of protein lipidation via click chemistry
One way to study specific protein-lipid interactions is the use of photoactivatable and clickable
(pac) lipid analogues[83]. After the introduction of click chemistry in 2001, different bifunctional
lipid species have been synthesised[83; 84]. Of these, pacSphingosine (pacSph, figure 5A) has been
used to define over 180 potentially sphingolipid-binding proteins, one of thembeingGPAA1which
was also identified as sphingolipid-binding protein in [85]. UV irradiation cross-links pacSph and
its metabolites via their photoactivatable diazirine ring to proteins in close proximity. Cross-
linked proteins are enriched (e.g. via IP) and specific protein-lipid interactions are detected via
copper-catalysed azide-alkyne cycloaddition (CuAAC, figure 5B) mediating covalent linkage of a
functional group (e.g. fluorphores) to the alkyne moiety of pacSph[85; 86].
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Figure 5: Structure of the bifunctional pacSph and bioorthogonal tagging of protein lipidation via
click chemistry. A) A photoactivatable diazirine ring allows for UV irradiation induced cross-link to pro-
teins, while the alkyne group is available for attachment of functional groups via copper-catalysed azide-
alkyne cycloaddition (CuAAC). Adapted from[85]. B) Simplified schemaof the CuAAC. Adapted andmodified
from[87].
3.3.3 Tagging of endogenous proteins via CRISPR/Cas9
A way to facilitate the analysis of endogenous proteins is genome engineering. For example,
addition of N- or C-terminal tags allow to study proteins in living cell as well as to extract protein
complexes with their endogenous stoichiometric subunit composition[88; 89]. Oneway to achieve
this, is the CRISPR/Cas9 system. [88; 90; 91; 92]. CRISPR stands for ClusteredRegularly Interspaced
Short Palindromic Repeats and describes a bacterial host defense systemwhich produces specific
small single stranded nucleotide stretches recognised by a nuclease to defend against foreign
genomic material[93; 94]. Jumping forward in time, specific alterations were made to adapt the
system for genomic engineering in eukaryotic cells. Nowadays, online tools1234 for the design of
sequences specific to certain genomic regions, in short called gRNAs, exist. When brought into
cells in conjunction with a nuclease, such as the CRISPR-associated protein-9 nuclease (Cas9),
they can be employed for gene inactivation or incorporation of designed sequences into the DNA
(see figure 6). Gene inactivation is mediated by the introduction of a double strand break in the
genomic region of the targeted gene. The DNA damage is repaired by an error prone process
called non-homologous end joining (NHEJ) and, through introduction or deletion of nucleotides,
shifting the reading frame and resulting in non functional proteins[95; 96]. If a template for repair
is available, the process is called homology directed repair (HDR). This process is a precise way for
genome modification by insertion of sequences of interest, such as tags for immunoprecipitation
or fluorescent proteins[88; 89]. For example, high throughput and high resolution mapping of
protein localization in mammalian brain by in vivo genome editing have been developed as well
as endogenous C-terminal tagged GAA1, the yeast homolog of human GPAA1, that allowed for
immunopurification of the whole transamidase complex and furthermore provided structural
insight by small-angle X-ray scattering [97; 98]. In summary, combinations of CRISPR/Cas9 and
detergent free extraction (e.g. SMA) of endogenous protein complexes are suitable tools to study
proteins containing TMDs.
1Zhang Lab (MIT, USA): http://crispr.mit.edu/
2Wittbrodt lab (COS, Germany): http://crispr.cos.uni-heidelberg.de/
3Joung lab (Massachusetts General Hospital, USA): http://www.jounglab.org/guideseq/
4Boutros’s lab (DKFZ, Germany)http://www.jounglab.org/guideseq/
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Figure 6: Genome engineering with CRISPR/Cas9 A) The nuclease Cas9 is directed, by the specific bind-
ing of a gRNA to its target sequence, to the genomic DNA and introduces a double strand break. Repair
will be facilitated through either NHEJ or HDR. B) Using two gRNAs and a Cas9 incapable of introducing a
double strand break increases precision of HDR. Figure adapted and modified from[99].
3.4 Aim of the thesis
The GPI-anchor is a lipid moiety attached to over 150 human proteins and plays a crucial role in
cell surface display at the plasmamembrane. The transamidase complex, located in the ER, trans-
fers the GPI-anchor to the receiving protein. Previously, interactions between the transamidase
complex subunit GPAA1 and a sphingolipid have been shown.
The aim of this thesis was to establish an experimental setup to analyse protein lipid interactions
of the transamidase complex. For this, a cell model suitable to study sphingolipids was employed.
Interactions were assessed via in-gel fluorescence and western blot quantification through click
chemistry with bifunctional sphingolipids in conjunction with transient expression of transam-
idase subunits. TLC was used to verify the metabolic status of exogenous pacSph at given time
points. CRISPR/Cas9 was utilised to created a cellular model to study sphingolipid interactions
with the endogenous transamidase complex. The subset of specific sphingolipid species interact-
ingwith the transamidase complexwere be elucidated by selective inhibition of enzymes involved
in the sphingolipid metabolism.
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4 Materials & Methods
All chemicals, solutions and enzymes are listed in table 2 with their name that is used throughout the thesis as well as the brand name,
except they were solely used for one set of experiments. If the latter is the case, the details are enclosed in the specific section containing
the description of the experimental procedures.
4.1 Tables
Table 2: Chemicals/Solutions used in this thesis in alphapetical order
Name Product name Provider Article number Purity [%]
Acrylamide Rotiphorese® Gel 30 (37,5:1) CarlRoth 3029.1 NA
AcOH Acetic acid AnalaR NORMAPUR® ACS VWR 20104.298 99.8
Agar Bacto™ Agar BD 214010 NA
Agarose Agarose NEEO, Roti®garose low
electroendosmosis
CarlRoth 2267.4 NA
APS Ammonium peroxydisulphate CarlRoth 9592.2 98
Alexa-647 Alexa Fluor® 647 Azide, Triethylammonium Salt ThermoFisher A10277 99
Biotin-azide PEG4 carboxamide-6-azidohexanyl biotin ThermoFisher B10184 research grade
Benzonase Benzonase® Nuclease HC Merck 71206 99
BSA Albumin Fraktion V CarlRoth 8076.2 98
CaCl Calcium chloride dihydrate Sigma-Aldrich 31307 99
CHCl3 LiChrosolv® Chloroforom Merck 102444 99.8
CHAPS CHAPS hydrate Sigma-Aldrich C5070 98
CHAPS CHAPS for 2D gel electrophoresis Sigma-Aldrich GE171314-01 NA
clickSM-
Standard
N-(octadec-17-yn)-Sphing-4-enin-1-
phosphocholine
synthesised in the lab NA NA
Coumarin 3-azido-7-hydroxycoumarin Jena Bioscience CLK-FA047-1 95
CuS04 Copper(II) sulfate pentahydrate Sigma-Aldrich 203165 99.999
Cu[MeCN]4BF4 Tetrakis(acetonitrile)copper(I)
tetrafluoroborate
Sigma-Aldrich 677892 97
Digitonin Digitonin Sigma-Aldrich D5628 50
=
18
=
4
M
A
T
ER
IA
LS
&
M
ET
H
O
D
S
Table 2: Chemicals/Solutions used in this thesis in alphapetical order
Name Product name Provider Article number Purity [%]
DMEM Dulbecco’s Phosphate Buffered Saline Sigma-Aldrich D6046 cell-culture grade
DTT DL-Dithiothreitol Sigma-Aldrich D0632 99
Ethylacetate Ethylacetate diverse suppliers NA 98
EtOH LiChrosolv® Ethanol Merck 111727 99.8
FBS Fetal bovine serum Merck S0615 EU-approved
FBS,delipid-
ated
Charcoal Stripped Fetal Bovine Serum ThermoFisher 12676029 research grade
Glycine Glycine Sigma-Aldrich 33226 99.7
HEPES PUFFERAN® Hepes CarlRoth 9105.4 99.5
Hexane n-Hexane ACROS Organics FisherScientific AC197360010 95
Hünig’s base N,N-Diisopropylethylamine Sigma-Aldrich 496219 99.5
LDS-sample
buffer
NuPAGE® LDS Sample Buffer ThermoFisher NP0007 NA
L-ascrobic
acid
(R)-5-[(S)-1,2-Dihydroxyethyl]-3,4-Dihydroxy-5-
(H)-Furan-2-one
AppliChem A1052,0100 99
MeOH Methanol Sigma-Aldrich 32213 99.8
b -Mercapto-
ethanol
2-Mercaptoethanol Sigma-Aldrich M6250 99
Milk Powdered milk CarlRoth T145.2 blotting grade
MOPS 4-Morpholinepropanesulfonic acid Sigma-Aldrich M1254 99
NaCl Sodium chlorid Sigma-Aldrich 31434-M 99.5
NaCHO3 1,1,3,3-Tetramethylbutyl isocyanide Sigma-Aldrich 226491 technical grade
Na-
deoxycholate
Deoxycholic acid sodium salt CarlRoth 3484.3 98
Nonident P40 Nonident P40 Substitute IGEPAL CA-630
(Octylphenoxy poly(ethyleneoxy)ethanol)
Sigma-Aldrich 11754599001 Roche NA
Octylglucosid n-Octyl-b -D-glucopyranoside CalBioChem 494459 NA
PBS Phosphate-buffered saline Sigma-Aldrich D8537 cell-culture grade
pacCer-
Standard
N-(9-(3-pent-4-ynyl-3-H-diazirin-3-yl)-
nonanoyl)-D-erythro-sphingosine
Avanti 900404P 95
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Table 2: Chemicals/Solutions used in this thesis in alphapetical order
Name Product name Provider Article number Purity [%]
pacSph-
Standard
(2S,3R,E)-2-amino-13-(3-(pent-4-yn-1-yl)-3H-
diazirin-3-yl)tridec-4-ene-1,3-diol
synthesised after[85] NA NA
pacPC-
Standard
1-(9-(3-pent-4-ynyl-3-H-diazirin-3-yl)-
nonanoyl)-2-oleoyl-sn-glycero-3-
phosphocholine
Avanti 900408P 95
pacGlucCer-
Standard
D-glucosyl-ß-1,1’ N-(9-(3-pent-4-ynyl-3-H-
diazirin-3-yl)-nonanoyl)-D-erythro-sphingosine
Avanti 900405P 95
Pen/Strep Penicillin and Streptomycin Sigma-Aldrich P4333 cell-culture grade
PIC cOmplete™, EDTA-free Protease Inhibitor
Cocktail
Roche 11873580001 NA
RbCl Rubidium chloride AlfaAsar 12892 99
SDS Dodecylsulfate-Na-salt Serva 20765 99
SDS-PAGE
standard
Precision Plus Protein™ All Blue Prestained
Protein Standards
Bio-Rad 1610373 NA
TBTA Tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine
Sigma-Aldrich 678937 97
TCEP Tris(2carboxyethyl)phosphine hydrochloride Sigma-Aldrich C4706 98
TEMED Tetramethylethylenediamine Bio-Rad 1610800 99
Thiourea Thiourea Sigma-Aldrich GERPN6301 NA
Triton-X-100 4-(1,1,3,3-Tetramethylbutyl)phenyl-
polyethylene
glycol
Merck 108643 98/Ph Eur
TRIS TPUFFERAN® Tris,
Tris(hydroxymethyl)-aminomethane
CarlRoth 4855.2 99.9
Trypan-Blue Trypan Blue solution Sigma-Aldrich T8154 cell-culture grade
Tryptone Bacto™ Tryptone BD 211705 NA
Tween-20 Polyoxyethylene-20-sorbitan monolaurate CarlRoth 9127.1 Ph Eur
Urea Urea Sigma-Aldrich 33247 99.5
Yeast Extract Bacto™ Yeast Extracts BD 212750 NA
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Table 3: Antibodies used for detection via western blotting.
Target Conjugate Species Provider Article number working dilution
a-calnexin rabbit Stressgene SPA-865 1:1000
a-CD59 mouse Santa Cruz Biotechnology sc-133170 1:500
a-PIGU rabbit NovusBio NBP1-98429 1:750
a-PIGK rabbit Proteintech 15151-1-AP 1:1000
a-PIGT rabbit Proteintech 16906-1-AP 1:1000
a-PIGS rabbit Proteintech 18334-1-AP 1:750
a-GPAA1 mouse Santa Cruz Biotechnology sc373710 1:750
a-GPAA1 rabbit NovusBio NBP2-16709 1:750
a-DDDDK tag rabbit Abcam ab1162 1:1000
a-DDDDK tag mouse Sigma-Aldrich F1804 1:1000
a-biotin IRDye® 800CW Streptavidin Li-cor 925-32230 1:10000
a-rabbit IgG (H+L) IRDye800CW goat Rockland 611-131-002 1:10 000
a-rabbit IgG (H+L) Alexa Fluor®680 goat ThermoFisher Scientific A-21076 1:10 000
a-mouse IgG (H+L) Alexa Fluor®680 goat ThermoFisher Scientific A-21075 1:10 000
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Table 4: Vectors and their corresponding sequencing primers
Target-Vector Name Sequence GATC standard primer
pCMV6+insert Origene_FW 5-’GGCACCAAAATCAACGGGAC-3’ no
pCMV6+insert Origene_Rev (inside of tag region) 5-’CGTCGTCATCCTTGTAATCCAG-3’ no
pCMV6+insert CMV-F 5’-CGCAAATGGGCGGTAGGCGTG-3’ yes
pCMV6+insert Origene_Rev2 (outside of tag region) 5’-ACTGGAGTGGCAACTTC-3’ synthesised at GATC
pCMV6-PIGT (RC201926) PIGT_middle 5’-CAATGACACTGACCACTAC-3’ synthesised at GATC
pCMV6-PPIGS (RC209631) PIGS_middle 5’-CAGGCCATGTCTTTGACTG-3’ synthesised at GATC
pCMV6-PPIGK (RC204728) PIGS_middle 5’-CAGGCCATGTCTTTGACTG-3’ synthesised at GATC
pME-mCherry–CD59 CD59_FW 5’-GTGAGCAAGGGCGAGGAGGAT-3’ synthesised at GATC
pME-mCherry-FLAG-CD59 CD59_Rev 5’-CTTGTACAGCTCGTCCATGCC-3’ synthesised at GATC
px458 (pSpCas9(BB)-2A-GFP) LKO1 (gRNA insertion site) 5’-GACTATCATATGCTTACCGT-3’ synthesised at GATC
AAVS1_Puro_PGK1_3xFLAG_Twin_Strep pcDNA3.1-RP/1 5’-CAAACAACAGATGGCTGGC-3’ yes
AAVS1_Puro_PGK1_3xFLAG_Twin_Strep pBR1 5’-CGAAAAGTGCCACCTGAC-3’ yes
AAVS1_Puro_PGK1_3xFLAG_Twin_Strep RHA (inside of tag region) 5’-ATCACGACATCGACTAC-3’ yes
hCas9 CMV-F 5’-CGCAAATGGGCGGTAGGCGTG-3’ yes
MLM3636 GATC-OS280-1566504 5’-CAGGGTTATTGTCTCATGAGCGG-3’ synthesised at GATC
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Table 5: 1.5mm 7.5% SDS page
Component Volume [mL]
Separation Stacking gel
H2O 4.85 3.05
1.5M Tris pH 8.8 2.5 -
0.5M Tris pH 6.8 - 1.25
30% Acrylamide 2.5 0.65
10% SDS 0.1 0.05
10% APS 0.1 0.05
TEMED 0.01 0.005
Table 6: Equipment and Materials used for SDS-PAGE and western blot
Modell/Article name Company Article number
Mini-PROTEAN® Tetra Vertical Electrophoresis Cell BioRad 1658004
Mini Trans-Blot® Cell BioRad 1703930
Odyssey® CLx Li-cor 9140
polyvinylidene fluoride (PVDF) membrane immobilon Merck IPVH00010
PowerPac Basic BioRad 1645050
Tube Roller StarLab N2400-701
Whatman® gel blotting paper Sigma-Aldrich WHA10426892
Table 7: gRNA sequences
# gRNA location on genomic strand Sequence
GPAA1_gRNA#1_A + 5-’ACACCTGAGATTGCCTGTCCGGGCG-3’
GPAA1_gRNA#1_B - 5-’AAAACGCCCGGACAGGCAGATCTCAG-3
GPAA1_gRNA#2_A + 5-’ACACCGAGATCTGCCTGTCCGGGCTG-3’
GPAA1_gRNA#2_B - 5-’AAAACAGCCCGGACAGGCAGATCTCG-3’
GPAA1_gRNA#3_A - 5-’ACACCATTCCAGAAAAGCAGCCAGCG-3’
GPAA1_gRNA#3_B + 5-’AAAACGCTGGCTGCTTTTCTGGAATG-3’
Table 8: Primer for amplification of genomic GPAA1
name sequence
genomic_GPAA1_FW2 5-’GTGGGATGGTGGTGGTCTTT-3’
genomic_GPAA1_REV2 5-’CAGCTCCAGCCTCAGTCCTA-3
genomic_GPAA1_FW3 5-’AAAAAAAAGAATTCGTGGGATGGTGGTGGTCTTT-3’
genomic_GPAA1_REV3 5-’AAAAAAAACTCGAGCAGCTCCAGCCTCAGTCCTA -3
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4.2 Cell Culture
All cell lines were maintained at 37°C in a humidified atmosphere with 5% CO2. Research group
(RG) Thil provided human Fibroblasts (growth medium: DMEM + 10% FBS, Pen/Strep, 4500mg/L
glucose). RG Wieland provided two cell lines, the mouse embryonic fibroblasts H806 (growth
medium: DMEM + 10% FBS, Pen/Strep, L-glutamine) and the mus musculus brain neuroblastoma
N2A (growth medium: DMEM + 10% FBS, Pen/Strep, L-glutamine). The adenocarcinomic human
alveolar basal epithelial cell line A549 (growth medium: DMEM + 10% FBS, Pen/Strep) was kindly
provided by RG Kräusslich. The hepatocarcinoma cell line Huh-7 (growth medium: DMEM high
glucose (41965, ThermoFisher), L-glutamine, without pyruvate) was kindly provided by RG
Ruggieri. The cervix carcinoma cell line HeLa and the human embryonic kidney cell line HEK293
(growth medium: DMEM + 10% FBS, Pen/Strep, L-glutamine) as well as the lymphoblast-like cell
line Raji (growth medium: RPMI1640 + 10% FBS, Pen/Strep) were already in our possession. All
research groups mentioned are associated with either Heidelberg University or the Heidelberg
University medical centre.
4.3 Creation of chemically competent cells
To create chemically competent cells, a pre-culture of the bacterial strain and 10 mL antibiotic
free LB-medium (see section 4.4) was grown overnight at 37°C and 180 rpm. The next day, 400 mL
antibiotic free LB-medium were inoculated with 4 mL of pre-culture and grown until OD600=0.4.
All the following aseptic steps were done on ice with pre-cooled reagents and materials. The
main culturewas centrifuged (15min/4000rpm/4°C) and the pellet resuspended in 50mL of sterile
filtered TFB1 buffer (50 mMMnCl, 100 mM RbCl, 10 mM CaCl, 30 mM potassium acetate, 15% gly-
cerol, pH 5.8 with acetic acid). The cells were pelleted (10min/3000rpm/4°C), resuspended in 10
mL sterile filtered TFB2 buffer (10 mM MOPS pH 7.0, 75 mM CaCl2, 10 mM RbCl, 15% glycerol),
distributed into 250 µL aliquots and stored at -80°C. TFB1 and TFB2 were stored at 4°C.
To determine transformation efficiency, chemically competent cells were transformed (see sec-
tion 4.4) with 1000/100/10pg of bacterial plasmid. Colony forming units (CFU) were counted the
next day and efficiency (CFU/µg of transfected DNA) was calculated according to the following
formula: transformation efficency= CFU on plateµg of DNA transfected 1000
ng
µg
4.4 Transformation of bacteria
Before addition of 10 ng plasmid, aliquots of chemically competent E. coli DH-5a (DSMZ 6897,
Deutsche Sammlung von Mikroorganism und Zellkulturen GmBH), E. coli Stbl3 (C737303, Thermo
Scientific), and E. coli BW23473 (kindly provided by RG Wieland, BZH, Heidelberg) were thawed
up on ice for 30 minutes. To facilitate plasmid DNA uptake, bacterial suspensions were subjected
to a 45-90 seconds long heat-shock at 42°C. Recovery of bacteria was achieved by short incuba-
tion on ice and followed by addition of 1 mL Luria-Bertani (LB) medium (1% (w/v) tryptone, 0.5%
(w/v) NaCl, 1% (w/v) yeast extract in H2O). After a growth phase (30min/180rpm/37°C), bacteria
were pelleted (1min/8000g/RT), resuspended and streaked out with a drigalski spatula on LB agar
plates with respective antibiotics. Bacteria were grown overnight at 37°C or for 3 days at room
temperature. Positive clones were identified by colony PCR/restriction digest or sequencing.
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4.5 Colony polymerase chain reaction
To analyse successful uptake of plasmid DNA after transformation of E. coli strains (see chapter
4.4), polymerase chain reaction was employed to screen bacterial transformants. In short, 2 µL
of 10x reaction buffer B, 0.8 µL of 50 mM MgCl2, 10 mM dNTPs (732-3182,VWR Peqlab), 0.4 µL
of 10 pmol forward and reverse primer, 14.7 µL H2O, and 0.2 µL of taq DNA polymerase (22466,
Axon Labortechnik) were mixed and inoculated with a freshly picked colony. PCR was performed
according to the following program: 5min/95°C, 30x (denaturing:30 sec/95°C, annealing: 52°C/30
sec, extension: 72°C/3 min 40 sec), 72°C/5min and stored at 4°C. Forward and reverse primers for
origene vectors with the pCMV6 backbone are listed in table 4.
4.6 Sequencing of plasmids
All plasmids used for transient expression were either named in their specific experiment,
were ordered from Origene, USA (RC200271 encoding for GPAA1, RC204728 encoding for PIGK,
RC209631 encoding for PIGS, RC201926 encoding for PIGT, and RC207146 encoding for PIGU), or
were already available in our lab, such as the vectors encoding for p24 and calnexin. Twenty µL of
plasmid containing solutions with a concentration of 50 ngmL were sent to for sequencing to GATC
Biotech AG. Primers used are listed in table 4. Primers sent to GATC for sequencingwere prepared
at 10 pmolmL .
4.7 Thin layer chromatography (TLC) and coumarin click reaction
To analyse in vivo metabolic conversion of pacSph after distinct labeling durations, cells
were washed four times with ice-cold PBS, scraped into 1.5 mL eppendorf tubes, centrifuged
(5min/4°C/3000g) and pellets resuspended in 300 µL PBS. Lipid extracts were prepared as de-
scribed in[85]. Briefly: 600 µL MeOH and 150 µL CHCl3 were added, mixed and centrifuged
(5min/14000g/RT). The supernatant was transferred into 2 mL eppendorf tubes, mixed with 300
µL CHCl3 and 600 µL 0.1% acetic acid in H2O and centrifuged (5min/14000g/RT). The lower phase
was transfered into a clean 1.5 mL eppendorf tube end evaporated under vacuum in a speed-
vac (20min/30°C). Lipids were then either used directly for a copper derived click reaction with
3-azido-7-hydroxycoumarin or overlaid with N2 and stored at -20°C.
A 10 mM [MeCN]4BF4Cu containing solution was prepared by resuspension of the lyophilized
powder in acetonitril according to the following formula: [MeCN]4BF4Cu[in mg]10
 3106
314.56 g/mol10 310 mM = mL. Final
clickmix consisted out of 250 µL 10mM[MeCN]4BF4Cu, 1 µL of 44mM3-azido-7-hydroxycoumarin
(in DMSO) and 1 mL EtOH. The standard mix consisted out of each 0.5 µL of 1 mM pacCer-
/pacGlucCer-/pacPC-/pacSph- and clickSM-standard. Lipids were redissolved in 7 µL CHCL3 and
30 µL of the click mix was added before evaporation in the speedvac (20min/45°C). Lipids were
resuspended in 20 µL and the standard in 100 µL of mobile phase I (CHCl3/MeOH/H2O/AcOH
65:25:4:1). 20µL of lipids and standard were applied on a 10x10cm HPTLC Silica 60 glas plate
(1.05641.001, Merck) with a CAMAG Linomat 5 and the TLCwas developed with the CAMAG AUTO-
MATIC DEVELOPING CHAMBER 2 (ADC 2) or manually. TLC plates were developed using mobile
phase I until 6 cm, followed by 8 cmwithmobile phase II (hexane/EtOAc 1:1). Lipids were fluores-
cently labeled with 4% (v/v) ‘Hünig’s base’ in hexane. Lipids were visualised using an Amersham
Imager 600 and analysed with ImageJ (https://imagej.nih.gov/ij/).
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4.8 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-
PAGE)
Separation of proteins by size was achieved by employment of Laemlli’s one-dimensional discon-
tinuous SDS-PAGE[100]. Table 5 shows exemplarily the composition of a 1.5mm 7.5% SDS-PAGE.
Samples mixed with SDS gel-loading buffer (for the respective loading buffers, see in the specific
method sections) were added into the wells of the SDS-PAGE gel and run together with the SDS-
PAGE pre-stained protein standard (1610373, Bio-Rad Laboratories GmbH) in SDS electrophoresis
buffer (25 mM Tris, 192 mM Glycine, 0.1% SDS) for 15 min at 100V and then for the rest of the
run at 200V. Detection of proteins was done by either a successive transfer to a PVDF membrane
(see section 4.9) or by colloidal coomassie (B2025, Sigma-Aldrich) staining of the gel according to
manufacturer’s instructions.
4.9 Western blot
SDS-PAGE separated proteinswere transferred onto a 45 µmpolyvinylidene fluoride (PVDF)mem-
brane via a wet blot protocol according to the Biorad Mini Trans-Blot® electrophoretic transfer
cell manual. The PVDF membrane was activated by MeOH incubation, followed by equilibration
in blotting buffer (25 mM Tris, 192 mM Glycine, 20% methanol). The transfer was conducted at
room temperature at either 100V for 70 min (0.75mm gels), 180 min (1.5mm gels) or in the cold
room at 30V for 16 hours (1.5mm gels). Afterwards, the membrane was blocked for one hour at
room temperature or overnight at 4°C in 5% skim milk in PBS-T (0.05 % Tween-20). To remove
unboundmilk components, themembrane was washed four times with PBS-T before being incub-
ated with primary antibodies for one hour at room temperature or overnight at 4°C. Incubation
with secondary antibodies took place for one hour at room temperature or overnight at 4°C after
the membrane was washed four times. All antibodies used are listed in table 3 and were diluted
in PBS-T with 3-5% BSA. Before analysis with Li-cor Odyssey® CLx, membranes were washed 4x
with PBS-T and taken up in PBS. Afterwards, membranes were taken up in MeOH and air-dried,
before being stored at room temperature. Quantification of blots was done with Image Studio™
Lite from Li-cor. Equipment used for SDS-page and western blot are listed in table 6.
4.10 Analysis of transient expression of transamidase subunits
4.10.1 Optimisation of transient transfection parameters
HeLa cells were seeded (1x105 cells per 12-well) and 24 hours later transiently transfected with
different concentrations of plasmid DNA (0.25/0.5/1/1.5 µg) encoding for the different subunits
(PIGK/S/T/U and GPAA1) and the corresponding amounts of FugeneHD (E2311, Promega) accord-
ing to manufacturer’s instructions. Cells were harvested 24 hours later by washing with ice-cold
PBS, incubated on ice (500 µL PBS/10min), scraped off in pre-cooled 1.5 mL tubes and pelleted
(6min/13000 g/4°C). Pellets were resuspended in 50 µL HEPES lysis buffer (100 mM HEPES-NaOH
pH 7.4, 100 mMNaCl, 5 mM EDTA, 1% (v/v) Triton-X-100, 0.5% (v/v) Na-deoxycholate, 1x PIC), in-
cubated on ice (40 min/agitated every 10 min) and centrifuged (8min/16000g/4°C). Supernatant
was transferred into a new 1.5 mL tube, while the pellet was resuspended with 50 µL of lysis
buffer. Samples were stored overnight at -20°C. 11.25 µL of samples and 3.75 µL of 4x sample
buffer were heated up (10min/95°C), loaded on a 13% SDS-PAGE (see section 4.8), transferred to
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a PVDF-membrane (see section 4.9) and developed with mouse a-DDDKK antibody (see table 3).
The amount of protein found in the supernatant was set into relation to the protein signal in the
pellet to define the solubilisation efficency as
A680Supernatant
A680Pellet
100. As a positive control, EGFP was
used. GPAA1 expression was analysed for 24 and 48 hours.
4.10.2 Optimisation of solubilisation parameters for transient transfected GPAA1
Different detergents were tested to optimise solubilisation efficiency of transient GPAA1 trans-
fections in HeLa cells (1x105 cells per 12-well, 0.25/0.5/1 µg plasmid DNA, 24 and 48 hours trans-
fection time). The basic buffer (100mMHEPES-NaOH pH 7.4, 100mMNaCl, 1x PIC) was completed
by addition of different detergents to form lysis buffer 1 (1% (v/v) Triton-X-100, 0.5% (v/v) Na-
deoxycholate), buffer 2 (1% (v/v) octylglucoside), buffer 3 (1% (v/v) Nonident P40), and buffer 4
(1% (v/v) CHAPS). Experiment was executed as described in section 4.10.1. Calnexin, an ER resid-
ent protein, served as solubilisation control.
4.11 Immunprecipitation of transiently expressed or endogenous trans-
amidase subunits
4.11.1 FLAG-beads: Immunoprecipitation (IP) of transiently transfectecd transamidase
complex subunits with FLAG-beads
HeLa cells were seeded (3x105 cells per 6-well) and 24 hours later transiently transfected with
1 µg of plasmid DNA encoding for the different subunits (PIGK/S/T/U and GPAA1) and the
corresponding amounts of Fugene HD (E2311, Promega) according to manufacturer’s instruc-
tions. Cells were harvested 24 hours later by washing with ice-cold PBS, incubation on ice (750
µL PBS/10min), scraped off in pre-cooled 1.5 mL tubes, pelleted (6min/13000 g/4°C). Pellets
were resuspended in 50 µL HEPES lysis buffer (100 mM HEPES-NaOH pH 7.4, 100 mM NaCl, 1%
(v/v) Nonident P40, 1x PIC), lysis was performed on a test-tube rotator (1 1/2h/4°C) in the
cold room and centrifuged (8min/16000g/4°C). Supernatant was transferred into a new 1.5 mL
tube and 13.5 µL were used as input sample for the immunnoprecipitation (IP input). The rest
of the supernatant was mixed with 50 µL three times pre-washed (500 µL PBS/30sec/8200g)
FLAG-beads (F2426, Sigma-Aldrich) and incubated overnight on a test-tube rotator in the cold
room. Samples were centrifuged (1min/8200g/4°C) and the supernatant transferred into a
new 1.5 mL tube to be used as the flow-through (FT) sample containing proteins that did
not bind to the FLAG-beads. Beads were washed as before and SDS sample loading buffer
(250 mM Tris, pH 6.8, 20% (w/v) SDS, 40% (v/v) glycerol, 20% (v/v) b -mercaptoethanol, and
0.02% (w/v) bromophenol blue) was added to the different tubes (IP input:6.25 µL, FT:6.25 µL,
beads: 25 µL), heated up (5min/95°C), loaded on a 13% SDS-PAGE (see section 4.8), transferred
to a PVDF-membrane (see section 4.9) and developedwithmousea-DDDKK antibody (see table 3).
4.11.2 FLAG-beads: Co-IP of transiently transfectecd transamidase complex subunits
To analyse if transiently expressed GPAA1 can co-immunoprecipitate (co-IP) transamidase sub-
units the following experiment was performed:
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HeLa cells were seeded (2x106 cells per 10 cm dish, 11 dishes overall) and 24 hours later transi-
ently transfected with 4.3 µg of plasmid DNA encoding for (10 dishes GPAA1, 1 dish EGFP) and
the corresponding amounts of Fugene HD (E2311, Promega) according to manufacturer’s instruc-
tions. Cells were harvested 24 hours later by washing with ice-cold PBS (10 mL/dish), scraped off
in ice-cold PBS and transferred into a pre-cooled 15mL tube, pelleted (1min/500g/4°C), resuspen-
ded pellet in 8mL lysis buffer (25mMHEPES-NaOH pH 7.6, 200mMNaCl, 0.5% (v/v) Nonident P40,
1x PIC), distributed equally into 1.5 mL ultracentrifuge tubes, and pelleted (90min/100.000g/4°C).
Supernatants were pooled, input samplewas taken (0.25% IP input: 20 µL + 4µl SDS sample loading
buffer, 15min/95°C), mixed with 120µL three times pre-washed (1 mL PBS/30sec/8200g) FLAG-
beads (F2426, Sigma-Aldrich) and incubated for 4 hours on a test-tube rotator in the cold room.
One of the pellets of the centrifugation step was mixed with 50 µL of SDS sample loading buf-
fer (250 mM Tris, pH 6.8, 20% (w/v) SDS, 40% (v/v) glycerol, 20% (v/v) b -mercaptoethanol, and
0.02% (w/v) bromophenol blue) and heated up (15min/95°C). 0.75 µL were taken out and mixed
with 23.25 µL of SDS sample loading buffer to create a 0.25% sample (P) for SDS-PAGE. Took flow-
through (FT) sample (0.25% FT: 20 µL + 4µl SDS sample loading buffer, 15min/95°C), transferred
beads into 1.5 mL tubes, washed 3 times with wash buffer (lysis buffer + 10mMDTT, 1min/8000g),
added 200 µL of SDS sample loading buffer and eluted bound protein by heating up (15min/90°C).
Samples were loaded on a 13% SDS-PAGE (see section 4.8), transferred to a PVDF-membrane (see
section 4.9) and developed with antibodies against PIGS/K (rabbit) and a-DDDKK (mouse) anti-
body (see table 3).
To analyse if transiently expressed PIGT can co-IP transamidase subunits the following experi-
ment was performed: HeLa cells were seeded (2x106 cells per 15 cm dish, 3 dishes overall) and
24 hours later transiently transfected with overall 12 µg of plasmid DNA encoding for PIGT and
the corresponding amounts of Fugene HD (E2311, Promega) according to manufacturer’s instruc-
tions. Cells were harvested 24 hours later by washing with ice-cold PBS (15 mL/dish), scraped off
in ice-cold PBS and transferred into a pre-cooled 15mL tube, pelleted (1min/500g/4°C), resuspen-
ded pellet in 8 mL lysis buffer (100 mM HEPES-NaOH pH 7.4, 100 mM NaCl, 1% (v/v) Triton-X-100,
0.5% (v/v) Na-deoxycholate, 1x PIC), incubated for 1 hour on a tube rotator in the cold room,
transferred into 2 mL tubes, centrifuged (20min/10000g/4°C), transferred into 1.5 mL ultra cent-
rifuge tubes and centrifuged (1h/100000g/4°C). Supernatant was pooled, mixed with 100 µL of
four times pre-washed (1 mL lysis buffer/30sec/8200g) FLAG-beads and incubated overnight. As
before samples before IP and not bound protein after IP were collected and used for SDS-PAGE. On
the next day, samples were washed as before and proteins were eluted three times for 30 minutes
in the cold room on the test tube rotator with 200 µL of 1 mg/mL FLAG-peptide (F3290,Sigma-
Aldrich). Afterwards, to analyse the elution efficiency, beads were heated up (10min/70°C) with
100 µL of sample buffer (100 mM Tris, pH 8.3, 4 M Urea, 8% (w/v) SDS, 10% (v/v) glycerol, 50 mM
DTT, and 0.01% (w/v) bromophenol blue). Samples were loaded on a 13% SDS-PAGE (see section
4.8), transferred to a PVDF-membrane (see section 4.9) and developed with antibodies against
PIGK/T/S (rabbit, see table 3).
4.11.3 CNBr-beads: Co-IP of endogenous transamidase complex subunits
4.11.3.1 Coupling of a-GPAA1 antibody to CNBr-beads CNBr-beads (GE17043001, Sigma-
Aldrich) were coupled with an a-GPAA1 antibody (sc-373710, SantaCruz) to immunoprecipitated
endogenous GPAA1 according to manufacturer’s instructions. Briefly, beads were washed with
10 mL of activation buffer (1 mMHCl). Antibodies were transferred into coupling buffer (100 mM
NaCHO3 pH 8.3, 500 mM NaCl) by using MicroSpin™ G-25 Columns (45001397, ThermoScientific)
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and mixed with activated CNBr-beads. Beads were washed three times with 1 mL coupling buffer
(1min/50g/4°C) and were blocked by addition of 1 mL of blocking buffer (100 mM TRIS-HCl pH 8)
for 2 hours in the cold room. Afterwards, beads were washed (90sec/50g/4°C) four times, altern-
ating with wash buffer A (100 mM AcOH, 500 mM NaCl) and B (100 mM TRIS-HCl pH 8, 500 mM
NaCl). Finally, the beads were stored in 1 mL PBS (long term sotrage with 0.02% (w/v) sodium
azide).
4.11.3.2 Validation of a-GPAA1 coupled CNBr-beads capability to IP endogenous GPAA1
from HeLa cell line To validate the functionality of the a-GPAA1 coupled CNBr-beads, HeLa
cells were seeded (2x106 cells per 15 cm dish, 10 dishes overall) and grown for three days until
approximately 90% confluency (around 1x108). Cells were harvested 24 hours later by washing all
plates with ice-cold PBS, scraped off in total 7mL lysis buffer (20mMHEPES-NaOH pH 7.6, 200mM
NaCl, 0.5% (v/v) Nonident P40, 1x PIC), washed plates with additional 7 mL lysis buffer and pooled
samples. The overall 15 mL of lysate were incubated for 1 hour on a test tube rotator in the cold
room. Samples were equally distributed in ultracentrifuge tubes, centrifuged (1h/100000g/4°C),
pooled in a 15 mL falcon tube, mixed with CNBr-beads and rotated overnight in the cold room.
One pellet of the centrifugation step was mixed with 50 µL of SDS sample buffer (250 mM Tris,
pH 6.8, 12.5 mM EDTA, 500 mM DTT, 10% (w/v) SDS, 25% (v/v) glycerol, 0.1% (w/v) bromophenol
blue), heated up (5min/95°C) and 5.2 µL of the solution was taken out and mixed with 16 µL SDS
sample buffer and 59.2 µL H2O to create a 0.13% pellet fraction for the SDS-PAGE. Beads were
pelleted (3min/100g/4°C) and 80 µL of the supernatant wasmixedwith 16 µL of SDS sample buffer
and heated up as before. Proteins were eluted from the beads by the following procedure. First,
beads were washed twice (90sec/50g/4°C) with 1 mL PBS to reduce the detergent concentration.
Beads were taken dry, placed on ice, mixed with 100 µL of elution buffer (100 mM glycine, pH
adjusted to 2.4 with HCl), centrifuged (1min/50g/4°C), supernatant transferred into a new tube
and mixed with neutralisation buffer (500 mM TRIS, 1500 mM NaCl) until the pH was between
6-7. The volume required was determined bymixing elution and neutralisation buffer in a 1.5 mL
tube and periodically checking the pH value with pH paper. Beads were washed (1min/50g/4°C)
with 1 mL elution buffer followed by 1 mL neutralisation buffer, repeated and stored in PBS at
4°C. Of the samples, 20 µL were loaded (pellet: 0.13%, flow-through:0.16%, eluate:7.81%) on four
13% SDS-PAGEs (see section 4.8), transferred to a PVDF-membrane (see section 4.9) and developed
with a-PIGK/S/T/U (rabbit) and a-GPAA1 (mouse/rabbit) antibodies (see table 3).
4.11.3.3 Detection of endogenous transamidase complex with CNBr-beads from Raji cell
line Raji cells (growth medium: RPMI1640 + 10% FBS, Pen/Strep) were grown in T75-flasks and
1x108 cells were harvested by centrifugation (5min/200g/4°C), resuspended once in ice-cold PBS,
pooled in a 15 ml falcon tube, centrifuged (2min/200g/4°C), resuspended in 10 mL lysis buffer (20
mM HEPES-NaOH pH 7.6, 200 mM NaCl, 0.5% (v/v) Nonident P40, 1x PIC) and incubated on a test
tube rotator for 30 minutes in the cold room. Samples were transferred into 2 mL test tubes and
two times centrifuged (20min/10000g/4°C, 1h/100000g/4°C). CNBr-beads from 4.11.3.2 were used
and proceeded as described in that section. Only difference was that this time an input sample
was taken and only input (0.135%), flow-through (0.135%) and the eluate (7.81%) were loaded.
Experiment was repeated once more, this time with 1x109 cells and 12.7% of the eluate loaded.
4.11.3.4 Efficency of GPAA1 IP between CNBr-beads and FLAG-beads To verify that CNBr-
beads enrich a significant portion of GPAA1 available in a cell lysate, two 15 cm dishes of HeLa
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cells were seeded (2x106) and 24 hours later transiently transfected with GPAA1 encoding plas-
mid (8 µg/dish) and the corresponding amounts of Fugene HD (E2311, Promega) according to
manufacturer’s instructions. Cells were harvested 24 hours later by washing with ice-cold PBS
(10 mL/dish), scraped off in ice-cold PBS and transferred into a pre-cooled 15 mL tube, pelleted
(1min/500g/4°C), resuspended pellet in 1.8 mL lysis buffer (20 mM HEPES-NaOH pH 7.6, 200 mM
NaCl, 0.5% (v/v) Nonident P40, 1x PIC). Lysate was pre-cleared with two centrifugation steps
(20min/10000g/4°C, 1h/100000g/4°C). 1.6% input sample was taken before the lysate was mixed
with the CNBr-beads and incubated overnight on a test tube rotator in the cold room. Proteins
were eluted as described in 4.11.3.2. 20% of eluate and 1.6% of flow-through (FT) were mixed with
according volumes of SDS sample buffer (250 mM Tris, pH 6.8, 12.5 mM EDTA, 500 mM DTT, 10%
(w/v) SDS, 25% (v/v) glycerol, 0.1% (w/v) bromophenol blue) and heated up (5min/95°C). The rest
of the eluate was mixed with 30 µL three times pre-washed (1 mL lysis buffer/30sec/8200g) FLAG-
beads (F2426, Sigma-Aldrich) and incubated overnight in the cold room. Beads were washed as
before and bound protein was eluted by heating up (15min/90°C) after addition of 30 µL of SDS
sample loading buffer. 1.6% flow-through (FT2) was taken and processed as before. Samples were
loaded on a 13% SDS-PAGE (see section 4.8), transferred to a PVDF-membrane (see section 4.9) and
developed with mouse a-DDDKK antibody (see table 3).
4.11.4 NHS-activated column: Co-IP of endogenous transamidase complex subunits
4.11.4.1 Coupling of a-GPAA1 antibody to NHS-activated column HiTrap® NHS (N-
hydroxysuccinimide)-activated High Performance column (GE17071601, Sigma-Aldrich) was
coupled with an a-GPAA1 antibody (sc-373710, SantaCruz) to immunoprecipitate endogenous
GPAA1 according to manufacturer’s instructions. To verify that the coupling reaction was suc-
cessful before addition of the antibody, a test experiment was performed using BSA. Afterwards,
the experiment was repeated with the antibody.
Briefly, coupling buffer (200 mM NaHCO3, 500 mM Nacl, adjusted to pH 8.3), wash buffer A (500
mM ethanolamine, 500 mM NaCl, adjusted to pH 8.3), wash buffer B (100 mM sodium acetate,
500 mM NaCl, adjusted to pH 4), and activation buffer (1 mM HCl) were filtered through a 0.45
µM filter before use. Antibody was transferred into coupling buffer by using PD-10 columns
(GE17085101, Sigma-Aldrich) and impurities were removed by an amicon Ultra-15 centrifugal fil-
ter unit (UFC901008, Merck). The NHS-column was connected to an GE Healthcare ÄKTA pure,
washed with activation buffer and incubated with the antibody solution (30min/4°C) followed
by three times recirculation of the anitbody solution over the column. Coupling efficiency was
measured according to manufactures instructions. Column was stored at 4°C in storage buffer
(50 mM Na2HPO4 pH 7, 0.1% sodium acetate).
4.11.4.2 Validation of a-GPAA1 coupled NHS-column capability to IP endogenous GPAA1
from HeLa cell line Five dishes of HeLa cells were seeded (5x106/15cm dish) and 24 hours later
transiently transfectedwith GPAA1 encoding plasmid (8 µg/dish) and the corresponding amounts
of Fugene HD (E2311, Promega) according to manufacturer’s instructions. Cells were harvested
24 hours later by washing with ice-cold PBS (15 mL/dish), scraped off in ice-cold PBS and trans-
ferred into pre-cooled 15 mL tube, pelleted (5min/300g/4°C), resuspended pellet in 13 mL lysis
buffer (20mMHEPES-NaOH pH 7.6, 200mMNaCl, 0.5% (v/v) Nonident P40, 1x PIC), incubated on a
test tube rotator for 30 minutes in the cold room, and centrifuged (3min/300g/4°C). Supernatant
was pre-cleared (20min/10000g/4°C, 1h/100000g/4°C) and NHS-column (see section 4.11.4.1) was
equilibratedwith lysis buffer. Pellets from both centrifugation steps weremixedwith SDS sample
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buffer (250 mM Tris, pH 6.8, 12.5 mM EDTA, 500 mM DTT, 10% (w/v) SDS, 25% (v/v) glycerol, 0.1%
(w/v) bromophenol blue) and heated up (5min/95°C). The sample was injected via super loop
(19785001, GE LifeSciences), column was washed with lysis buffer, proteins were eluted with elu-
tion buffer (100 mM glycine pH 3), and 250 µL fractions were taken. Eluted fractions were mixed
1:10 with neutralisation buffer (1 M glycine pH 9). 20 µL of the fractions were mixed with 5 µL
SDS sample buffer and heated up (5min/95°C). After sample application, the flow-through was
mixed with 40 µL three times pre-washed (1 mL lysis buffer/30sec/8200g) FLAG-beads (F2426,
Sigma-Aldrich) and incubated overnight in the cold room. Beads were washed as before, taken
dry, mixed with 30 µL of SDS sample loading buffer and bound protein was eluted by heating up
(15min/90°C). An input sample was taken before mixing sample with beads and a flow-through
sample was taken after the overnight incubation. Both were mixed with SDS sample buffer and
heated up as before. Samples were loaded on a 13% SDS-PAGE (see section 4.8), transferred to a
PVDF-membrane (see section 4.9) and developed with mouse a-DDDKK antibody (see table 3).
4.11.5 FLAG-beads: Separation of transiently expressed transamidase subunits via 2D-gel
electrophoresis
A 2D-gel electrophoresis experiment was conducted to simultaneously analyse protein-lipid in-
teractions of different transamidase subunits (PIGK/T/S and GPAA1). For this experiment, an
Ettan IPGphor 3 IEF System, kindly provided by professor Krauth-Siegel from the BZH Heidel-
berg, was used together with 7 cm long Immobiline® DryStrip pH 3-11 NL(GE17600373, Sigma).
Strips were rehydrated overnight with 150 µL of rehydration solution (7 M urea, 2 M thiourea, 2%
(w/v) CHAPS, 0.5% (v/v) IPG buffer (RPN6301, GE Healthcare), 0.002% bromophenol blue) in an
immobiline drystrip reswelling tray and covered with cover fluid (GE171335-01, GE Healthcare).
Samples used for the experiment were prepared according to the following procedure. HeLa cells
were seeded (2x106 cells per 10 cm dish) and 24 hours later transiently transfected with 4.3 µg
of plasmid DNA (PIGK/T/S or GPAA1) and the corresponding amounts of Fugene HD (E2311, Pro-
mega) according to manufacturer’s instructions. Cells were harvested 24 hours later by washing
with ice-cold PBS (10 mL/dish), scraped off in 1 mL of ice-cold PBS, centrifuged (5min/300g/4°C),
resuspended in 800 µL lysis buffer (20mMHEPES-NaOH pH 7.6, 200mMNaCl, 0.5% (v/v) Nonident
P40, 1x PIC) and incubated for 30 minutes on a test-tube rotator in the cold room. Not solubil-
ised proteins were removed by two centrifugation steps (10min/10000g/4°C, 1h/100000g/4°C)
and 80 µL of the supernatant was mixed with 16 µL of sample loading buffer (250 mM Tris, pH 6.8,
20% (w/v) SDS, 40% (v/v) glycerol, 20% (v/v) b -mercaptoethanol, and 0.02% (w/v) bromophenol
blue). Pellets of the centrifugation steps were mixed with 50 µL of sample loading buffer and all
samples were heated up (10min/95°C). 20 µL of the supernatant sample (2%) and an equal amount
of the pellets (1 µL with 19 µL of sample loading buffer) were loaded on a 13% SDS-PAGE (see sec-
tion 4.8), transferred to a PVDF-membrane (see section 4.9) and developed with mouse a-DDDKK
antibody (see table 3). Supernatants were pooled, mixed with 30 µL three times pre-washed (1
mL PBS/30sec/8200g) FLAG-beads (F2426, Sigma-Aldrich) and incubated overnight. Beads were
washed 3 times with lysis buffer, eluted for 5 minutes with 100 µL of elution buffer (100 mM
glycine-HCL pH 3.5), centrifuged (5sec/8200g), supernatant transferred into new tube, pH adjus-
ted by addition of 10 µL of buffer B (500 mM TRIS-HCL pH 7.4, 1500 mM NaCl), snap frozen in
liquid N2 and stored at -20°C.
After verification of successful expression of the different subunits via western blot, the input
samples as well as the eluted IP fractions were used for 2D-gel electrophoresis. Protein concen-
trations were measured via BCA-Assay (23225, ThermoFisher) and 20 µg of each sample set (input
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IP, eluted IP fraction) were desalted according to Wessel Flügge[101]. Proteins were resuspended
in 30 µL sample preparation solution (7M urea, 2M thiourea, 4% (w/v) CHAPS, 2% (v/v) IPG buffer,
40mM DTT, 0.002% bromophenol blue), pooled together and applied to the IPG strip via cup load-
ing. Isoelectric focussing was performed overnight with a two-step program (Grad at 700V for
12-16 hours and Step at 3000 V for 2-4 hours). After isoelectric focussing, the IPG strip was equi-
librated for SDS-PAGE. First, the strip was rinsedwith H2 before placed in SDS equilibration buffer
(75 mM Tris-HCl pH 8.8, 6 M Urea, 29.3% (v/v) glycerol, 2% (w/v) SDS, 0.002% bromophenol blue)
for 10 minutes each. The strip was then, together with a whatman cellulose filter paper soaked
with 3 µL of SDS-PAGE standard, placed on top of a 12% SDS-PAGE separation gel and overlaidwith
agarose (20 mL Läemmli[100] buffer (60 mM Tris-Cl pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 5%
(v/v) b -mercaptoethanol, 0.01% bromophenol blue), 100 mg agarose, 0.002% bromophenol blue).
After solidification, SDS-PAGE and the following western blot were performed as before. For de-
tection, mouse and rabbit a-DDDKK antibodies were used and the gel was stained with colloidal
coomassie.
To determine hydrophobic properties of different transamidase subunits and their susceptibility
for 2D-gel electrophoresis, the grand average of hydropathy (GRAVY) score was calculated with
the bioinformatics tool http://www.gravy-calculator.de/. Sequences used as input for this tool
are listed in the appendix (see section 8.5).
4.12 CRISPR/Cas9 guided cell line generation and validation containing
C-terminal tagged GPAA1 to study protein-lipid interactions of the
transamidase complex
The general principal of the endogenous tagging of GPAA1 is the introduction of a double strand
break in the genomic sequence of GPAA1. To achieve this, specific guide RNAs (gRNA) target the
CRISPR associated protein 9 (Cas9) into close proximity of the 3’-terminal region of the genomic
GPAA1 sequence. Once in place, Cas9 will introduce a double strand break in the DNA and, by
providing a homologous DNA template containing the 3xFLAG-Twin-Streptag, the cellular homo-
logy directed repair (HDR) mechanism is hijacked. Positive single cell clones are selected via PCR
and insertion is verified by sequencing of the PCR products (see chapter 4.6).
The plasmids necessary to facilitate the addition of a 3xFLAG-Twin-Streptag to the c-terminal part
of endogenous GPAA1 were purchased from Addgene (Cambridge, USA). The vector MLM3636 for
expression of GPAA1 specific gRNAs was a gift from Keith Joung (Addgene plasmid # 43860). The
plasmid hCas9[102] encodes for a human codon optimised caspase 9 and was a gift from George
Church (Addgene plasmid # 41815). The vector containing the tag, AAVS1-Puro-PGK1-3xFLAG-
Twin-Strep[88] was a gift from Yannick Doyon (Addgene plasmid # 68375).
4.12.1 Selection of cell line for endogenous tagging
Different cell lines (human fibroblasts, mouse embryonic fibroblasts H806, mus musculus brain
neuroblastoma N2A, adenocarcinomic human alveolar basal epithelial cell line A549, hepato-
carcinoma cell line Huh-7, cervix carcinoma cell line HeLa, human embryonic kidney cell line
HEK293, lymphoblast-like cell line Raji) were tested for endogenous GPAA1 expression levels to
select a cell line suitable for C-terminal tagging of GPAA1.
Cells were washed once with ice-cold PBS, resuspended (PBS with 2xPIC), centrifuged
(1h/100000g/4°C), resuspended with lysis buffer (PBS, 1% (v/v) Triton-X-100, 0.1% (v/v), 1x PIC)
= 32 =
4 MATERIALS & METHODS
and rotated for one hour on a spinning wheel in the cold room. Protein concentrations were
measured via BCA-Assay (23225, ThermoFisher) and 50 µg of cell lysate were precipitated accord-
ing to Wessel Flügge [101]. Proteins were resuspended in 20 µL SDS sample buffer (250 mM Tris,
pH 6.8, 12.5 mM EDTA, 500 mM DTT, 10% (w/v) SDS, 25% (v/v) glycerol, 0.1% (w/v) bromophenol
blue), heated up (10min/95°C), loaded on a 13% SDS-PAGE (see section 4.8), transferred to a PVDF-
membrane (see section 4.9) and developed with a mouse a-GPAA1 antibody (see table 3). GPAA1
intensities were quantified and compared against the signal of the HeLa cell line.
4.12.2 Design of gRNAs for genomic GPAA1 loci
To design guide RNAs (gRNA), the genomic context of the GPAA1 loci on chromosome 8 was
retrieved from Ensembl (release 84, 25.02.2016, ftp://ftp.ensembl.org/pub/release-84/fasta/
homo_sapiens/dna/, for full sequence see section 8.1) and a search query containing partially
GPAA1 exon 12, the stop codon and a short sequence of the 3’untranslated region (UTR) (CCCT-
GCTGGCTGCTTTTCTGGAATGTGCTCTTCTGGAAGTGAGATCTGCCTGTC) was designed and used as
input for the gRNA prediction tool CRISPR Design (http://crispr.mit.edu/) from the Zhang
lab (MIT, USA) to retrieve possible gRNA candidates. The top 3 candidates were ordered as
5’-phosphorylated single stranded nucleotides (biomers.net GmbH) containing 5’-ACACC and 3’-G
on the plus strand as well as a 5-’AAAAC and 3’-G on the minus strand (see table 7 for the full se-
quences). Plus and minus strands oligonucleotides for each gRNAs were mixed in a 1:1 ratio and
heated upuntil 95°C before stepwise lowering the temperature to 4°C to create gRNAdimers ready
for insertion into the gRNA vector MLM3636.
4.12.3 Cloning of gRNAs into MLM3636
10 µg of MLM3636 were digested (30min/50°C) with 25 units BsmBI (R0580S, New England Bio-
labs), heat-inactivated (20min/80°C) and ethanol precipitated. In short: One tenth volume of
sodium acetate pH 5.0 and two and a half volume of 100% EtOH were added to digested plasmids.
DNA was precipitated (20min/-20°C), centrifuged (15min/17900g), pellet washed with 1 mL 70%
EtOH (5min/17900g), and air dried. Pellet was resuspended in 20.25 µL H2O and dephosporylated
(30min/37°C) with 25 units calf intestinal alkaline phosphatase (M0290L, New England Biolabs).
Finally, DNA was separated by agarose gel electrophoresis and fragments of interest were puri-
fied with the QIAquick Gel Extraction Kit (28706, Qiagen). To insert the gRNA into MLM3636, the
amount of insert and vector DNA needed for the ligation reaction were calculated according to
the following formula.
insert [ng]= insert size [bp]vector size [bp] ng of vector5 (for blunt end) or 3 (for sticky end) ligation
T4 DNA Ligase (M0202S, New England Biolabs) catalysed ligation reaction took place at 16°C
overnight in a total volume of 10 µL and bacteria were transformed as described before (see sec-
tion 4.4).
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4.12.4 Determination of gRNA capabilities to induce double strand breaks in genomic
GPAA1
To determine the capability of selected gRNAs to introduce double strand breaks in the genomic
region of GPAA1, HelaDS1PL cells were seeded at a concentration of 1x105cells/6-well and co-
transfected 24 hours later with 0.6 µg of MLM3636-gRNA# 1-3 and hCas9, respectively. After 24
and 72 hours transfection, cells were washed twice with ice-cold PBS, scraped off in 500 µL PBS
and pelleted (5min/3000g/4°C). After resuspension in 200 µL PBS, genomic DNA was extracted
according to manufactures instructions with the DNeasy Blood & Tissue Kit (69504, Qiagen) and
used for amplification of a 1350bp long fragment covering the area around the STOP codon of the
genomic GPAA1 loci. For this, the primer pair genomic_GPAA1_FW2 and genomic_GPAA1_REV2
was used (see table 8). PCR fragments from wild-type and gRNA transfected cells were mixed in
a 1:1 ratio, heated up (10min/95°C) to create single stranded DNA fragments which then were
allowed to form DNA-heteroduplexes by stepwise temperature reduction to 4°C. Employing the
fact that specific nuclease exist that cut mismatched double stranded DNA, such as the result of
an error in the double strand break repair mechanism, the surveyor mutation detection kit for
standard gel electrophoresis (71269249, Integrated DNA Technologies, Belgium) was used accord-
ing to manufactures instruction to determine which gRNA was able to introduce a double strand
break.
4.12.5 Design and cloning of homology arms for creation of 3xFLAG and 2xStrep-tag donor
plasmid
To generate the donor plasmid carrying the homology directed repair template, a 747bp long
section upstream and a 776bp long section downstream of the genomic GPAA1 stop codon se-
quence were selected and complemented with restriction enzyme target sequences (5’-NdeI/3’-
NgoMIV for the upstream section, 5’-BstBI/3’-EcoRI for the downstream section) as well as a
short 5’- and 3’-poly(A)-section to facilitate restriction enzyme binding. All mentioned enzymes
(R0111S/R0564S/R0519S/R3101S) were obtained from New England Biolabs. The upstream sec-
tion represents the left homology arm (LHA), while the downstream section represents the right
homology arm (RHA). LHA andRHAwere synthesized as g-Block fragments (Integrated DNATech-
nologies, Belgium). For exact sequences used, see section 8.4. 100 ng of LHA were digested with
20 units of NdeI and NgoMIV (30min/37°C) and the ready-to-insertion fragments were gel puri-
fied as described in section 4.12.3. 33ng of the LHA were used in an overnight ligation reaction
with 50 ng of NdeI/NgoMIV digested pAAVS1_Puro_PGK1_3xFLAG_Twin_Strep. Following heat-
inactivation (20min/65°C), the ligation reaction was used for transformation (see section 4.4) of
E. coli DH-5a . After verification of successful integration of the LHA, 10 µg of plasmid were se-
quentially digested with 30 units of EcoRI (1h/37°C, 20min/65°C heat-inactivation) and 30 units
BstBI (1h/65°C). 50 ng Methanol precipitated plasmid (see section 4.12.3) was then used for liga-
tion reaction with 39 ng identically digested RHA g-BLock fragment. Finally, clones were tested
by sequencing for correct insertion of LHA and RHA and used for the CRISPR experiment.
4.12.6 Endogenous tagging of GPAA1 and selection of positive clones
HelaDS1PL cells were seeded at a concentration of 1x106cells on a 10 cm dish and 24 hours
later triple transfected with 2 µg MLM3636-gRNA#1-3, 2 µg hCas9 and 4 µg of the donor plas-
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mid as described in [88]. After 72 hours of transfection, single cell clones, derived by serial di-
lutions, were seeded in 96 well plates and propagated until 6-well format was reached. At this
point cells were harvested and genomic DNA was extracted as before (see section 4.12.4) and
success of tag integration was determined for each single cell clone via PCR with the primer
pair genomic_GPAA1_FW2/genomic_GPAA1_REV2 (see table 8). Clones containing one band at
1527bp were expected to be a successful homozygous tag integration, while one band at 1350bp
defined a wild-type clone. Having two bands at the respective heights were termed a hetero-
zygous integration, containing wild-type and tagged allele of GPAA1. Verification of clones
was achieved by gel-purification of the PCR product and amplification with the primer pair
genomic_GPAA1_FW3/REV3 (see table 8). The 1356bp product was digested with EcoRI/XhoI
(40min/37°C, heat-inactivated for 20min/65°C), ethanol precipitated (see section 4.12.3), ligated
into EcoRI/XhoI digested pCMV6 (4816bp), and transformed into bacteria as before (see section
4.4). Finally, positive clones were verified by sequencing as described in 4.6 with the primers
genomic_GPAA1_FW2 and genomic_GPAA1_REV2 from table 8.
4.12.7 Affinity enrichment of endogenous C-terminal tagged GPAA1
The following experimentswere conducted to determine if the endogenous addition of C-terminal
3xFLAG and 2xStrep-tag allows for affinity enrichment of GPAA1. For experiments regarding the
ability to enrich transamidase complex subunits over the FLAG-tag, see section 4.12.8.
4.12.7.1 Streptactin affinity enrichment of endogenous GPAA1 from whole cell lysate To
determine conditions for successful enrichment of endogenous GPAA1 with streptactin-beads
(2120125, Iba), the following experiment was conducted. Three dishes of HeLaDS1PL GPAA1#76
cells were seeded (3x106 cells/ 10 cm dish) per condition. 24 hours later, cells were washed once
with ice-cold PBS, scraped off in 1 mL ice-cold PBS, centrifuged (5min/3000g/4°C), resuspended
in 1 mL lysis buffer (100 mM Hepes-NaOH ph 7.4, 100 mM NaCl, 1% (v/v) Triton-X-100, 0.1% (v/v)
Na-deoxycholate, 2x PIC) and rotated for 1 hour on a test tube rotator in the cold room. Su-
pernatant was cleared up by two centrifugation steps (20min/10000g/4°C and 1h/100000g/4°C)
and all three tubes of one condition were pooled. 150 µL were taken out as an input sample and
MeOH/CHCl3 preciptated as described in 4.12.7.2 with the following volumes used for first step:
600 µL MeOH, 300 µL CHCl3, 450 µL H2O. Samples were resuspended (10 µL 4% SDS in lysis buf-
fer, 10min/1400rpm/37°C), mixed with 10 µL SDS sample buffer (250 mM Tris, pH 6.8, 12.5 mM
EDTA, 500 mM DTT, 10% (w/v) SDS, 25% (v/v) glycerol, 0.1% (w/v) bromophenol blue), heated up
(10min/95°C) and stored at -20°C. The supernatant was diluted with lysis buffer to a final volume
of 9 mL and 10% SDS containing lysis buffer was added to a final concentration of 0.1% SDS. The
sample was mixed with 60/400 µL of three times pre-washed (800 µL lysis buffer, 1min/100g/4°C)
streptactin-beads slurry (2120125, Iba) and rotated overnight on a test tube rotator in the cold
room. Beads were washed as before and flow-through was taken and precipitated as the input
sample. Beads were taken dry, mixed with 400 µL of elution buffer (SDS sample buffer with
30 mM biotin), incubated (15min/RT), heated up (15min/95°C), distributed into 2 mL tubes and
MeOH/CHCl3 preciptated (800 µL MeOH, 400 µL CHCl3, 600 µL H2) and resuspended (20 µL 4% SDS
in PBS, 10min/1400rpm/37°C) and transferred into a new tube. Samples were loaded on a 7.5%
SDS-PAGE (see section 4.8), transferred to a PVDF-membrane (see section 4.9) and developed with
a mouse a-DDDKK antibody (see table 3).
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4.12.7.2 Streptactin affinity enrichment of Alexa-647-N3 clicked whole cell lysate and
MeOH/CHCl3 precipitation steps HeLaDS1PL GPAA1#76 cells were seeded (4x106 cells/ 10
cm dish). 24 hours later, cells were washed once with 10 mL PBS and labeled with 5 mL of
labeling media (DMEM containing Pen/Strep, DL-FBS (delipidated FBS) and 5 µM pacSph). After
4 hours of labeling time, cells were washed 3x with 10 mL ice-cold PBS, then overlayed with
5 mL and subjected to UV-light irradiation under a high intensity lamp for 5 min. PBS was
aspirated and cells were scraped off in 1 mL ice-cold PBS and centrifuged (5min/4°C/3000g).
The pellet was taken up in 1 mL lysis buffer (PBS, 1% (v/v) Triton-X-100, 0.1% (v/v) SDS, 0.125
U/mL benzonase, 2x PIC), resuspended by sonication (5x10 seconds, on ice between) and lysis
was performed for 2 hours on a test-tube rotator in the cold room. Supernatant was centrifuged
twice (20min/10000g/4°C, 1h/100000g/4°C), distributed equally on four tubes (250 µL/tube) and
snap frozen in liquid N2 and stored overnight at -20°C.
Proteins were two times MeOH/CHCl3 precipitated. First, samples were sequentially mixed with
600 µL MeOH/200 µL CHCl3/850 µL H2O, centrifuged (5min/14000g/RT), upper phase removed,
400 µL MeOH added, centrifuged (30min/14000g/RT, swing out rotor) and supernatant decanted.
Pellet was air-dried, resuspended (vortex/sonicate/37°C at 1400rpm) in 50 µL buffer A (4%
SDS in PBS, 2x PIC) and diluted to 1% SDS by addition of 150 µL buffer B (PBS, 2x PIC). For the
second precipitation round, 480 µL MeOH, 160 µL CHCl3, and 680 µL H2O were used. Protein
concentrations were measured via BCA-assay (23225, ThermoFisher) and adjusted to 100 µg per
tube. 3.25 µL of the click mix (1.36 µL 40 mM CuSO4 in H2O, 1.08 µL 50 mM TCEP H2O, 0.54 µL
10 mM TBTA, and 0.54 µL 10 mM Alexa-647-N3) was added to 200 µL supernatant and incubated
in the dark (4h/1000rpm/37°C). Afterwards, the click reaction was two times MeOH/CHCl3
precipitated as before, only that samples were pooled between the first and the second precipit-
ation, snap frozen in N2 and stored overnight at -20°C. After the second precipitation, 10% input
sample was taken, mixed with SDS sample buffer (250 mM Tris, pH 6.8, 1.8% (w/v) SDS, 45%
(v/v) glycerol, 22.5% (v/v) b -mercaptoethanol and 0.003% (w/v) bromophenol blue) and heated
up (10min/95°C). The rest of the sample was diluted to 0.1% SDS concentration by addition
of lysis buffer, mixed with 50 µL three times pre-washed (800 µL lysis buffer, 1min/100g/4°C)
streptactin-beads (2120125, Iba) and rotated for 2 hours on a test tube rotator in the cold room.
Beads were washed three times with lysis buffer, proteins were eluted by addition of 15 µL
elution buffer (100 mM Tris/HCl pH 6.8, 4% SDS (w/v), 4% (v/v) b -mercaptoethanol), heated up
(15min/95°C) and transferred into a new 1.5 mL tube. Beads were subjected to a second elution
step (20 µL SDS sample buffer, 15min/95°C), supernatant taken off an pooled with first elution
step. 0.3% flow-through (FT) sample was taken and treated as the input sample before. Samples
were loaded on a 7.5% SDS-PAGE (see section 4.8), in-gel fluorescence was measured, transferred
to a PVDF-membrane (see section 4.9) and developedwith amousea-GPAA1 antibody (see table 3)
4.12.7.3 Streptactin affinity enrichment of Alexa-647-N3 clicked whole cell lysate and
MeOH precipitation steps This experiment was, except the listed changes in this paragraph,
conducted as before (see 4.12.7.2) to investigate the possibility to exchange the MeOH/CHCl3 pre-
cipitation steps with MeOH precipitation steps. Cell lysate was distributed in 4 tubes with each
200 µL and directly snap frozen in N2. After samples were thawed up, a BCA-Assay (23225, Ther-
moFisher)was conducted and 3.25 µL of clickmixwere added to each aliquot. Click reactionswere
stopped by addition of 1.8 mL of ice-coldMeOH and stored overnight at -80°C. Samples were cent-
rifuged (20min/17000g/4°C in a swing out rotor), pellets resuspended (vortex/sonication) in 1mL
of MeOH, and centrifuged as before. This step was redone 1-3 times and finally the pellets were
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air dried and resuspended with 20 µL of 4% (w/v) SDS in PBS. Aliquots were pooled and protein
concentrations were determined by BCA-Assay. Samples were diluted to 0.1% SDS concentration
by addition of lysis buffer, mixed with streptactin beads, and incubated on a test tube rotator
(1h/RT in the dark). Beads were washed three times, 20 µL 3 mM biotin (29129, ThermoFisher)
was added to the beads, incubated for 15 minutes, heated up (15min/95°C), and supernatant was
transferred to a new tube. For each sample, 400 µL flow-through (3.5%) was taken, split into two
2 mL test tubes, precipitated according to Wessel Flügge [101], resuspended in 20 µL of 4% (v/v)
SDS in lysis buffer, pooled, mixed with 10 µL SDS sample buffer (250 mM Tris, pH 6.8, 12.5 mM
EDTA, 500 mM DTT, 10% (w/v) SDS, 25% (v/v) glycerol, 0.1% (w/v) bromophenol blue) and heated
up (10min/95°C). SDS-PAGE and the rest of the experiment was conducted as before (see section
4.12.7.2).
In a variation of this experiment, the click reaction was diluted to 0.1% SDS concentration and
directly applied to the streptactin beads, without previous precipitation steps, and incubated
overnight.
4.12.7.4 Neutravidin affinity enrichment of Alexa-647-N3 clicked whole cell lysate To
verify that the strep tag did not interact in anywaywithneutravidin-beads (29202, ThermoFisher)
used for the biotin click protocol, an Alexa-647-N3 experiment as described in 4.12.7.2 was con-
ducted. The only difference was that, instead of Streptactin-beads for affinity enrichment,
neutravidin-beads were used.
4.12.8 Separation of endogenous transamidase subunits via SDS-PAGE
To analyse if it is possible to separate the endogenous subunits with comparablemolecularweight
(PIGS/T and GPAA1) via SDS-PAGE, different commercially available kits as well as a hand made
gel electrophoresis chamber were compared. The commercial kits NuPAGE™ 4-12% Bis-Tris pro-
tein gel, NuPAGE™ 7% Tris-Acetate protein gel and the Bolt™ 8% Bis-Tris plus gel (NP0321BOX,
EA0355BOX, NW04120BOX, ThermoFisher) were used according to manufactures instructions.
Additionally, 7% and 10% tris-glycine gels (as described in 4.8) were compared and run until only
the 37 kDa protein marker band was left on the gel. Furthermore, a hand made 7% tris-glycine
gel with dimensions 18x16cm was cast to see if the elongated separation gel allows for speara-
tion of the subunits. This gel was then transferred to a Trans-Blot® Cell(1703946,Bio-Rad), kindly
provided by RG Wieland from the BZH Heidelberg, blotted for 16 hours, the PVDF-membrane cut
into four equal size sections, and developed as described before (4.9). To measure the effective
separation range, the width of the marker sizes and the distance between the 37, 50 and 75 kDA
bands were measured with a ruler.
Samples were prepared as follows: fully confluent 15 cm dishes with HeLaDS1PL GPAA1#76 cells
were washed once with ice-cold PBS, scraped off, centrifuged (5min/3000g/4°C), resuspended in
1 mL lysis buffer (100 mM HEPES-NaOH pH 7.5, 100 mM NaCl, 1% (v/v) Triton-X-100, 0.1% Na-
Deoxycholate, 1xPIC), rotated for 1 hour on a spinning wheel in the cold room, centrifuged twice
(20min/10000g/4°C, 1h/100000g/4°C) and used for IP as described in 4.11.1.
4.12.9 Purification of endogenous transamidase complex using styrene maleic anhydride
(SMA) co-polymer
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4.12.9.1 FLAG-IP of endogenous transamidase complex after solubilisation with SMA A
fully confluent 15 cm dish of HeLaDS1PL GPAA1#76 was used for the experiment. Cells were
washed with 13 mL ice-cold PBS, scraped off in 1 mL ice-cold PBS in a 1.5 mL ultracentrifuge
tube, centrifuged (5min/3000g/4°C), and supernatant was aspirated and pellet’s wet weight was
determined. The pellet was resuspended with 500 µL homogenisation buffer (100 mM Hepes pH
7.2, 500mMNaCl, 2x PIC, 1 µL benzonase/2mL buffer) per 25mgwet weight by pipetting and son-
ication until solutionwas homogeneous. 1 µL of cell solutionwasmixedwith 4 µL homogenisation
buffer and 5 µL trypan blue and applied to a Neubauer counting chamber to verify successful dis-
ruption of the cell wall. Membrane fractions were created by centrifugation (1h/100.000g/4°C/)
and the wet weight of the pellet was determined. To aid formation of styrene maleic anhydride
co-polymer (XIRAN SL30010 S30, Polyscope) micro domains, protein solutions were adjusted to
42.5 mg/mL. Volume of SMA lysis buffer needed for solubilisation was calculated according to the
following formula. wet weight pellet42:5mgmL
 1000 = Volume of 2.5% SMA solution. A 10% SMA stock was
created (100 mM Hepes, pH 6.5, 500 mM NaCl, 2x PIC, 10% SMA) and the protein was resuspen-
ded as before in 75% of the calculated volume with SMA devoid buffer (100mM Hepes pH 6.5, 500
mM NaCl, 2.66x PIC). To create a 2.5% SMA concentration in the lysate, the solution was adjusted
to the calculated volume by addition of the 10% SMA stock. Lysis was performed for 2 hours on
test tube rotator in the cold room. Samples were centrifuged (1h/100000g/4°C), 10% of the su-
pernatant was taken as input sample, buffer was added until a final volume of 100 µL, and stored
overnight at -20°C. The rest of the supernatant was mixed with 50 µL three times pre-washed
(1 mL buffer, 1min/500g/4°C) FLAG-beads (F2426, Sigma-Aldrich) and incubated overnight on a
test-tube rotator in the cold room. Beads were washed as before and 10% flow-through was taken
and adjusted to 100 µL. Input and sample were precipitated according to Wessel Flügge [101]. Pel-
lets were resuspended in 40 µL sample buffer (250 mM Tris, pH 6.8, 20% (w/v) SDS, 40% (v/v)
glycerol, 20% (v/v) b -mercaptoethanol, and 0.02% (w/v) bromophenol blue) and heated up (10
min/95°C). Proteins were eluted from the beads by addition of 40 µL sample buffer under the
same conditions. All samples were loaded on a 13% SDS-PAGE (see section 4.8), transferred to a
PVDF-membrane (see section 4.9) and sequentially developedwith rabbita-PIGU/K/T andmouse
a-DDDKK antibody (see table 3).
The same experiment was repeated, this time with the order of sequentially administered anti-
bodies being rabbit a-PIGK/S and mouse a-DDDKK antibody.
4.12.9.2 FLAG-IP of endogenous transamidase complex after solubilisation with SMA and
mass spectrometric analysis Experiment was performed as described in section 4.12.9.1 with
the following differences: 8x15 cm dishes of HeLaDS1PL GPAA1#76 were seeded. On day two,
beads were washed, transferred to a glass tube, volume was brought to 500 µL with wash buffer
and handed to Iris Leibrecht for lipid extraction. Mass spectrometric analysis was performed
jointly with Christian Lüchtenborg (both RG Brügger).
4.12.10 Validation of transamidase function by monitoring GPI-anchor protein CD59 sur-
face arrival via surface biotinylation
HeLaDS1PL GPAA1#76 and HeLaDS1PL cells were seeded (3x105 cells/ 6-well) and 24 hours later
transfected with 1 µg pME-mCherry-FLAG-CD59-GPI, which was a gift from Reika Watanabe (Ad-
dgene plasmid # 50378). After 48 hours, cells were washed once with PBS Ca/Mg (1 mM MgCl2,
0.1 mM CaCl2), incubated under shaking conditions (30min/4°C) with incubation buffer (824 mM
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Sulfo-NHS-SS-Biotin, 10 mM Triethanolamine pH 9.0, 150 mM NaCl, 2 mM CaCl2), washed with
quenching buffer (PBS Ca/Mg, 100 mM Glycine), and incubated 20 minutes under previous con-
ditions. Cells were washed with ice-cold PBS, scraped off, centrifuged (5min/3000g/4°C), and
the pellet was resuspended in 300 µL lysis buffer (PBS, 1% (v/v) Triton-X-100, 0.1% (w/v) SDS
in PBS, 2x PIC) by pipetting and sonication until solution was quite homogeneous. After lysis
(15min/1200rpm/24°C) and centrifugation (10min/16000g/4°C), supernatant was transferred
into a new tube, 30 µL were taken out as 10% input sample and stored at -20°C. The rest of the
supernatant was mixed with 50 µL three times pre-washed (500 µL lysis buffer, 1min/3000g/4°C)
high capacity BCA-assay beads (29202, ThermoFisher) and incubated overnight on a test-tube ro-
tator in the cold room. Beadswerewashed as before and 10% flow-through (FT) samplewas taken.
Input and FT weremixed 1:1 with SDS sample buffer (250mMTris, pH 6.8, 12.5 mM EDTA, 500mM
DTT, 10% (w/v) SDS, 25% (v/v) glycerol, 0.1% (w/v) bromophenol blue). 50 µL of SDS sample buf-
fer were added to elute proteins from beads. All samples were incubated (30min/1000rpm/50°C)
before being loaded on a 13%SDS-PAGE (see section 4.8), transferred to a PVDF-membrane (see
section 4.9) and sequentially developed with rabbit a-DDDKK and a-CD59 antibody (see table 3)
Input and eluate signal intensities were quantified and derived ratios (eluateinput ) used to test for dif-
ference between both cell lines via two-sided T-Test.
4.13 Analysis of protein-lipid interactions of transiently transfected
GPAA1
4.13.1 Optimisation of pacSph labeling of transiently transfected GPAA1 in HeLaDS1PL
cells
4.13.1.1 CuAAC of Alexa-647-N3 on FLAG-beads with Nonident P40 HeLaDS1PL cells were
seeded (1:5x105 cells per 6-well) and 24 hours later transiently transfectedwith 0.75 µg of plasmid
DNA encoding for GPAA1 and the corresponding amounts of Fugene HD (E2311, Promega) accord-
ing to manufacturer’s instructions. The next day, cells were washed once with PBS before 1 mL
labelingmedia (DMEMcontaining Pen/Strep, delipidated FBS, 3 µMpacSph)was added and incub-
ated for 30 minutes (37°C/5% CO2). Cells were washed with ice cold PBS (3x 1 mL), overlaid with 1
mL ice-cold PBS, subjected to UV-light irradiation under a high intensity lamp for 5 min, scraped
off in 1 mL of ice-cold PBS, centrifuged (5min/3000g/4°C) and the pellet resuspended in 100 µL
of lysis buffer (20 mM HEPES-NaOH pH 7.5, 200 mM NaCl, 1% (v/v) Nonident P40, 1x PIC). Lysis
was performed on a test-tube rotator (1h/4°C) in the cold room, centrifuged (8min/16000g/4°C),
supernatant transferred into a new 1.5 mL tube and diluted to a concentration of 0.1% Nonident
P40 by addition of 900 µL of lysis buffer without Nonident P40. 30 µL supernatant were used as IP
input sample, mixed with 7.5 µL of SDS sample buffer (250 mM Tris, pH 6.8, 12.5 mM EDTA, 500
mM DTT, 10% (w/v) SDS, 25% (v/v) glycerol, 0.1% (w/v) bromophenol blue) and the rest of the
supernatant was mixed with 50 µL three times pre-washed (1 mL lysis buffer with 0.1% Nonident
P40, 30sec/8200g/4°C) FLAG-beads (F2426, Sigma-Aldrich) and incubated overnight on a test-tube
rotator in the cold room. Pellets were mixed with 50 µl SDS sample buffer and stored at -20°C
overnight. Beads were washed four times as before and 30 µL of flow-through sample were taken
and mixed with 7 µL of SDS sample buffer. Protein on the beads were subjected to CuAAC. In
short, 0.68 µL 40 mM CuSO4 in H2O, 0.54 µL 50 mM TCEP H2O, 1.08 µL 10 mM TBTA, and 0.27 µL
10 mM Alexa-647-N3 were mixed, added to the beads, incubated in the dark (3h/800rpm/37°C)
and finally heated up together with the other samples (10min/70°C) after addition of 25 µL SDS
sample buffer. Samples were loaded on a 13% SDS-PAGE (see section 4.8), in-gel fluorescence was
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measured before proteins were transferred to a PVDV-membrane (see section 4.9) and developed
with antibody against DDDDK-tag (rabbit, see table 3).
To analyse if the addition of the fluorophor plays a role in the weak GPAA1 signal after the click
reaction on the beads, HeLaDS1PL cells were processed as before, labeled for 15 minutes with
1.5 mL of 3µM pacSph labeling media, and split before the IP. One sample was afterwards sub-
jected to click reaction, while the other one was not. The samples that did undergo the click
reaction where eluted in two steps. First, 25 µL SDS sample buffer were added, the sample heated
up (10min/70°C), centrifuged (30sec/8000g/RT) and supernatant transferred into a new 1.5 mL
tube. Second step, 25 µL of SDS sample buffer were added, the sample heated up (10min/95°C),
centrifuged and all off the sample were subjected to SDS-PAGE as before.
4.13.1.2 CuAAC of Alexa-647-N3 in whole cell lysate with Nonident P40 HeLaDS1PL cells
were seeded (1:5x105 cells per 6-well) and 24 hours later transiently transfected with 0.75 µg of
plasmid DNA encoding for GPAA1 and the corresponding amounts of Fugene HD (E2311, Promega)
according to manufacturer’s instructions. The next day, cells were washed once with PBS before
addition of 1 mL labelling media (DMEM containing Pen/Strep, delipidated FBS, 4.5 µM pacSph)
and incubated for 30 minutes (37°C/5% CO2). Cells were washed with ice cold PBS (3x 1 mL), over-
laid with 1 mL ice-cold PBS, subjected to UV-light irradiation under a high intensity lamp for
5 min, scraped off in 1 mL of ice-cold PBS, centrifuged (5min/16000g/4°C) and the pellet resus-
pended in 230 µL of lysis buffer (20 mM HEPES-NaOH pH 7.5, 200 mM NaCl, 1% (v/v) Nonident
P40, 1x PIC). Lysis was performed on a test-tube rotator (1h/4°C) in the cold room, centrifuged
(8min/16000g/4°C), supernatant transferred into a new 1.5 mL tube and 3.25 µL of the click mix
(1.36 µL 40 mM CuSO4 in H2O, 1.08 µL 50 mM TCEP H2O, 0.54 µL 10 mM TBTA, and 0.54 µL 10 mM
Alexa-647-N3) was added to 200 µL supernatant and incubated in the dark (4h/1000rpm/37°C).
The other 30 µL were used as input sample before click and mixed with 12 µL of SDS sample buf-
fer (250 mM Tris, pH 6.8, 12.5 mM EDTA, 500 mM DTT, 10% (w/v) SDS, 25% (v/v) glycerol, 0.1%
(w/v) bromophenol blue). The cell pellet was mixed with 50 µL of SDS sample buffer and both
samples were heated up (10min/95°C) before being stored overnight at -20°C. The click reaction
was stopped by addition of 1.8 mL of ice-cold methanol and stored at -80°C until the next day.
Methanol precipitated proteins were pelleted (20min/17000g/4°C), supernatant decanted, resus-
pended in 1 mL ice-cold methanol (vortex, sonication) and again pelleted. This step was done
twice, pellets were resuspended, air dried for 10 minutes, and resuspended (vortex, sonication)
in 20 µL 4% SDS. Sample was diluted to 1:10 by addition of 180 µL of 0.1% Nonident P40 lysisbuffer
before 10 µL of input IP sample (+ 5 µL of SDS sample buffer) were taken and the sample ulti-
mately being diluted to 0.1% SDS concentration. The sample was then incubated overnight on
50 µL three times pre-washed (1 mL lysis buffer with 0.1% Nonident P40/1min/8000g/4°C) FLAG-
beads (F2426, Sigma-Aldrich). Beads were washed 3 times as before, taken dry and eluted (30 µL
SDS sample buffer) by heating up (10min/95°C) and flow-through sample was taken (100 µL + 25
µL SDS sample buffer). SDS-PAGE and western blot were done as described in section 4.13.1.1.
4.13.1.3 Efficiency of Nonident P40 and Triton-X-100 on CuAAC in whole cell lysate Ex-
periment was performed as described in 4.13.1.2, except the following changes. 300 µL of two
different lysis buffer (A: 20 mMHEPES-NaOH pH 7.5, 200 mMNaCl, 1% (v/v) Nonident P40, 2x PIC,
B:100mMHEPES-NaOH pH 7.5, 100 mMNaCl, 1% (v/v) Triton-X-100, 0.1% (w/v) Na-deoxycholate,
2x PIC) were compared. After lysis cells were pelleted (10min/3000g/4°C) and everything was
transferred to 2 mL tubes. After resuspension in 4% SDS, samples were diluted to 0.1% SDS with
a Tritin-X-100 (1% (v/v) Triton-X-100 in PBS, 2xPIC) based buffer. The same buffer was used to
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wash the beads. Proteins were eluted two times with 25 µL SDS sample buffer (100 mM Tris, pH
8.3, 4 M Urea, 8% (w/v) SDS, 10% (v/v) glycerol, 50 mM DTT, and 0.01% (w/v) bromophenol blue)
from beads by heating up (10min/75°C).
4.13.2 Analysis of sphingolipid binding kinetics of transiently expressed GPAA1 by con-
tinuously labeling with pacSph and detection with Alexa-647-N3
HeLaDS1PL cells were seeded (1:5x105 cells per 6-well) and 24 hours later transiently transfec-
ted with 1 µg of plasmid DNA encoding for GPAA1 or P24 and the corresponding amounts of Fu-
gene HD (E2311, Promega) according to manufacturer’s instructions. The next day, cells were
washed once with PBS before addition of 2 mL labeling media (DMEM containing Pen/Strep, de-
lipidated FBS, 2 µM pacSph) and incubated for 15/60/120/180/360 minutes (37°C/5% CO2). Cells
were washed with ice-cold PBS (4x 1 mL), overlaid with 1 mL ice-cold PBS, subjected to UV-light
irradiation under a high intensity lamp for 5 min, scraped off in 500 µL of ice-cold PBS, centri-
fuged (5min/3000g/4°C), pellet resuspended in 300 lysis buffer (100 mM HEPES-NaOH pH 7.5, 100
mM NaCl, 1% (v/v) Triton-X-100, 0.1% (w/v) Na-deoxycholate, 2x PIC). Lysis was performed on a
test-tube rotator (1h/4°C) in the cold room, centrifuged (8min/16000g/4°C), supernatant trans-
ferred into a new 1.5mL tube, 15 µL input sample weremixedwith 15 µL of SDS sample buffer (100
mM Tris, pH 8.3, 4 M Urea, 8% (w/v) SDS, 10% (v/v) glycerol, 50 mM DTT, and 0.01% (w/v) bro-
mophenol blue), and pellets were mixed with 50 µL of sample buffer. Supernatant was subjected
to click reactions with Alexa-647-N3 as described in 4.13.1.2.
4.13.3 Analysis of sphingolipid binding kinetics of transiently expressed GPAA1 by pulse-
chase labeling with pacSph and detection with Alexa-647-N3
Experiment was done as described in section 4.13.2. Variations of this procedure were the fol-
lowing. First, cells were pulse-chase labeled with 2 µM pacSph as described in 4.13.5. Second,
cells were clicked on FLAG-beads as described in 4.13.1.1. Third, lysis buffer used in this exper-
iment was (100 mM HEPES-NaOH pH 7.5, 100 mM NaCl, 1% (v/v) Triton-X-100, 0.1% (w/v) Na-
deoxycholate, 2x PIC).
4.13.4 Comparing pulse-chase and continuously labeling of transiently expressed GPAA1
with pacSph and detection with Alexa-647-N3
Experiment was done as described in section 4.13.3. The single variation was, that only the con-
centrations 2 and 6 µM were tested for 6 hours.
4.13.5 Analysis of sphingolipid binding kinetics of transiently expressed GPAA1 by pulse-
chase labeling with pacSph and detection with biotin-azide
For each indicated condition, one 10 cm dish (2x106 cells per dish) and one 6-well of HelaDS1PL
cells (3x105 cells per well) in DMEM (10% FBS, Pen/Strep) were seeded 24 hours before trans-
fection. Cells were transfected the next day with plasmid DNA containing either GPAA1 or the
known sphingomyelin binding protein p24 [15] (transfection mix: 5.8 µg DNA, added up Op-
tiMEM until 282.6 µL, 17.4 µL Fugene HD). The next day, cells were washed once with ice-cold
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PBS before addition of 5 mL (10cm dish) or 2 mL (6-well) of 2 µM pacSph containing labeling
media (DMEM containing Pen/Strep, DL-FBS (delipidated FBS)). After 10 min of labeling, cells
were washed four times with PBS and then overlaid with normal DMEM growth medium. For
the 10 cm dishes, the media was aspirated at indicated time points (0/15/60/120/240min), cells
were overlaid with 5 mL of ice-cold PBS, subjected to UV-light irradiation under a high intensity
lamp for 5 min, scraped off in 1 mL ice-cold PBS, centrifuged (5min/4°C/3000g), resuspended in
lysis buffer (1xPBS, 2xPIC, 0.125 U/µL benzonase (71206, Merck)) by 5x5 seconds of sonification,
and incubated for 1 hour on ice before addition of 23 µL lysis reagent (10% SDS in PBS, 2xPIC).
Samples were heated up (10min/70°C), centrifuged (5min/4°C/3000g) and the supernatant trans-
ferred into 2 mL eppendorf tubes. To remove not cross-linked pacSph, proteins were two times
MeOH/CHCl3 precipitated. First, 607 µL MeOH, 202 µL CHCl3, and 800 µL H2O were mixed, cent-
rifuged (5min/14000g/RT), the upper phase removed, 300 µL MeOH added and once more cent-
rifuged (30min/14000g/RT, swing out rotor). Pellet was air-dried, resuspended (vortex/sonic-
ate/37°C at 1400rpm) in 50 µL buffer A (4%SDS in PBS, 2x PIC) and diluted to 1% SDS by addition of
150 µL buffer B (PBS, 2xPIC). For the second precipitation round, 480 µL MeOH, 160 µL CHCl3, and
680 µL H2Owere used. Half of the samplewas frozen in N2 and stored at -80°C, while the other half
was subjected to click reactions. 25 µL click mix consisted out of 5 µL 25 mM CuS04, 5 µL 25 mM L-
ascorbic acid (both in H20), 5µL 2.5mMbiotin-azide and 5 µL 2.5mMTBTA (both in DMSO). CuS04,
L-ascorbic acid and TBTA were prepared freshly, while 25 mM biotin-azide aliquots were stored
at -20°C. CuS04, L-ascorbic acid and biotin-azide were brought together, vortexd for 10 seconds,
spun down and incubated for 2 min at RT before TBTA was added. After 3h/37°C/800rpm in the
dark, 75 µL PBS were added and the samples were once more MeOH/CHCl3 precipitated, resus-
pended in 50 µL buffer A, frozen in liquid N2 and stored at -20°C overnight. The 6-well samples
were washed once with ice-cold PBS, then scraped off in 500 µL MeOH and stored at -80°C until
time of lipid extraction for TLC.
The next day, samples were thawed up (10min/37°C/1400rpm), 150 µL of PBS were added,
MeOH/CHCl3 precipitated, resuspended in 50 µL of 4% SDS in PBS and diluted to 1% SDS in PBS
by addition of 150 µL PBS. 10 µL were taken as input sample, mixed with 10 µL of 3x sample buf-
fer (250 mM Tris, pH 6.8, 1.8% (w/v) SDS, 45% (v/v) glycerol, 22.5% (v/v) b -mercaptoethanol and
0.003% (w/v) bromophenol blue) and heated up (5min/95°C). The samples were diluted further to
to 0.2% SDS in PBS by addition of 760 µL PBS+2x PIC. For pull-down of biotinylated protein-lipid
complexes, 50 µL slurry of neutravidin-beads (29202, ThermoFisher) was pre-cleared (washed 3 x
with 1 mL 0.2% SDS in PBS, 1min/500g/4°C) before it was given to the samples and incubated for
one hour at RT on the test-tube rotator. To analyse non-lipid cross-linked protein populations,
20 µL of flow-through was combined with 20 µL 3x sample buffer, denaturated (15min/95°C) and
kept at RT. Beads were washed 10x with 1% SDS in PBS, before samples were eluted in two steps.
Supernatant of the first step (20 µL of elution buffer (4% SDS (w/v), 4% b -mercaptoethanol (v/v),
100 mM Tris/HCl pH 6.8)) was combined with the supernatant of the second step (15 µL of 3x
sample buffer, 15min/95°C, 1min/RT/FS). Samples were analysed by 1.5mm 13% SDS-PAGE and
via western blot (see section 4.9). To analyse the pacSphmetabolites at the indicated time points,
6-well samples were taken out of -80°C, 300 µL of PBS, 100 µL of MeOH and 150 µL of CHCl3 were
added, lipids were extracted and TLC was performed as described in section 4.7.
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4.14 Analysis of protein-lipid interactions of endogenous transamidase
complex subunits
4.14.1 Sphingolipid binding of endogenous transamidase complex subunits in whole cell
lysate
Eighteenhours before labeling, two 10 cmdishes per condition ofHelaDS1PLGPAA1 #76 (4 5x106
cells per dish) in DMEM (10% FBS, Pen/Strep) were seeded. Cells were washed once with 10 mL
PBS, before being labeled with 6 µM pacSph (DMEM containing Pen/Strep, 10% DL-FBS (delipid-
ated FBS) and pacSph). After 4 hours of labeling time, cells were washed 3x with 10 mL ice-cold
PBS, then overlayed with 5 mL and subjected to UV-light irradiation under a high intensity lamp
for 5 min. PBS was aspirated and cells were scraped off in 1 mL ice-cold PBS and centrifuged for
5min/4°C/3000g. The pellet was taken up in 200 µL lysis buffer (PBS, 1% Triton-X-100, 0.1% SDS,
0.125 U/mL benzonase, and 2x Protease inhibitor cocktail (11836170001, Roche) in PBS, resuspen-
ded by sonication (5x10 seconds, on ice between) and the lysis was performed for 2 hours on a
test-tube rotator in the cold room. Post-nuclear supernatant (8min/4°C/16000g) was snap frozen
in N2 and stored overnight at -20°C.
On the next day, samples were thawed up on ice and not cross-linked pacSph was removed by
MeOH/CHCl3 precipitation after Wessel Flügge[101]. In short, 800 µL MeOH, 400 µL CHCl3, and
600 µL H20 were sequentially added and rigorously mixed by vortexing for 10 seconds. After
phase separation (2min/RT/20000g), the upper phase was carefully removed without disturbing
the intermediate phase. 600 µL MeOH were added, mixed and centrifugated (5min/RT/16000g
in swing out rotor) before the liquid phase was decanted and the pellet air-dried for 10 minutes.
After resuspension of the pellets by addition of 50 µL 4% SDS in PBS (vortex/sonicate/37°C at
1400rpm), the lysates of each condition were combined in one tube, diluted to 1% SDS concentra-
tion by addition of 330 µL of PBS and 2x1 µL were used for protein concentration determination
via BCA-assay. Lysate aliquots of 187 µL (200-400 µg/tube) were subjected to click reactions by
addition of 13 µL click mix, which consisted out of 5 µL 40 mM CuS04, 4 µL 50 mM TCEP (both in
H20), 2 µL 10 mM biotin-azide and 2 µL 10 mM TBTA (both in DMSO). CuS04, TCEP and TBTA were
prepared freshly, while biotin-azide aliquots were stored at -20°C. CuS04, TCEP and biotin-azide
were brought together, vortexd for 10 seconds, spun down and incubated for 2 min at RT before
addition of TBTA. After 4h/37°C/800rpm in the dark, the click reaction was stopped by addition
of 1800 µL of ice-cold MeOH and stored at -80°C overnight.
To remove click reagents, proteins were pelleted (20min/4°C/16000g in swing out rotor), MeOH
decanted, pellet resuspended in 1 mL ice-cold MeOH by alternations of vortexing and sonication
until solution cleared up and precipitated a second time for 1h at -80°C. After centrifugation as
before, pellet was air-dried for 10 minutes and resuspended (vortex/sonicate/37°C at 1400rpm)
with a maximum of 70 µL 4% SDS in PBS per condition. Insoluble material was removed by cent-
rifugation (5min/RT/3000g) and supernatant was transferred into a new tube. PBS+2x PIC was
added for a total volume of 400 µL and 40 µL were taken aside for 10% input sample (+13.40 µL
LDS sample buffer, 15 min 95°C, stored at room temperature). The remaining sample was diluted
to 0.2% SDS by addition of 760 µL of PBS+2x PIC. For pull-down of biotinylated protein-lipid com-
plexes, 50 µL FLAG-beads (F2426, Sigma-Aldrich) slurry was pre-cleared (washed 3 x with 1 mL
0.2% SDS in PBS, 1min/500g/4°C) before it was added to the samples and incubated (3h/RT) on
the test-tube rotator. 40 µL of flow-through were combined with 15 µL LDS sample buffer, denat-
urated (15min/95°C) and kept at RT. Beads were washed 15x with 1% SDS in PBS, before samples
were eluted in two steps. Supernatant of first elution (20 µL of LDS sample buffer, 15 min at 95°C,
1min/RT/FS) was combined with supernatant of second elution (20 µL of LDS sample buffer, 15
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min at 95°C, 1min/RT/full speed). Samples were analysed by 1.5mm 7.5% SDS-PAGE and western
blot (see section 4.9).
4.14.2 Sphingolipid/cholesterol binding of endogenous transamidase complex subunits
in membrane fractions
Procedure was the same as described in section 4.14.1. The only difference was that instead of
whole cell lysate a membrane fraction was prepared before lysis. In short, after subjection of
the cells with 5 mL of labeling media/10 cm dish (4 hours with 6µM pacSph, 30 minutes with
10 µM pacChol), cells were washed 3x with 10 mL ice-cold PBS, overlayed with 5 mL and subjec-
ted to UV-light irradiation under a high intensity lamp for 5 min. PBS was aspirated and cells
were scraped off in 1 mL ice-cold PBS, transferred into 1.5 mL ultracentrifuge tubes (357448,
Beckman Coulter), centrifuged for 5min/4°C/3000g and the dry weight of the pellet was determ-
ined with an analytical balance (ABJ-120-4N, KERN & SOHN GmbH). Pellets were resuspended in
500 µL
25 mg dry weight homogenisation buffer (PBS, 2x PIC) by pipetting and sonication (5x10 seconds).
One µL of the cell suspension was mixed with four µL homogenisation buffer and five µL 0.4%
trypan blue (T8154, Sigma-Aldrich) and used for verification of successful cellular disintegration
via Neubauer counting chamber. 50 µL pf the homogenate were transferred to Iris Leibrecht
and Christian Lüchtenborg, who performed a lipid extraction and follow up lipidomics for sphin-
golipids as desribed in[103]. After centrifugation (1h/100.000g/4°C), the cytosolic fraction was
discarded and the membrane pellet was resuspended in 200 µL lysis buffer. The rest of the exper-
iment was performed as described before.
4.14.3 In silico analysis of cholesterol and sphingolipid binding sites in the transamidase
complex
UniProt protein sequences (see appendix 8.5) of all transamidase subunits (PIGK/T/S/U and
GPAA1) were screened in silicowith the ScanProsite tool (http://prosite.expasy.org/scanprosite/)
to define possible cholesterol interacting motifs. CRAC sequence search term: [LV]-X(1,5)-Y-
X(1,5)-[KR], CARC sequence search term [KR]-X(1,5)-[YF]-X(1,5)-[LV]. The sphingolipid binding
sequence was [VITL]-X(2)-[VITL][VITL]-X(2)-[VITL][FWY]. Hits taken into account required at
least one amino acid of the motif to be located in a transmembrane domain.
4.14.4 Inhibition of sphingolipid binding of endogenous GPAA1 with PPMP
In a first experiment, the concentrations of PPMP required for successful inhibition of metabolic
conversion of pacSph to pacGlucCer were determined. 1 mg of DL-threo-PPMP hydrochloride
(17236, Cayman Chemical) was resuspended in 130 µL EtOH to create a 15 mM stock solution.
HelaDS1PL GPAA1 #76 (3x105 cells/6-well) were seeded and 24 hours later pre-incubated with 2
mL of labeling media (DMEM containing Pen/Strep and delipidated FBS) containing 8/20/41 µM
PPMP. After one hour, cells were washed with PBS andmedia was exchanged with labeling media
containing 4 µM pacSph and 8/20/41 µM PPMP. Four hours later, cells were harvested and a TLC
was conducted as described in section 4.7.
The labeling experiment was performed as described in section 4.14.2. Cells were pre-incubated
for one hour with 5 mL medium. After 4 hours, media was exchanged with 5 mL of 25 µM PPMP
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and 4 µM pacSph containing media. 50 µL of samples labeled with either pacSph with or without
PPMPwere taken aside before the 100000g centrifugation step for lipid extraction andmass spec-
trometric analysis. Blots were developed with mouse a-DDDKK antibody (see table 3). Group dif-
ferences were calculated by a two sided Student’s t-test. Group differences between spingolipid
metabolites, as measured via mass spectrometry, were analysed via one-way ANOVA and Tukey’s
honestly significant difference post hoc test.
4.14.5 Inhibition of sphingolipid binding of endogenous GPAA1 with FB1
In a first experiment, the concentrations of Fumonisin B1 (62580, Cayman Chemical) required for
successful inhibition of metabolic conversion of pacSph to pacCer were determined. 0.5 mg of
FB1 was resuspended in 46 µL PBS (pH 7.2) to create a 15 mM stock solution. HelaDS1PL GPAA1
#76 (3x105 cells/6-well) were seeded and 24 hours later pre-incubated for 15 hours with 2 mL
of labeling media (DMEM containing Pen/Strep and delipidated FBS) containing 25/50/150 µM
FB1. The labeling was then performed for 4 hours with 4 µM pacSph containing labeling media
and freshly prepared FB1. Cells were harvested and a TLC was conducted as described in section
4.7.Furthermore, the following conditions were tested. 15 hours pre-incubation with 25/50/100
µM FB1 and one/four hours of labeling with 1 µM pacSph.
The labeling experiment was performed as described in section 4.14.2. Cells were pre-incubated
for 16 hours with 5 mL medium containing 100 µM FB1. 5 mL fresh media containing 100 µm FB1
and 1 µM pacSph were added for one hour. 50 µL of samples labeled with either pacSph with
or without FB1 were taken aside before the 100000g centrifugation step for lipid extraction and
mass spectrometric analysis. Blots were developed with mouse a-DDDKK antibody (see table 3).
Group differences were calculated by a two sided Student’s t-test. Group differences between
spingolipid metabolites, as measured via mass spectrometry, were analysed via one-way ANOVA
and Tukey’s honestly significant difference post hoc test.
4.14.6 Inhibition of sphingolipid binding of endogenous GPAA1 with D609
Experiments to determine the concentrations of D609 (13307, Cayman Chemical) required for
successful inhibition of metabolic conversion of pacSph to pacCer were performed. 0.5 mg of
D609 was resuspended in 125 µL PBS (pH 7.2) to create a 15 mM stock solution. HelaDS1PL GPAA1
#76 (3x105 cells/6-well) were seeded and 24 hours later pre-incubated for 1 hour with 2 mL of
labeling media (DMEM containing Pen/Strep and delipidated FBS) containing 37.5/75/150/300
µM D609. The labeling was then performed for 4 hours with 4 µM pacSph containing labeling
media and freshly prepared D609. Cells were harvested and a TLC was conducted as described in
section 4.7.
Furthermore, the following conditions were tested and the labeling media always contained the
respective D609 concentration. 1.: 1 and 4 hours pre-incubation with 187.5/375 µM D609 and
labeling with 0.5/4 µM pacSph. 2.: 4 hours pre-incubation with 375 µM D609 and 4 hours labeling
with 0.5/2 µM pacSph. 3.: 15 hours pre-incubation with and without 250 µM D609 and 4 hours
labeling with 4 µM pacSph. 4.: No pre-incubation and labeled with 1 µM pacSph and 250/375 µM
D609 for 1 hour.
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5 Results
5.1 Transient expression of transamidase subunits in HeLa cells
HeLa cells were transiently transfected with DDK-tagged transamidase subunits (PIGK/T/S and
GPAA1) to establish a transient expression system for the study of protein-lipid interactions in
the transamidase complex.
In a first step, HeLa cells were transiently transfected for 24 hours with varying concentrations
of plasmids (0.25/0.5/1/1.5 µg). Cells were then harvested, solubilised, separated by SDS-PAGE,
via western blot transferred to a PVDF-membrane and the subunits were visualised by an anti-
body against the DDK-tag (see figure 7A). EGFP-DDK served as a solubilisation and transfection
control while unspecific reactions of the antibody were monitored by a non-transfection control.
Increasing amounts of plasmid DNA resulted in increased quantified signal in both, the solubil-
ised (S) and the non-solubilised fraction (P) (see figure 7A). Furthermore, signal retention in the
loading well was observed for PIGK/T and GPAA1, but not for PIGS. Calculation of the solubil-
isation efficiency by dividing the signal intensities SP  100 revealed a reduction for PIGS/T and
GPAA1 with increasing DNA concentrations (see figure 7B). PIGK solubilisation efficiency was not
affected by varying plasmid DNA concentrations.
Figure 7: Optimisation of transient transamidase subunit expression and solubilisation in HeLa cells
A) Cultivation of HeLa cells and transfected with varying concentrations of plasmids (0.25/0.5/1/1.5) en-
coding different transamidase subunits, a non-transfection and a transfection control (EGFP). Shown are
representative western blots from at least two independent experiments. P, non-solubilised fraction after
lysis; S, Supernatant after lysis B) Quantification of regions of interest indicated by arrows in A) and cal-
culation of solubilisation efficiency ( SP 100). Mean, SD, n=6 for EGFP, n=2 for PIGK/S/T, GPAA1.
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In a second step, lysis buffers containing different detergents (Nonident P40, Triton-X-100, Oc-
tylglucosid, CHAPS) were tested to optimise solubilisation of transiently transfected (24 and 48
hours) GPAA1-DDK in HeLa cells (see figure 8A). As a control for solubilisation the endogenous ER
residing protein calnexin was used. Results for Triton-X-100 and Nonident P40 were comparable
(see table 10), while CHAPS and Octylglucosid provided very weak signal intensities for GPAA1
and thus rendering the quantification values unreliable. Furthermore, 24 hours transfection of
GPAA1 and cell lysis at 4°C seemed to yield the highest signal intensities (data not shown). Sol-
ubilisation of the one TMD containing ER protein calnexin seemed to be detergent independent
and more robust than GPAA1 (7 TMDs) solubilisation.
In a third step, only Triton-X-100 and Nonident P40 were used to analyse the solubilisation ef-
ficiency of HeLa cells transiently transfected with 0.25 and 0.5 µg of plasmid DNA encoding for
GPAA1-DDK (see figure 8B). The best efficiencies were achieved for 0.25 µg and 24 hours (see
table 9), but the overall signal intensities were to low for a reliable quantification. As Nonident
showed lower protein aggregation in the SDS-PAGE pockets than Triton-X-100 in both exper-
iments (data not shown), the decision was made to continue with the following experimental
conditions: Nonident P40 as the detergent of choice, 24 hours transfection with 1 µg of GPAA1
encoding plasmid, and cell lysis at 4°C.
The last transamidase subunit PIGU could not be tested, as the commercially available plasmid
contained a stop codon which prevented expression after transient transfection (not shown).
After fixing the sequence aberration, it was not possible to amplify the plasmid in a bacterial
host and therefore no material was available for transfection experiments with the correct cDNA
sequence.
Figure 8: Solubilisation of transiently expressed GPAA1 in HeLa cells A) Effect of different detergents
on solubilisation of HeLa cells transiently transfected with 1 µg of a plasmid encoding GPAA1-DDK. As a sol-
ubilisation control, the endogenous ER residing protein calnexin was used in cells expressing GPAA1-DDK
as well as in not transfected cells. Shown are representative western blots from at least two independent
experiments. Quantification data is shown in table 10. I, input sample before lysis; P, non-solubilised frac-
tion after lysis; S, solubilised proteins after lysis B) HeLa cells transiently transfected with either 0.25 µg
or 0.5 µg of GPAA1-DDK encoding plasmid to test solubilisation efficiency of the detergents Triton-X-100
and Nonident P40. Shown are representative western blots from at least one experiment. Quantification
data are shown in table 9.
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Table 9: Solubilisation efficiency1 of transiently expressed GPAA1 and endogenous calnexin at 4°C. Values are derived from the analysis shown in figure 8
Nonident P40 Triton-X-100
time2 DNA3 GPAA1 Calnexin GPAA1 Calnexin
24h
0:25 0:6110:0034 0:8735 0:6240:1714 0:9465
0:50 0:3490:0:0294 0:8805 0:4100:1944 0:9065
        0:9805
48h
0:25 0:2940:0464 0:8510:0:0624 0:1600:0054 0:8640:0554
0:50 0:2240:0674 0:8080:0:0154 0:1420:0:0994 0:7850:0564
    0:9205   0:9605
1 division of signal intensities of solubilised and non-solubilised fraction SP ,
2duration of transi-
ent expression,3 µg oftransfected plasmid encoding for GPAA1-DDK, 4 mean+SD of two biological
replicates,5single experiment quantification, 5single experiment quantification
Table 10: Analysis of parameters effecting transiently expressed GPAA11 and endogenous calnexin solubilisation efficiency2
GPAA1 Calnexin
time3 degree4 Nonident P40 Triton-X-100 Octylglucosid9 CHAPS9 Nonident P40 Triton-X-100 Octylglucosid9 CHAPS9
24h
4°C 0:5210:1765 0:6380:0717 0:7090:2296 0:3790:2585 0:6550:0087 0:6888 0:6850:0347 0:3620:0447
RT 0:5400:1405 0:5260:2147 0:4920:3546 0:6020:2495 0:6520:0277 0:6788 0:6670:0227 0:8020:0145
48h
4°C 0:3140:0127 0:5640:1407 0:9520:0477 0:6380:2587 0:8680:01277 0:8880:0857 0:8510:1517 0:8100:1017
RT 0:3160:07307 0:2950:1337 0:7380:2367 0:2920:2837 0:7840:0197 0:7360:1237 0:8750:1367 0:8020:1017
1 1 µg of transfected plasmid encoding for GPAA1-DDK, 2 division of signal intensities of solubilised and non-solubilised fraction SP ,
3duration of transient expression, 4 lysis conditions,
5 7 mean+SD of four, three, or two biological replicates, 8single experiment quantification, 9 quantification values not reliable due to low signal intensities (see figure 8A)
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In a fourth step, the ability to enrich transiently transfected transamidase subunits (PIGK/T/S,
GPAA1) via their C-terminal tag was analysed. As seen in figure 9A, all subunits as well as the pos-
itive control EGFP were successfully IP, while the negative control showed no signal. To assess if
the transiently transfected subunits GPAA1 and PIGT integrated successfully into the transami-
dase complex, Co-IP experiments were performed. GPAA1 (see figure 9B) and PIGT (not shown)
showed both the capability to pull down endogenous PIGS and PIGK. PIGU could not be detected.
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Figure 9: IP of transiently transfected transamidase subunits in HeLa cells A)HeLa cells were transfec-
ted with 1 µg of plasmid encoding for different DDK-tagged transamidase subunits (PIGK/T/S and GPAA1)
and afterwards IP via FLAG-beads. EGFP-DDK served as a positive control. Not transfected cells (-) served
as controls for western blot and FLAG-bead specificity. Blots shown are representatives of two independ-
ent experiments. B) Co-IP of HeLa cells transfected with GPAA1 to analyse pull down of transamidase sub-
units. EGFP used as internal IP control. Detection of subunits by subsequently administration of antibodies
(a-PIGS, a-FLAG, and a-PIGK with fluorescently tagged (700/800 channel dyes) secondary antibodies). I,
input sample before IP; P, non-solubilised fraction after lysis; FT, proteins not bound to beads; IP, proteins
enriched via FLAG beads.
5.2 Optimisation of pacSph labelling in HeLaDS1PL cells transiently trans-
fected with GPAA1
HeLaDS1PL cells were transiently transfected with a GPAA1 encoding plasmid and fed with 3 µM
pacSph for 30 minutes, followed by UV irradiation to cross-link pacSph and its metabolites via
their photoactivatable diazirine ring to proteins in close proximity. Proteins were allowed to
bind to a-FLAG beads before attachment of Alexa-647-N3 via CuAAC to the alkyne group (click
= 49 =
5 RESULTS
reaction) of the pacSph metabolites. Proteins were eluted with SDS sample buffer and subjected
to SDS-PAGE. The fluorophor was detected by in-gel fluorescence before the proteins were
transferred to a PVDF-membrane and detected via antibody against the FLAG-tag. To evaluate
the influence of pacSph and Alexa-647-N3 on the IP, not transfected cells were subjected to click
reaction with or without previous UV irradiation. As seen in figure 10A, no bands appeared
in the region where the GPAA1 signal was to be expected. Only a signal for Alexa-647 at the
expected position for the heavy chain of the FLAG-beads antibody was visible. The a-FLAG signal
for GPAA1 was detectable in the pellet, input and faint in the IP section with a slight overlap
with the Alexa-647 signal. Additionally, a strong Alexa-647 signal is visible slightly above the
expected GPAA1 band.
Figure 10: Optimisation of CuAAC for transient transfections of GPAA1 in HeLaDS1PL cells A)
HeLaDS1PL cells were transfected a GPAA1 encoding plasmid and labelled for 30 minutes with 3 µM of
pacSph. Controls for pacSph specificity are not transfected cells with or without UV irradiation. CuAAC
was performed on proteins bound to FLAG-beads. I, input sample before IP; P, non-solubilised fraction
after lysis; FT, proteins not bound to beads; IP, proteins enriched via FLAG beads after click reaction B)
HeLaDS1PL cells were transfected a GPAA1 encoding plasmid and labelled (15 minutes with 3 µM of pac-
Sph). Sample was split before IP and one half was subjected to click reaction (+). This sample was eluted
with SDS sample buffer twice, once for 10 minutes at 70°C (E2) and once for 10 minutes at 95°C (E1). C)
HeLaDS1PL cells transfected with GPAA1 and labelled with 4.5 µM pacSph for 15 minutes. Click in lysate.
Shown are the IP fractions of samples with and without previous UV irradiation. D) Comparison between
lysis buffer with either 1% Triton-X-100 or 1% Nonident P40 for click reaction in lysate. P, non-solubilised
fraction after lysis, Ic, input sample before click reaction in lysate; Ip, input sample before IP; FT, proteins
not bound to beads; red, Alexa-647-signal; green, a-GPAA1 signal; orange, red/green signal overlap.
An experiment was performed to determine if this loss of signal is a result of the click reaction.
For this, the samplewas split before IP and onehalfwas subjected to click reaction, while the other
half was not. Furthermore, the sample that underwent click reaction was eluted in two steps, to
verify if the temperature (70°C and 95°C) had any impact on the elution of the GPAA1-pacSph-
fluorophor product. As seen in figure 10B, the GPAA1 signal in the minus click sample is strong
as expected, but after the click reaction, the signal is lost, independent of the temperature used
for elution. This did not have any influence of the click reaction for p24, a positive control for
pacSph interactions (not shown.)
A different click reaction protocol was used to analyse if this is a specific effect of bead bound
GPAA1. This time the click reaction was performed in the cell lysate before IP and followed by
multiple methanol precipitation steps to remove remaining unreacted click reagents. As a result,
a strong signal for GPAA1 under all conditions (+UVclick,  UV+click) could be observed (see
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figure 10C), but the Alexa-647-signal (+UV+click) was not very prominent.
To increase the click reaction efficiency in the cell lysate, two different detergents (Triton-X-100,
Nonident P40) were compared against each other (see figure 10D). Samples were two times eluted
(10min/70°C) to see if protein was left on the beads during the first elution step. For Triton-X-
100, a strong signal for GPAA1 was observed throughout the whole experiment while Nonident
P40 signal seemed to diminish after the click reaction andnothing could be observed in the second
elution step. Furthermore, the second elution step for Triton-X-100 showed a signal, indicating
still boundprotein on the beads after the first elution round. Additionally, the overall background
signal of the click reaction was more prominent in samples containing Nonident P40 than Triton-
X-100. For next stage experiments, lysates were generated with Triton-X-100 as the detergent of
choice and Alexa-647-N3 click reactions were performed in whole cell lysate.
5.3 Analysis of sphingolipid binding kinetics in HeLaDS1PL cells transi-
ently transfected with GPAA1
To test whether GPAA1 interacts with a specific sphingolipid, HeLaDS1PL cells were transfected
with a plasmid encoding for GPAA1 and labelled for different periods of time (15/60/120/180/360
minutes) with 2 µM pacSph. Cells transfected with p24, a known interacting protein with the
sphingosine metabolite sphingomyelin[15], and labelled for 360 minutes served as positive con-
trol (see figure 11A). For all time points, Alexa-647-signals were observed at the position of FLAG-
signal that represents GPAA1. While for GPAA1 both signal overlap, a shift between the Alexa-
647-signal and the FLAG-signal of p24 is observed. Afterwards, the IP signals for Alexa-647 (GPAA1
click) and FLAG (GPAA1) were quantified, the ratios calculated GPAA1clickGPAA1 , and plotted to visualise
the GPAA1 sphingolipid binding kinetics (see figure 11C). An increase of labelling intensities is
visible up to 180 minutes and then flattens out. When compared to the overall intensity of the
Alexa-647-signal during the time course, (see figure 11B), a steadily increase was observed. To
correlate the binding kinetics with available pacSph metabolites at time of UV-irradiation, a TLC
with lipids extracted at the same time points as in the previous experiment was conducted (see
figure 11D). At the first time points (15/60/120 minutes) sphingosine (48%, 45%, 33%) and ceram-
ide (40%, 45%, 43%) are the dominant species, while sphingomyelin takes over at the 360 minutes
time point (40%). Hexosylceramides are the lowest abundant species at all time points, but stead-
ily increase and reach their maximum (slightly below 10%) at 360 minutes.
To exclude that continuous labelling conditions of the experiment influenced available amounts
and species of pacSph metabolites at the time of UV-irradiation, a pulse-chase experiment was
conducted. The only change to the protocol was that after 10 minutes of labelling, cells were
washed three times with PBS and then overlaid with pacSph devoid growth media. Cells were
UV-irradiated at the same time points as before.
Before the experiment was conducted, the protocol was ironed out by analysis of different tech-
nical parameters. In a first experiment, varying pacSph concentrations (2/3/4/5/6 µM) were
tested to determine the minimal amount of pacSph needed for detection via TLC in a pulse-chase
experiment (see figure 12A). The concentration of 2 µM pacSph, as used in the continuous la-
belling experiment (see figure 11), proved to be sufficient. However it was observed that the
signal of 3-azido-7-hydroxycoumarin (lane C in figure 12A) overlapped with the signal of the pac-
Sph metabolite pacGlucCer (lane 2-6 in figure 12A). To separate the two signals, the development
distance of the mobile phase II in the TLC protocol was increased from 7.5 cm to 8 cm (see figure
12B). In the same experiment, 3-azido-7-hydroxycoumarin was titrated (9/35/70 µM) to determ-
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Figure 11: Analysis of sphingolipid binding kinetics of GPAA1 in transiently transfected HeLaDS1PL
cells via Alexa-647-N3 A) HeLaDS1PL cells were transfected with a GPAA1 encoding plasmid and labelled
for certain periods of time with 2 µM of pacSph and detected via Alexa-647-N3. Cells transfected with the
known sphingosinemetabolite sphingomyelin interacting protein p24 served as positive control. Shown is
one of two biological replicates. I, input sample before IP; P, non-solubilised fraction after lysis; red, Alexa-
647-signal; green, a-GPAA1 signal; orange, red/green signal overlap B) GPAA1-Alexa-647-signal intensity,
n=2, SD. C) Analysis of GPAA1 sphingolipid binding kinetics. Quantification data of Alexa-647-signal in
the 700 channel (GPAA1 click) and FLAG signal in the 800 channel (GPAA1) were used to calculate the
GPAA1click
GPAA1 ratio for an experiment containing two biological experiments D) Quantification of pacSph in
vivometabolism in HeLaDS1PL cells in one pilot study via TLC.
ine the concentration with the best trade-off between overall signal intensity in the sample and
the background signal of 3-azido-7-hydroxycoumarin, as it might be the case that it is not pos-
sible to successfully separate pacGlucCer and the 3-azido-7-hydroxycoumarin signal. For the final
pulse-chase experiment, 2 µM of pacSph were used for labelling and 35 µM of pacSph were used
for the click reaction. One representative TLC is shown in figure 12C and the overall results of
the quantification of three biological replicates are displayed in figure 12D. Compared with the
continuous labelling experiment, depicted in figure 11D, a strong decline in pacSph concentra-
tion is visible at all time points, while the other metabolites (pacCer, pacSM, pac-GlucCer) show
similar behaviour. This is furthermore independent of the transfected proteins present in the
cell, namely GPAA1 or p24. To determine if the reduction in pacSph levels during the pulse-chase
experiment had an influence on the outcome of the GPAA1-pacSph metabolite labelling kinetics,
an Alexa-647-N3 pulse chase experiment was conducted. HeLaDS1PL cells were pulsed with the
previously established minimal dose (see figure 12A) of 2 µM pacSph for 10 minutes, before being
chased with delipidated DMEM for varying amounts of time (0.25/1/2/4/6h).
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Figure 12: Analysis of sphingolipidmetabolite binding kinetics in HeLaDS1PL cells via TLC in a pulse-
chase experiment A) HeLaDS1PL cells were labelled with varying concentrations of pacSph (2/3/4/5/6
µM) and detected via 3-azido-7-hydroxycoumarin. B) HeLaDS1PL cells were labelled with two concentra-
tions of pacSph (3/6 µM) and detected with different amounts of 3-azido-7-hydroxycoumarin in the click
reaction master mix (9/35/70 µM). Additionally, the TLC development protocol was changed from 7.5 cm
mobile ph II to 8 cm. C) HeLaDS1PL cells were transfected with a GPAA1 or p24 encoding plasmid (pGPAA1,
pP24) and 24 hours later pulse-chase labelled for 0.25/1/2/4 hours with 2 µM of pacSph and detected on a
TLC with 3-azido-7-hydroxycoumarin (35 µM). Shown is one of three biological replicates. D) Quantifica-
tion of three biological replicates from C) by TLC. DL, delipidated DMEM; L, DMEM; S, standard containing
pacCer, pacGlucCer, pacPC, pacSph, and clickSM; C, 3-azido-7-hydroxycoumarin.
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Figure 13: Pulse-chase experiment of sphingolipid binding kinetics of GPAA1 in transiently transfected HeLaDS1PL cells via Alexa-647-N3
HeLaDS1PL cells were pulse-labelled with 2 µM pacSph for ten minutes, before being chased in delipidated DMEM for varying amounts of time
(0.25/1/2/4/6h). Blots shown are the results of one single experiment. P, not solubilised proteins after lysis; I, input sample before IP; FT, not bound
protein after IP; IP, non-solubilised fraction after lysis; IP, immunoprecipitated fraction; * depicts a weak signal for the GPAA1-pacSph-Alexa-647-complex.
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As seen in figure 13, very weak (0.25/2/4/6h) or no (1h) signals for the GPAA1-pacSph-Alexa-
647-complex could be detected. The same was true for the positive control p24. On the other
hand, clear signal intensities for the non-clicked proteins were detected. To analyse if this was
the result of overall low intracellular pacSph levels due to the short labelling time of 10 minutes,
an experiment to compare directly both, pulse-chase and continuously labelling was performed
(not shown). The result verified the experimental data from the pulse-chase experiment shown
in figure 13 and the continuously labelling experiment shown in figure 11 by demonstrating that
the conditions of a pulse-chase experiment are sufficient for detection of pacSph metabolites on
TLC level (see figure 12), but not sufficient for detection of GPAA1-pacSph-Alexa-647-complexes
on western blot level (see figure 13).
Figure 14: Analysis of sphingolipid binding kinetics of GPAA1 in transiently transfected HeLaDS1PL
cells via biotin-N3 A)HeLaDS1PL cells were transfectedwith GPAA1 for 24 hours and continuously labelled
with 2 µMpacSph (0.25/1/2/4h). Interactions between GPAA1 and pacSphmetabolites were detected, after
UV-irradiation and attachment of biotion-N3, via neutravidin-mediated enrichment of protein-lipid com-
plexes. Cells transfected with the known sphingosine metabolite sphingomyelin interacting protein p24
served as positive control. Shown are selected blots out of three biological replicates. I, input before incub-
ation with neutravidin-beads; F, flow-through of proteins not bound to neutravidin-beads; PD, pull-down
fraction containing all proteins that were enriched via neutravidin-beads. B) depicts the ratio between
quantified signal intensities PDXIX at time point X of three biological replicates from A.
To verify the previous results with a different method, biotin-N3 was chosen as an alternative to
Alexa-647-N3 to enrich GPAA1-pacSph-complexes. In the experimental setting, HeLaDS1PL cells
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were transfected with GPAA1 and continuously labelled with 2 µM pacSph for different times
(0.25/1/2/4h). Controls used were labelling without addition of pacSph, with/without GPAA1
transfection, withoutUV-irradiation aswell as p24 transfected cellswith/withoutUV-irradiation.
The results are shown in figure 14A. Clear and distinct signals are visible in all lanes and negative
controls show no signal at all. To determine pacSph labelling kinetics, the signal intensity of the
biotin-enriched fraction (PD) was divided by signal intensity for the biotin-pull-down input (I).
The result of three biological replicates are shown in figure 14B and the trend is comparable to
the data from the Alexa-647 experiment (see figure 11C).
5.4 CRISPR/Cas9 guided cell line generation and validation containing C-
terminal tagged GPAA1 to study protein-lipid interactions of the trans-
amidase complex
5.4.1 Enrichment of endogenous transamidase complexes
As transiently expressed GPAA1 and PIGT did not allow for IP of stoichiometric correctly com-
posed transamidase complexes (see figure 9), the decision was made to work directly with the
endogenous transamidase complex. An a-GPAA1 antibody (sc-373710) was coupled to CNBr-
activated beads and used in multiple experiments for IP of the endogenous transamidase com-
plex. In a first experiment with 1x108 HeLa cells, it was possible to IP endogenous GPAA1 and
PIGS, while for the other subunits no signal (not shown) was detected (see figure 15A). To analyse
if the low signal intensities corresponds with the amount of intracellular GPAA1, cells used for
this experiment were increased by one order of magnitude. To handle this amount of cells, the
suspension culture cell line Raji (lymphoblast-like cells) was used. 1x109 Raji cells were used, but
only a weak signal for GPAA1 and no signal at all for the other subunits (not shown) was observed
(see figure 15B). But as in both experiments a signal for the heavy and light chain of the coupled
antibody was detected and the relation between the GPAA1 signal and the signal of the heavy
chain went from a strong GPAA1 signal (15A) to a weak GPAA1 signal(15B), an experiment was
designed to analyse the GPAA1 binding capacity of the CNBr-beads (see figure 15C).
For this, 4x106 HeLa cells were transiently transfected with GPAA1 and subjected to an IP with
CNBr-beads. Unbound material was taken as input for an IP with FLAG-beads. The amount of
GPAA1 in the flow-through was higher than what was enriched via the CNBr-beads (see figure
15C). As a conclusion, the approach with the CNBr-beads was not further followed, instead NHS-
columns were coated with the antibody sc-373710 and used for high performance liquid chroma-
tography (HPLC) with an ÄKTATM Pure system. Here, GPAA1 was transiently expressed in 1x107
HeLa cells and applied to the column according to manufacturer’s instructions. Small aliquots of
the eluted fractions (elution buffer: 100 mM glycine pH 3) were used for SDS-PAGE, but no GPAA1
signal was detected at all (not shown). Therefore, the flow-through was subjected to enrichment
via FLAG-beads and resulted in a strong GPAA-1 signal (see figure 15D).
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Figure 15: IP of endogenous transamidase subunits fromHeLa cells A) 1x108 HeLa cells were harvested
and used for IP with an a-GPAA1 (sc-373710) antibody coupled to CNBr-beads. Sequentially antibodies
against GPAA1, PIGT/S/K were used for detection of endogenous transamidase subunits. Only for GPAA1
and PIGS a signal was observed. P, non-solubilised fraction after lysis; FT, proteins not bound to beads,
IP, proteins enriched via CNBR-beads. B) 1x109 Raji cells were used as in A). Only for GPAA1, a signal was
observed. I, input sample before IP.C) 4x106 HeLa cells were transiently transfectedwith GPAA1, harvested
and subjected to CNBr-beads IP. The flow-through of the CNBr-beads was used as input sample for a follow
up FLAG-IP to analyse the GPAA1-binding capacity of the CNBr-beads. D) NHS-columns were coated with
sc-373710 and used for a high performance liquid chromatography (HPLC) with an ÄKTATM Pure system.
GPAA1 was transiently expressed in 1x107 HeLa cells, harvested, lysed and used with the HPLC according
to manufactures instructions. Before loading the samples onto the HPLC, two lysate clearing steps were
(P10=10.000g for 20 min; P100=100.000g for 60 min) performed. The wash step was subjected to an IP with
FLAG-beads. The elution fractions were loaded on different SDS-PAGEs, but as there was no signal at all,
only the result of the FLAG-IP is shown. Data in A/B/D was jointly produced with Rainer Beck.
5.4.2 Selection of CRISPR/Cas9 generated cell lines containing C-terminal tagged GPAA1
The most important parameter for the CRISPR/Cas9 guided cell line generation containing C-
terminal tagged GPAA1was the intracellular available amount of GPAA1. A screening experiment
of different cell lines (human fibroblasts hFib, mouse embryonic fibroblasts H806, mus musculus
brain neuroblastoma N2A, adenocarcinomic human alveolar basal epithelial cell line A549, hep-
atocarcinoma cell line Huh-7, cervix carcinoma cell line HeLa, human embryonic kidney cell line
HEK293, and lymphoblast-like cell line Raji) was performed and 50 µg of whole cell lysate were
subjected to SDS-PAGE, transferred to a PVDF-membrane and analysed with an a-GPAA1 anti-
body. It was possible to detect weak signals for HeLa, HEK293, Raji, N2A, Huh-7 and hFib (see
figure 16A). Signal intensities were, except for the HeLa cell line, poor and barely visible. Nev-
ertheless, signals at the expected kDa height for GPAA1 were quantified, normalised against the
GPAA1 signal in HeLa cell line and listed in table 11. To control for the solubilisation efficiency
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of endogenous ER resident proteins, calnexin was used and did not show any exceptional strong
deviation between the different cell lines. To verify the assumption that HeLa cell lines are the
most suitable ones for the generation of the endogenous tagged cell line, a second experiment
was performed. In this, membrane fractions of HeLa, HEK293, hFib and Raji cell lines were gen-
erated to improve the signal intensities of the whole cell lysate experiment. Loading of 50 µg
of membrane fractions did show generally clearer signals (see figure 16B), but the unsatisfying
signal to background ratio did not allow for a reliable quantification. HeLa cells were, as they
provided the most consistent results over all experiments, selected as the prime candidate for
the CRISPR/Cas9 experiment.
Table 11: Endogenous GPAA1 levels of different cell lines normalised to HeLa from figure 16A
[n] HeLa HEK293 Raji N2A Huh-7 hFib
11 100% 8.5% 68.3% 35.4% 28.5% 5.2%
1 Signal intensities divided by HeLa signal intensities*100
Figure 16: Analysis of endogenous GPAA1 levels in different human and murine cell lines A) 50 µg
of whole cell lysates of different cell lines were separated by two different SDS-PAGE, transferred to PVDF-
membranes and analysed with a-GPAA1 (sc-373710) antibody. To compare quantification intensities, the
same HeLa lysate sample was loaded on both blots. Furthermore, the endogenous ER resident protein
calnexin was used as a control for solubilisation of ER proteins. L, whole cell lysate; P, non-solubilised
proteins; hFib, human fibroblasts; H806, mouse embryonic fibroblasts; N2A, mus musculus brain neuro-
blastoma N2A; A549, adenocarcinomic human alveolar basal epithelial cell line; Huh-7, hepatocarcinoma
cell line; HeLa, cervix carcinoma cell line; HEK293, human embryonic kidney cell line; Raji, lymphoblast-
like cell line. B) 50 µg of membrane fractions from selected cell lines of A) were compared with each
other. Two biological replicates are shown and were used for quantification. M, membrane fraction; P,
non-solubilised proteins after membrane fraction.
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5.4.3 Design of gRNAs for genomic GPAA1 loci
To design guide RNAs (gRNA), the genomic context of the GPAA1 loci on chromosome 8 was re-
trieved from Ensembl and a search query containing partially the C-terminal end of GPAA1 exon
12, and a short sequence of the 3’UTR was designed and used as input for the gRNA prediction
tool CRISPR Design (http://crispr.mit.edu/) from the Zhang lab (MIT, USA). The top 9 candidates
and their orientation on the genomic sequence are shown in figure 17. The top 3 candidates were
selected, their detailed location in the genomic loci determined (figure 17B) and their capability
to induce double strand breaks was assessed. For this, HeLa cells were double transfected with
the vector containing the coding sequence for the Cas9 molecule (hCas9) and the vector contain-
ing any of the three gRNAs (MLM3636-gRNA#1-3). As a control, wild-type cells were used. After
72 hours, genomic DNA was extracted and a fragment, containing the C-terminal part of the ge-
nomic GPAA1 loci (as depicted in figure 17B), was amplified. PCR fragments from wild-type and
gRNA transfected cells were heterodimerised (1:1 ratio) and cut at positions containing a base pair
mismatch. All gRNA-candidates, as seen in figure 18A), successfully introduced a double strand
break, and gRNA#1 was selected for the CRISPR/Cas9 generation of a HeLa cell line containing
C-terminal tagged GPAA1.
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Figure 17: Predicted guide RNAs and their position in the genomic loci of GPAA1 A) Results of the gRNA prediction tool CRISPR Design (http:
//crispr.mit.edu/) for the C-terminal part of last exon of the GPAA1 loci. Shown are top 9 guide (g)RNA-candidates, their location and orientation in the
genomic context. For in detail results of genomic off targets, see figure 31 for Guide#1, figure 32 for Guide#2 and figure 33 for Guide#3. B) Position on a
base per base sequence and the corresponding amino acids of gRNA-candidates #1, #2, and #3. Shown are the C-terminal part of GPAA1 (in orange), the
stop codon (in red), the 3’-UTR, the gRNA sequences, and the exact position where Cas9 is expected to introduce the double strand break (arrow). PAM,
protospacer adjacent motif sequence.
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Figure 18: Assessment of gRNA-candidates capability to introduce DNA double strand breaks HeLa
cells were transfected for 72 hours with a vector containing either gRNA#1, #2, or #3. Genomic DNA was
extracted and a fragment, containing the C-terminal part of the genomic GPAA1 loci (as depicted in figure
17B), amplified. PCR fragments from wild-type (wt) and gRNA transfected cells were mixed in a 1:1 ratio,
heated up to create single stranded DNA fragments which then were allowed to form DNA-heteroduplexes
by stepwise temperature reduction. Employing the fact that specific nuclease exist that cut mismatched
double stranded DNA, such as the result of an error in the double strand break repair mechanism, the
surveyormutation detection kit was used according tomanufactures instruction. Expected fragment sizes:
1350nt for GPAA1 fragment (digestion products at 905nt, 445nt) and 633nt for surveyormutation detection
Kit controls G and C (digestion products at 400nt, 200nt). L, ladder; -, negative control; G/C/G+C, positive
controls from the kit.
5.4.4 Generation and selection of specific HeLaDS1PL cell line containing endogenous C-
terminal tagged GPAA1
HelaDS1PL were triple transfected (gRNA#1, Cas9, and donor plasmid containing the to be in-
serted tag sequence) for 72 hours. Serial diluted cells were seeded into 96 wells and propagated
until 6-well format was reached. At this point cells were harvested, genomic DNA was extrac-
ted and success of tag integration was determined for each single cell clone via PCR (see figure
19A). Clones containing one band at 1527nt were expected to represent a successful homozygous
tag integration, while one band at 1350nt defined a wild-type clone. Samples with two bands at
the respective heights were termed to reflect a heterozygous integration, containing wild-type
and tagged allele of GPAA1. Out of 55 clones tested, 14 were determined to be heterozygous for
tag insertion (25%), while two clones (#76, #39) were homozygous (3.6%). The screening results
of #76 and #39 as examples for a homozygous insertion and #18 for a wild type are displayed in
figure 19B). Sequencing of all three clones confirmed the integration for #76 and #39 (see fig-
ure 19C). HeLaDS1PL GPAA1#76 was selected as mutant cell line of choice for further validation
experiments.
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Figure 19: CRISPR mediated C-terminal tagging of endogenous GPAA1 A) Schematic drawing of a PCR
on genomic DNA to determine positive insertions of the 3xFLAG-Twin-Strep tag. Cells without insertion
of the tag are coded with wild type (wt) and successful integration with mutant (mt). Primer positions are
decoded with black arrows. Expected sizes: wt=1350, mt=1527nt B) PCR results of three single cell clones
derived from gRNA#1 transfectedHeLaDS1PL cells displayed homozygous integration of the tag (#39/76) or
a wt allele (#18). C) Sequencing results of B) showed variability in the 3’-UTR, closely to the Cas9 cleavage
site. Inserted sequence is colour coded according to A) and contains a double stop codon (red).
5.4.5 Characterisation of HeLaDS1PL GPAA1#76
Functionality of the integrated 3xFLAG-Twin-Strep tag in the HeLaDS1PL GPAA1#76 clone was
assessed in the following. After a FLAG-IP it was possible to co-IP the transamidase subunits
PIGS and PIGK (see figure 20A), indicating an integration of GPAA1-(FLAG)3 into the transami-
dase complex. Furthermore, a pull-down experiment with streptactin-beads proved successful
in enrichment of GPAA1 (see figure 20B). To verify that the C-terminal tag did not interfered with
the actual attachment of GPI-anchors to proteins containing the respective GPI-anchor attach-
ment sequence, the cell surface localisation of the GPI-anchored protein CD59 was determined
via cell surface biotinylation. No difference was observed for the endogenous (see figure 20D)
and overexpressed CD59 (see figure 20C/E).
To rule out that the two internal streptags unspecifically interact with neutravidin beads, thus
rendering them incompatible with the biotin-click protocol (see figure 14), an experiment was
performed where HeLaDS1PL GPAA1#76 were labelled with pacSph and clicked in lysate with
Alexa-647-N3 (see figure 21B). No signal was observed in the eluted fraction after neutravidin-
beads enrichment, while the in gel fluorescence showed the respective signal for GPAA1.
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Figure 20: Validation of tag integration and functionality of the transamidase complex inHeLaDS1PL
GPAA1#76 A) FLAG-IP of endogenous C-terminal (FLAG)3-tagged GPAA1 from 5x107 HeLaDS1PL GPAA1#76
pre-cleared (P10=10.000g for 20min, P100=100.000g for 20min) whole cell lysate. The blot was sequentially
developed with antibodies against GPAA1 and PIGS/K. I, input sample; FT, flow-through sample; IP, pro-
teins enriched via FLAG beads. B) Streptactin enrichment of GPAA1 from 2x107 whole cell lysate. Samples
were bound to streptactin-beads and incubated over night, before being eluted with 3mM biotin. E, en-
riched fraction after elution and MeOH-CHCl3 precipitation. C) Ratios of quantified signal intensities
SP
I
of three biological replicates from E are shown and were tested for significant differences between groups
by way of a two-sided T-test. D) Endogenous CD59 expression levels in 3x105 HeLaDS1PL and HeLaDS1PL
GPAA1#76 cells as detected by surface biotinylation. SP, enriched fraction containing biotinylated protein.
E) Construct from [55] was used to assess differences of CD59 cell surface recruitment in 3x105 HeLaDS1PL
and HeLaDS1PL GPAA1#76 via surface biotinylation.
When replacing the neutravidin-beads with streptactin-beads, strong signals were obtained for
in-gel fluorescenc as well as for western blot (see figure 21A). According to the streptactin pro-
tocol, before loading the sample on the beads, the chemicals from the click reaction are to be
removed via several MeOH precipitation steps. To validate the necessity of these washing steps,
samples were precipitated not at all, once, twice or three times (see figure 21C/D). No difference
was observed between one and three times, while the signal intensity without any washing step
appeared to be lower. Furthermore, compared to the overexpressed experiments where 2 µM
pacSph was the limit with regards to cell viability, in the HeLaDS1PL GPAA1#76 cell line, 3 and 5
µM could be used without any major increase in cell mortality (data not shown). A final experi-
ment with 5 µM pacSph and one MeOH washing step provided a clear and strong signal for in-gel
fluorescenc as well as for western blot (see figure 21E).
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Figure 21: Alexa-647-N3 click in HeLaDS1PL GPAA1#76 whole cell lysate A) Alexa-647-N3 click in 4x106
whole cell lysate and enrichment via streptactin-beads. I, input sample; FT, flow-through sample; E, pro-
teins enriched via streptactin-beads; red, in gel fluorescence; green, a-FLAG antibody. B) In-gel fluores-
cence of Alexa-647-N3 click in 2x107 whole cell lysate and enrichment via Neutravidin-beads. Psol , non-
solubilised pellet; Pclick, non-solubilised pellet before click reaction; PE , non-solubilised pellet before the
sample was given on the beads; Iclick, lysate before click reaction; IE , solubilised sample before mixing with
neutravidin-beads; FT, sample bound by beads; E, bead eluate after enrichment. C/D) Alexa-647-N3 click
in 2x107 whole cell lysate was precipitated zero to three times, before being loaded on streptacin-beads. E)
One time precipitation of Alexa-647-N3 clicked whole cell lysate (2x107) and enrichment with streptactin-
beads.
5.4.6 Enrichment of endogenous transamidase complex in native lipid environment from
HelaDS1PL GPAA1#76
HelaDS1PL GPAA1#76 were harvested and the transamidase complex was, surrounded by its
native lipid environment, enriched via styrene maleic anhydride (SMA) co-polymer. Follow-
ing this approach, it was possible for the first time, to co-IP all transamidase subunits (for
GPAA1/PIGT/U/K see figure 22A, for GPAA1/PIGS/PIGK see figure 22B).
Figure 22: Purification of endogenous transamidase complex using styrene maleic anhydride (SMA)
co-polymer A) 8x106 HelaDS1PL GPAA1#76 cells were seeded, solubilised via SMA and enriched over FLAG-
beads. Blot was sequentially developed with rabbit a-PIGU/K/T and mouse a-DDDKK antibodies. I, input
sample before IP; FT, proteins not bound to beads; IP, proteins enriched via FLAG beads. B) Same as in A,
but developed with rabbit a-PIGS und a-PIGK.
In a proof-of-principle experiment, it was possible to detect viamass spectrometry lipids from en-
dogenous transamidase complexes enriched via FLAG-IP from SMA treated HeLaDS1PL GPAA1#76
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Figure 23: Mass spectrometric analysis of lipids derived via FLAG-enrichment of endogenous GPAA1 using styrene maleic anhydride (SMA) co-
polymerMass spectrometric spectra from lipids extracted from a FLAG-beads IP fromHelaDS1PL GPAA1#76 cells. Data produced jointly with Iris Leibrecht
and Christian Lüchtenborg.
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membrane fractions (see figure 23). Comparing the amplitude of the standards at 650 and 678m/z
with the amplitudes of the rest of the spectra shows the substantial amount of lipids extracted.
5.4.7 Separation of transamidase subunits via different protein gel systems
Having verified the functionality of the CRISPR/Cas9 inserted tag, the next target was to find a
way to assess labelling specificity for all transamidase subunits in one experiment and on the
same protein gel. PIGS, PIGT, and GPAA1 should be, as depicted in figure 24A and according
to their predicted molecular weight (PIGT: 65.1 kDa, UniProt: Q969N2, PIGS: 61.65, Uni-Prot:
Q96S52, GPAA1: 67.623, UniProt: O43292), size-wise closely matched and it is already difficult
to successfully separate a 3kDa difference. Furthermore, the the tag sequence (see figure 19C)
is to be added upon the GPAA1 molecular weight. According to the ExPASy tool compute pI/Mw
(https://web.expasy.org/cgi-bin/compute_pi/pi_tool), an additional molecular weight of 6.245
kDa attributes to an overall 71.868 kDa for GPAA1. Theoretical, PIGT should be separated by 6.78
kDa from GPAA1 and by 3.45 kDa from PIGS. Furthermore, the other two subunits PIGS (45.252
kDa, UniProt: Q92643) and PIGU (50.052 kDa, UniProt: Q9H490) should also to be resolved on the
same protein gel. The commercial kits NuPAGETM 4-12% Bis-Tris protein gel (see figure 24B),
NuPAGETM 7% Tris-Acetate protein gel (see figure 24C) and the BoltTM 8% Bis-Tris plus gel (see
figure 24E) from ThermoFischer were procured and tested together with a hand cast 18x16cm
Tris-Glycine protein gel (figure 24D). For the experiment, 1x107 HeLaDS1PL GPAA1#76-cells were
harvested, the transamidase subunits enriched via FLAG-IP and separated on the different gel
systems. To analyse their characteristics, the height of the different marker bands as well as the
distance between 37-50 kDa and 50-75 kDa bands was measured with a ruler and are displayed in
table 12. Here the BoltTM 8% Bis-Tris plus gel showed the highest resolution as it focussed bands
more than all other commercial gel systems (0.1 cm against 0.2-0.3cm) and provided the highest
distance between the 50-75 kDa marker bands (1.4 cm against 0.95-1.05 cm) on an 8x8 cm gel.
Contrary to the theoretical expectations, not GPAA1 with its higher molecular weight was to be
detected closest to the 75 kDa marker band, but PIGT. PIGS is seen on the expected height. While
the NuPAGETM 4-12% Bis-Tris protein gel showed a separation between the PIGS and GPAA1 band,
no separation was detectable between GPAA1 and PIGT. The NuPAGETM 7% Tris-Acetate protein
gel failed to separate any of the bands and only the BoltTM 8% Bis-Tris plus gel showed the po-
tential to differentiate between all three bands. The space in-between the bands of PIGT/S and
GPAA1 was not deemed to be sufficient for a successful separation, knowing that p24 and the
p24-pacSph metabolite complex show a different SDS-PAGE running behaviour. A manually cas-
ted 18x16 cm 8% Tris-Glycine gel was chosen to analyse the change in separation behaviour when
the maximal separation distance was increased (previously 8x8 cm). Even though the distance
between the 50-75 kDa marker bands increased from the 1.4 cm of the BoltTM 8% Bis-Tris plus gel
to 3.1 cm, the sharpness of bands decreased as the marker width range increased from 0.1 cm to
0.3-0.65 cm (see figure 24D). Furthermore, no differentiation between the GPAA1 and PIGS signal
was observed.
Additionally, separation properties of manually cast 8x8 cm 7% and 10% Tris-Glycine gels were
compared directly with each other. If the 37 kDa protein marker band nearly reached the end of
the separation gel (not shown), no difference in separation capabilities were observed and it was
not possible to create distinct bands for PIGS, PIGT and GPAA1.
Therefore, the approach was changed and the samples were loaded on a 2D-gel electrophoresis
system (see figure 24F). Even though a nice separation was observed for different unspecific pro-
teins, no signal at all for any of the transamidase subunits could be detected. Therefore, the
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decision was taken to go for a traditional approach by splitting samples on two different gels, to
detect PIGT, GPAA1, and PIGS on different gels without overlapping signals.
Figure 24: Separation of transamidase subunits GPAA1, PIGS and PIGT A) Schematic view of expected
protein transamidase subunit sizes and distances (1-5) to bemeasured to analyse the separation properties
of the different gel systems. B) FLAG-IP loaded on a NuPAGE™ 4-12% Bis-Tris protein gel. C) NuPAGE™ 7%
Tris-Acetate protein gel. D) Hand cast 18x16 cm 8% Tris-Glycine protein gel. E) Bolt™ 8% Bis-Tris Plus
Gel. F) 2D-gel electrophoresis of overexpressed PIGK/T/S and GPAA1. Samples were first separated on an
IPG-strip in the first dimension, before being transfered from the IPG-strip to an SDS-PAGE to resolve he
second dimension.
Table 12: Separation of transamidase subunits on different gel systems
corresponding figure gel system marker width distance between marker bands [cm]
[cm] 37-50 kDa 50-75 kDa
24B NuPAGE™ 4-12% Bis-Tris 0.2 0.9 0.95
24C NuPAGE™ 7% Tris-Acetate 0.2-0.3 0.8 1.05
24D 8% Tris-Glycine (18x16cm) 0.3-0.65 1.61 3.1
24E Bolt™ 8% Bis-Tris Plus 0.1 0.9 1.4
1 not shown in figure 24D
5.5 Endogenous transamidase subunits protein-lipid interactions
5.5.1 pacChol and pacSph labelling characteristics of endogenous transamidase subunits
in HeLaDS1PL GPAA1#76
After verification of endogenous tagged GPAA1 functionality in theHeLaDS1PL GPAA1#76 cell line
and the decision to detect all different transamidase subunits on two different blots, labelling
experiments were conducted to analyse specificity of protein-lipid interactions in the transam-
idase complex. Whole cell lysate was labelled with pacSph and enriched via biotin-N3. Without
biotin-N3 click reaction, no transamidase subunit showed any enrichment (see figure 25A-C). On
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the other hand, only GPAA1 showed substantial enrichment when subjected to a click reaction
The same experimentwas repeatedwith cell lysates frommembrane fractions obtained from cells
labelled with pacChol(see figure 25B) and pacSph (see figure 25C). In both experiments, only for
GPAA1 labelling was observable. To summarise, strong labelling signals could be observed for
GPAA1 with both, pacSph and pacChol.
To analyse if the observed labelling results correlate with the occurrence of cholesterol (CRAC/-
CARC) binding sites, the amino acid sequences for the transamidase subunits were retrieved from
UniProt and used as input samples for the ScanProsite tool. The search terms for cholesterol
binding sites (CRAC: [LV]-X(1,5)-Y-X(1,5)-[KR], CARC: [KR]-X(1,5)-[YF]-X(1,5)-[LV]) were retrieved
from the literature [104] and the search term ([VITL]-X(2)-[VITL][VITL]-X(2)-[VITL][FWY]) for the
sphingolipid binding motif was retrieved from [15];[16]. All sequences that did correspond to one
of the bindingmotifs (see table 13)were considered a hit, when at least one amino acidwas located
inside a transmembrane domain (TMD). When retrieving the protein sequence of PIGU, no data
with respect to the orientation of the N- and C-terminal part (lumenal or cytosolic) was provided
by UniProt. The results are displayed in figure 26. CARC cholesterol binding motifs could be de-
tected for the TMD of PIGT, both PIGS TMDs, the TMDs five and six of GPAA1 and TMDs two, seven
and eight of PIGU. CRAC binding motifs were detected in the first TMD of GPAA1, the PIGK TMD
and TMD three of PIGU. The sphingolipid binding motif of GPAA1 is located in TMD four, and a
partially covered binding motif is present in TMD eight of PIGU. The specific PIGU region with a
similarity to a conserved sequence in long-chain fatty acid elongases [105], was determined to be
between the TMDs four and five. Experimentally, GPAA1 showed labelling for pacChol and pac-
Sph which fits also with the specific motifs found in the in silico screen. Even though a cholesterol
binding motif was suggested for PIGK/U and PIGT, no labelling was detected in the in vivo exper-
iments. As prime candidate for a protein-sphingolipid interaction, only GPAA1 was assessed in
the following experiments.
= 68 =
5 RESULTS
Figure 25: Lipid interactions of transamidase subunits 1x107 HeLaDS1PL GPAA1#76 were seeded, la-
belled for 4 hours with 6 µM pacSph or for 30 Minutes with 10 µM pacChol, harvested and protein-lipid
complexes were enriched by attachment of biotin to the azide group of the bifunctional lipid via a CuAAC
reaction. Western blot signal intensities of three biological replicates were measuered and the interaction
between the lipid and the specific transamidase subunit was determined by the ratio between the enriched
fraction (E) and the 10% Input sample. Shown on the left are the results of one representative experiment.
On the right are the results of the data quantification displayed (n=3). Labellings were either performed in
whole cell lysates (A) or in membrane fractions (B/C).
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Table 13: In silico1 identification of protein lipid interaction motifs in the mammalian transamidase com-
plex subunits.
CRAC2 CARC3 Sphingolipid binding motif4
gene position sequence TMD5 position sequence TMD5 position sequence TMD5
PIGK
66 - 74 Lsv...Yrsvk.R N 54 - 62 Rfwfn.Yrh...V N 274 - 392 LwaLIimVF N
381 - 392 Vffkt.YgikhmK Y 122 - 128 Rs....Yevt..V N
193 - 200 Krr...Ynel..L N
248-257 Rytf..Yvlef.L N
PIGS
66 - 74 Lsv...Yrsvk.R N 17 - 29 KraalfFaavaiV Y
94 - 101 Lk....Ykmki.K N 37 - 46 Kttet.Yras..L Y
331 - 341 LahsplYiqd..K N 43 - 54 Raslp.YsqisgL N
507 - 518 Llhll.YfpddqK N 81 - 87 Klp...Ftv...V N
103 - 112 Rfqka.Yrra..L N
222 - 233 Ksslg.YeitfsL N
252 - 262 RryvqpFlna..L N
367 - 374 Kt....Ynasv.L N
384 - 395 Rvmev.FlaqlrL N
518 - 527 Kfai..Yiplf.L Y
PIGT
63 - 71 Vsh...Yrlfp.K N 60 - 68 RegvshYr....L N 130 - 138 LsnVLsgIF N
76 - 83 Lisk..Ysl...R N 67 - 73 Rl....Fpka..L N 238 - 246 LrqTLsvVF N
171 - 178 Lr....Yavlp.R N 95 - 104 Rtr...YwgppfL N
358 - 365 Vsg...Yglq..K N 209 - 220 RlfhtsYhsqa.V N
368 - 379 Lstll.YnthpyR N 262 - 268 Rm....Fsrt..L N
386 - 394 LdtvpwYl....R N 312 - 321 RktyaiYdl...L N
498 - 507 VsdgsnYfv...R N 356 - 363 Ryvsg.Yg....L N
538 - 549 VcygsfYnllt.R Y 379 - 386 Ra....Fpvll.L N
394 - 400 Rl....Yvht..L N
441 - 451 Kvsiq.Feral.L N
507 - 515 Rl....YtepllV N
PIGU
201 - 210 Vpgll.Yllq..R Y 16 - 24 Raal..Frss..L N 368 - 376 LfpVLwhLW Y
207 - 218 Llqrq.YipvkmK Y 21 - 32 RsslaeFiser.V N
344 - 353 Vwnhl.Yrfl..R N 104 - 113 Kvv...FkkqklL N
400 - 411 Llisd.YfyaflR N 139 - 146 Kvalf.Yl....L N
401 - 412 LisdyfYaflr.R Y 176 - 186 Kgsa..FlsaifL Y
416 - 425 Lthgl.Ylta..K N 210 - 215 Rq....Yip...V N
327 - 335 Ks....YptvgdV Y
350 - 358 RflrniFv....L Y
411 - 420 Rrey..Ylthg.L N
GPAA1
99 - 110 Vglev.YtqsfsR N 171 - 181 Rgqi..YwakdiV N 464 - 472 VvlTLlaIY Y
124 - 134 NVsgtnvYgil..R N 178 - 184 Kdiv..Fl....V N
326 - 335 Rqyk..Ydlva.V N
337 - 349 KalegmFrklnhL N
352 - 362 RlhqsfFlyl..L N
499 - 510 KlvaliYlalq.L Y
541 - 550 Rtl...YaallvL Y
1In silico determination of cholesterol and sphingolipid binding sequences of transamidase subunits. Amino acid
sequences of subunits were derived from UniProt (see appendix 8.5 for full sequences) and used with the Scan-
Prosite tool (http://prosite.expasy.org/scanprosite/) to identify possible cholesterol[104] and sphingolipid[15];[16]
interacting sites.
Search queries: 2CRAC: [LV]-X(1,5)-Y-X(1,5)-[KR]; 3CARC: [KR]-X(1,5)-[YF]-X(1,5)-[LV]; 4sphingolipid bindingmotif:
[VITL]-X(2)-[VITL][VITL]-X(2)-[VITL][FWY]. Capital characters denote essential amino acids of the binding motifs
as defined in the search queries. Not essential characters are displayed in lower case.
5 Only sequences containing at least one amino acid inside a trans membrane domain (TMD) were considered and
are displayed in the schematic drawing (see figure 26).
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Figure 26: In silico determination
of cholesterol and sphingolipid
binding sequences of trans-
amidase subunits. Amino acid
sequences of subunits (PIGK/S/T/U
and GPAA1) were derived from
UniProt (see appendix 8.5 for full
sequences) and used as inputs
for the ScanProsite tool (http:
//prosite.expasy.org/scanprosite/).
Search term for cholesterol[104]
(CRAC/CARC) binding sequences
([LV]-X(1,5)-Y-X(1,5)-[KR]/[KR]-
X(1,5)-[YF]-X(1,5)-[LV]) were derived
from[104]. Hits taken into account
required at least one amino acid
of the motif to be located in a
transmembrane domain. The com-
plete list of hits are displayed in
table 13. The sphingolipid binding
sequence (search term: [VITL]-X(2)-
[VITL][VITL]-X(2)-[VITL][FWY]) was
derived from[15];[16]. For PIGU, no
sequence information was available
regarding the lumenal/cytosolic ori-
entation of the molecule. Dark blue
defines the section hypothesised to
be responsible for recognition of
long-chain fatty acids in GPI[105].
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5.5.2 Inhibition of pacSph labelling of endogenous GPAA1 in HeLaDS1PL GPAA1#76
HeLaDS1PL GPAA1#76 were labelled with pacSph and different specific inhibitors (PPM-
P/FB1/D609) of the sphingolipid pathway (see figure 27A) to determine the specific experimental
settings and functionality of these inhibitors. PPMP inhibits glucosylceramide synthase, FB1 acts
on the ceramide synthase and D609 reduces sphingomyelin synthase activity.
Different concentrations (8/20/41 µM) of PPMP showed a strong decrease of pacGlucCer meta-
bolites on TLC level (see figure 27 C). For the analysis of the influence of PPMP on GPAA1-pacSph
metabolite interactions, cells were labelled with 4 µM pacSph and 25 µM PPMP for 4 hours,
clicked in lysate of membrane fractions with biotin-N3 and enriched over Neutravidin-beads (see
figure 27E). No interaction was observed in pacSph labelled cells without click. Samples that
were subjected to click reactions showed interactions with GPAA1 independent of PPMP pres-
ence. When quantifying the signal intensities of three biological replicates, no difference between
either group (pacSph or pacSph + PPMP) was detectable (p=0.7895, see figure 27G). Furthermore,
mass spectrometric analysis of inhibition via lipidomics[103] (see figure 28B), did not show any
significant differences in lipid composition of the sphingolipid pathway due to high variability
in-between the 3 replicates. To find the optimal experimental conditions for FB1, different con-
centrations and pre-incubation times where tested:
• pre-incubation: 4 hours with 75/150 µM FB1, labelling 0.5 µM pacSph 4 hours (not shown)
• pre-incubation: 15 hourswith 25/50/150µMFB1, labelling 4 µMpacSph 4hours (not shown)
• pre-incubation: 16 hourswith 25/50/150µMFB1, labelling 4 µMpacSph 4hours (not shown)
• pre-incubation: 16 hours with 25/50/100 µM FB1, labelling 1 µM pacSph for 1 or 4 hours
(see figure 27B)
None of these 4 hours settings ( to be directly comparable with the PPMP experiment) provided
satisfying results with regards to reduction and reproducibility of the sought after inhibitory
effect and therefore did not allow for a 1:1 comparison with the PPMP results achieved at four
hours. Furthermore, in all experimental settings it was not possible to achieve a complete
inhibition of the pacSph metabolic pathway. Therefore, the choice was made to switch from
4 hours pacSph labelling with 1 µM to 1 hour labelling (see figure 27B). Here FB1 was able to
increase the amount of pacSph compared to cells without inhibitor present. Furthermore, nearly
no levels or only low levels of the pacSphmetabolites glucosylceramide (GlucCer), sphingomyelin
(SM) and ceramide (Cer) were detectable. Interestingly, only the bands depicting long chained
variants of Cer and SM disappeared, while the short chain-variants seemed to be, even though
on lower level than compared to the control, unaffected. For the analysis of the influence of
FB1 on GPAA1-pacSph metabolite interactions, cells were pre-incubated with 100 µM FB1 for
16 hours, labelled for 1 hour with 1 µM pacSph in presence of 100 µM FB1, clicked in lysate of
membrane fractions with biotin-N3 and enriched over Neutravidin-beads (see figure 27D). Here
a significant reduction of enriched GPAA1-pacSph metabolite complexes between cells with or
without FB1 was observed (p=0.0313, see figure 27F). As with PPMP, the high variability of the
three samples of FB1 did not allow for a reliable quantification with lipidomics, but showed a
significant decrease in sphingomyelin levels (p<0.0001, see figure 28A).
As displayed in figure 27A, after successfully employing the inhibitors FB1 and PPMP, the next
step was to test for a potential contribution of sphingomyelin (SM) to the protein-lipid interac-
tion.
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Figure 27: Analysis of the effect of specific inhibitors of the pacSph metabolism on
GPAA1-sphingolipid interactions in HeLaDS1PL GPAA1#76 cells via TLC and western blotA) Simpli-
fied schematic view of the sphingolipid biosynthetic pathway, the entry point of pacSph (blue), sites of
actions of the inhibitors (PPMP/FB1/D609) and the in HeLaDS1PL cell line knocked out part of the path-
way (red cross). B) Cells were pre-incubated with the ceramide synthase inhibitor Funmonisin B1 (FB1) for
16 hours, before being labelled with 1 µM pacSph for 1 or 4 hours. C, c3-azido-7-hydroxcoumarin only; +,
pacSph only; -, labelling media only; S, standard mix containing pacCer, pacGlucCer, pacPC, pacSph, and
clickSM. C) Cells were labelled with 4 µMpacSph and different concentrations (8/20/41 µM) of glucosylcer-
amide synthase inhibitor D-threo-PPMP (PPMP) for 4 hours and detected via 3-azido-7-hydroxycoumarin.
Et, EtOH control. D) 1x107 cells were seeded, pre-incubated with 100 µM FB1 for 16 hours and labelled
for 1 hour with 1 µM pacSph in presence of 100 µM FB1. Shown is one representative blot of three biolo-
gical replicates. I, Input; FT, flow-through; E, enriched fraction. E) 1x107 cells were seeded, labelled for 4
hours with 4 µM pacSph and 25 µM PPMP. Shown is one representative blot of three biological replicates.
F/G) Ratio between E and I signal intensities of three biological replicates from D/E) are shown. Error bars
represents the standard deviation. T-test was used to test for differences between groups.
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Therefore, different conditions with the SM inhibitor D609 were tested, but none of them showed
any decrease in SM concentrations:
• pre-incubation: 1/4 hour with 25/50 µM D609; labelled: 4 hours with 4 µM (see figure 28C)
• pre-incubation: 1 hours with 187.5/375 µM D609; labelled: 0.5/4 µM pacSph (not shown)
• pre-incubation: 4 hours with 375 µM D609 and 4 hours labelling with 0.5/2 µM pacSph (not
shown)
• pre-incubation: 15 hours with 250 µM D609 and 4 hours labelling with 4 µM pacSph (not
shown)
• no pre-incubation: 250/375 µM D609 labelled with 1 µM pacSph for 1 hour (not shown)
Figure 28: Analysis of the effect of specific inhibitors of the pacSph metabolism on
GPAA1-sphingolipid interactions in HeLaDS1PL GPAA1#76 cells via mass spectrometry and TLC
Shown are sphingolipids measured via mass spectrometry, displayed as mol% of total measured lipids, of
cells treated with A) FB1 and B) PPMP (see figure 27). Data produced jointly with Iris Leibrecht and Chris-
tian Lüchtenborg. Group differences were analysed via one-way ANOVA and Tukey’s honestly significant
difference post hoc test. SM, sphingomyelin; Cer, ceramide; HexCer, hexoyslceramide, contains measur-
ments of glucosyl- und galactosylceramides; HexCer2, lactosylceramide. C) Cells were pre-incubated for
one or four hours with 20/50 µM of spingomyelin synthase inhibitor D609, before being subjected to 4
hours of pacSph labelling. C, c3-azido-7-hydroxcoumarin only; +,= pacSph only; -, labelling media only; S,
standard mix containing pacCer, pacGlucCer, pacPC, pacSph, and clickSM.
To summarise, GPAA1-pacSph metabolite interaction could be inhibited through the ceramide
synthase inhibitor FB1, while the glucosylceramide synthase inhibitor PPMP did not interfere
with the interaction. The sphingomyelin synthase inhibitor D609 proved unable to decrease SM
concentrations in any of the tested conditions and additional experiments were suspended.
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6 Discussion
The aim of this thesis was to establish an experimental setup to analyse protein lipid interac-
tions of the transamidase complex, which is responsible for GPI-anchor attachment. Two ap-
proaches were tested and the experimental setup will be briefly described and the implications of
the results will be discussed. The first approach contained transiently transfection of four of the
transamidase subunits (PIGK/T/S, GPAA1), experimental optimisation of solubilisation paramet-
ers (temperature, duration of cell lysis, detergent of choice), best method for analysing transam-
idase subunits on a gel system as well as detection of sphingolipid-protein interactions through
bifunctional pacSph via click-reactions. The second approach shifted from an over-expression to
an endogenous system containing tagged GPAA1, while keeping variations to the rest of the work
flow (pacSph, click-reaction) to a minimum.
6.1 Analysis of protein-lipid interactions of the transamidase complex via
transient expression
6.1.1 Optimisation of experimental parameters of transient expression and solubilisation
of transamidase subunits
In a first approach, transient expression of four transamidase subunits (PIGK/T/S, GPAA1) was
conducted and a concentration dependent solubilisation efficiency was determined for GPAA1
(see figure 7), the prime candidate for a sphingolipid protein interaction [16; 85]. GPAA1 contains
seven TMDs and therefore hosts, compared to PIGK/T with one TMD and PIGS with two TMDs, an
increased amount of hydrophobic amino acids whichmight play a role in its selectivity for certain
solubilisation parameters. The fifth subunit PIGU, which in contrast to GPAA1 did not show up in
a screen for sphingolipid protein interactions[16], might have shown comparable characteristics
due to its hypothetical nine TMDs (see figure 26), but due to a non-functional cDNA the experi-
ments could not be performed during the course of this work.
To generate reproducible and stable western blot signals, the best conditions for solublisation
of GPAA1 were determined by analysis of different detergents (Triton-X-100, Nonident-P40, OG,
CHAPS). Of these, the non-ionic detergent Nonident P40 was selected as the candidate of choice
(figure 8). The other non-ionic detergent Triton-X-100, chemically nearly identical withNonident
P40 (which is not to be confused with the detergent NP-40) proved to be the second best deter-
gent in this experiment. These findingsmatch protocols used in literature, where NP-40[105; 106],
Nonident-P40 [51; 52], digitonin [51; 52], Triton-X-100[16] were used. Furthermore, detergent free
lysis via sonication[85] proved efficient. With this setting, it was possible to immunoprecipitate
all tested subunits (see figure 9A), as well as Co-IP all subunits with the exception of PIGU (see e.g.
figure 9B). This one might be due to the disruptive characteristics of Nonident P40 and Triton-X-
100, and aligns well with reports where mild detergents such as digitonin are needed to Co-IP all
subunits, indicating a tightly associated core complex containing PIGK/T/S and GPAA1, as well
as a loosely attached PIGU[52; 105].
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6.1.2 Optimisation of experimental parameters of click reactions to detect GPAA1-lipid
complexes in transiently transcfected HeLaDS1PL cells
GPAA1-sphingolipid interactions have been shown before in HeLa cells labelled with [3H]-photo-
Sph precursor[16] and in HeLaDS1PL cells labelled with pacSph[85]. Surprisingly, labeling
HeLaDS1PL cells with pacSph and a subsequent click reaction with Alexa-647-N3 on proteins
bound to FLAG-beads did not result in the expected GPAA1-lipid complex signal in in-gel fluor-
escence and subsequent western blot analysis (figure 10B). The reason for the discrepancy with
published data might be due to a combination of the high hydrophobicity of the seven TMDs of
GPAA1 and the interference of the click reaction reagents with the GPAA1-pacSph metabolite
complex binding to FLAG-beads as biotin-N3 enrichment via neutravidin beads (see figure 4F-G in
[85] and figure 14 of this work) provided results in agreement with[85]. This behaviour might be
characteristic for GPAA1, as the positive control p24 (not shown in this experiment, but visible in
figure 11) did worked as expected in Alexa-647-N3 click reaction of proteins bound to FLAG-beads
(see figure 6 of article [18]). Repeating the same experiment, but performing the click reaction
in whole cell lysate (see protocol 4.13.1.2) before IP with FLAG-beads, resulted in the expected
detection of the GPAA1-pacSph metabolite complex (see figure 10C). To increase the reproducib-
ility and signal intensity of the click reaction, the influence of the two detergents known best to
solubilise GPAA1, Triton-X-100 and Nonident P40, were compared with regards to their influence
on labelling efficiency (see figure 10D). Triton-X-100 showed a clear superior result, which was in
line with a similar analysis of click reaction parameters [107], and compensated for the slightly
lower GPAA1 solubilisation efficiency.
6.1.3 Analysis of sphingolipid binding kinetics in HeLaDS1PL cells transiently transfected
with GPAA1
The cell line HeLaDS1PL[18] was selected to study protein-sphingolipid interactions. Previous
experiments performed in the Brügger group have shown a time dependent increase of GPAA1
labelling with [3H]-photo-Sph over time, with a sharp rise in the first 15-30 minutes. Based on
these data, it was hypothesised that the prime candidate for an interaction with GPAA1 might
be ceramide, the first metabolite of sphingosine (see figure 1). Based on this assumption, a time
course to assess GPAA1 labelling kinetics with pacSph was performed and provided similar res-
ults (see figure 11A/C). TLC analysis of pacSph metabolism (see figure 11D) depicted pacSph and
pacCer to be the most abundant sphingolipid species during the first two hours. Therefore, a
certain uncertainty exists regarding the question which one of these species is incorporated in
the GPAA1-lipid complex. The observed kinetics of the pacSph metabolism in HeLaDS1PL cells
are in line with data of the same cell line[18]. When analysing the signal intensity of all available
metabolites for each given point in time, it is to be observed that over time the overall signal
intensity increases (see figure 10B). This indicates, that a constant influx of extracellular pacSph
takes place and the observed sphingolipid kinetics do not depict the actual intracellular meta-
bolic conversion rates. When labelling continuously with pacSph, it is not possible to correlate
a specific GPAA1-lipid complex signal at a given time point to a specific sphingolipid. Therefore,
the idea was to reduce the overall signal intensity and even out the variation in temporal sig-
nal intensity (as seen in figure 11B) through a pulse chase experiment (see figure 12C/D). The
temporal resolution of different pacSph metabolites aligned now with the ones observed in [85],
but still did not allow for matching a certain time period with a specific metabolite. Further-
more, the available level of sphingolipid fed into the cell did not prove sufficient for detection of
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protein-lipid complexes onwestern blot level (see figure 13). Additionally, the binding kinetics of
continuous labelling with pacSph and detection via Alexa-647-N3 (see figure 11C) were verified in
a second methodological setup via attachment of biotin-N3 to the cross-linked pacSph metabol-
ites (see figure 14B) similar to the approach in [85]. Here it was seen that the labelling kinetics of
GPAA1 did not differ at all from p24, which is known to interact specifically with sphingomyelin
18[15]. Therefore it should show different labelling kinetics than GPAA1, which is suspected to
interact with ceramide or a lipid in the early stages of the spingolipid biosynthetic pathway.
On another note, the transient transfection of GPAA1 in HeLaDS1PL cells limited the available la-
belling conditions compared to transfection with p24. When higher levels of pacSph (e.g. >3 µM)
were administered to cells transfected with GPAA1, an increased cell mortality (e.g. > 50%, data
not shown) was observed at prolonged labelling periods (e.g. >4 hours). Reducing pacSph concen-
trations allowed for labelling times up to 6 hours, but led to variations in the signal intensity for
Alexa-647-N3 detection. When cells were transfected with p24, none of these limitations applied
(not shown). In contrast, mouse embryonic fibroblasts (MEFs) did not show any susceptibility to
even harsher labelling conditions[85]. In future experiments, a careful analysis of suitable exper-
imental parameters (amount of GPAA1-plasmid DNA transfected, variation of labelling time and
concentration of pacSph) could be carried out to address these issues. A Co-IP of transamidase
complex subuits via transiently expressed GPAA1 (see figure 9B) or PIGT (not shown) showed the
capability to pull-down transamidase subunits, but lacking signal intensity compared to GPAA1.
This difference might be due to artificial DDK epitope tags for the primary IP targets, while the
subunits were detected via endogenous epitopes. Furthermore, when analysing the intracellu-
lar localisation of HeLaDS1PL cells transiently expressing GPAA1 via immunofluorescence mi-
croscopy (not shown), a cytosolic accumulation of GPAA1 was observed. Expected would be a
localisation in the ER. This accumulation in the cytosol has also been reported in studies of tumor
tissue with overexpression of GPAA1[108; 109]. This indicates that the amount of plasmid DNA
required for repeatable and detectable expression levels of GPAA1 on western blot level (see fig-
ure 8) introduced a high amount of GPAA1 not incorporated into the transamidase complex and
breaking its stoichiometric composition in Co-IP experiments. Therefore, the results obtained
with a transient expression system do not provide reliable information about the real lipid en-
vironment of the transamidase complex. Therefore, the decision was made to move forward and
establish an experimental system to work with the endogenous transamidase complex.
6.1.4 Separation of transamidase subunits via different protein gel systems
Another step for validation of this experimental setup was to assess whether all transamidase
subunits (see section 5.4.7) can be analysed on one SDS-page to circumvent variability of sig-
nal quantification between the same sample in one experiment. For this, different PAGE-systems
were evaluated, but none of them allowed for a clear separation of all subunits. As depicted in fig-
ure 24A, the subunits PIGT (65.1 kDa), PIGS (61.65 kDa) and GPAA1 (67.623 kDa endogenous, with
FLAG-tag 71.87 kDa) are supposed to be difficult to separate. The gel system closest to achieve
this would have been the 8% Bis-Tris plus gel, but the requirement of having a high resolution
between 37-75 kDa and especially in the region between 60-75 kDa were not fulfilled to a sat-
isfactory extent. Therefore, an attempt was made to separate the region between 60-75 kDa in
the vertical as well as the horizontal dimension via 2D-gel electrophoresis. After establishing a
robust protocol, it was not possible to detect any signal of the transamidase subunits (see figure
24F). Based on the isoelectric points of PIGS/T and GPAA1 it should have been possible, in com-
bination with the slightly different molecular weight, to distinguish between these subunits. As
= 77 =
6 DISCUSSION
high hydrophobicity of transmembrane regions can lead to precipitation events occurring un-
der the high voltage during the isoelectrical focussing in the IPG-strip, in certain conditions (e.g.
grand average of hydropathy (GRAVY) scores >0.5) a blue native PAGE is superior to isoelectric
focusing [110]. When calculating the scores of the transamidase subunits (see table 14), only PIGU
breached this threshold and GPAA1 came close to it (0.4). But as the calculation of the theoretical
GRAVY score did not account for post-translational modifications, this values might have been
off and the high hydrophobicity of the transmembrane regions might have led to precipitation
events occurring under the high voltage during the isoelectrical focussing in the IPG-strip, thus
preventing transfer to the second dimension. A possible solution for this problem could have
been to change the first dimension separation system to blue native PAGE or by using ionic de-
tergents (e.g. SDS, 16-BAC or CTAB)[110; 111]. Instead of spending further time consuming work
to optimise SDS-PAGE based separation of the transamidase subunits, the decision was taken to
go for a traditional approach by splitting samples on different gels to detect PIGS/T and GPAA1
on two different gels.
Table 14: Structural features of the transamidase complex subunits for 2D-gel electrophoresis
Name UniProtID isoelectric point1;2 grand average hydropathy (GRAVY) score2;3
GPAA1 O43292 8.19 0.40
PIGK Q92643 5.76 -0.22
PIGT Q969N2 8.68 -0.12
PIGS Q96S52 6.05 -0.06
PIGU Q9H490 7.74 0.92
1computationally derived values: www.web.expasy.org/compute_pi/
2input sequences are listed in Appendix 8.5.
3computationally derived GRAVY score: www.bioinformatics.org/sms2/protein_gravy
6.2 Analysis of lipid protein interactions of the endogenous transamidase
complex
Two approaches for the development of a system to study the endogenous transamidase complex
were followed. The first one was based on IP of endogenous subunits via an antibody specific
for GPAA1, while the second one relied on a CRISPR/Cas9 guided cell line generation containing
C-terminal tagged GPAA1.
6.2.1 IP of the endogenous transamidase complex
Coupling the anti-GPAA1 antibody (sc-373710) with CNBr-beads allowed for enrichment of the
endogenous GPAA1, but was not efficient to Co-IP transamidase subunits besides PIGS (see fig-
ure 15A). Increasing the amount of cells by the power of ten did not change this outcome (see
figure 15B). Instead, a limitation in the binding capacity of the CNBr-beads, when compared to
FLAG-beads in IP of GPAA1-DDK, was observed (see figure 15C). Repetitive usage of the same set
of CNBr-beads over the course of multiple experiments might have led to reduced binding capa-
cities of these bead due to the following reasons: First, the elution of the proteins might have
been incomplete. Second, the heavy chain of the antibody was detectable with increasing sig-
nal intensity in each experiment, while the GPAA1 signal intensity decreased. Third, the manual
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washing steps of the beads might have led to decreased bead volume.
To be able to handle even higher amounts of cellular material without the mentioned limitations
of the CNBr-beads, the antibody was coupled to a NHS-column. But as this did not provide a func-
tional coupling (see figure 15D), the decision was taken to go directly for the generation of a cell
line containing C-terminal tagged GPAA1.
6.2.2 CRISPR/Cas9 guided cell line generation containing C-terminal tagged GPAA1
When comparing tissue specific GPAA1 expression listed in the human protein atlas (HPA) project
(see figure 30 in the appendix), the cervix is generally one of the tissues with a higher than av-
erage expression of GPAA1. Data from the tissue-specific gene expression and regulation (TiGER)
database, even though quite outdated with a time stamp from 2008, points in a similar direc-
tion (see figure 29 in the appendix). An up to date reference is the EMBL-EBI Expression Atlas
which and can be found at (https://www.ebi.ac.uk/gxa/home). There, the search term GPAA1
lists over 33 different experiments that assessed GPAA1 expression levels in different tissues and
cell lines and classifies the cervix as a tissue with high expression (based on the same GTEx data-
set used in the HPA). The already available sphingosine-1-phosphate lyase deficient HeLa cell line
(HeLaDS1PL[18]) in our lab and the results of the GPAA1 protein level screening (see figure 16 and
table 11) set the rational to use HeLaDS1PL as the cell line for the genomic integration of a C-
terminal tag for GPAA1.
Having decided on a cell line, CRISPR/Cas9 was chosen as the technique of choice for generation
of a cellular model to study sphingolipid interactions within the endogenous transamidase com-
plex. Respective gRNAs were designed (see figure 17) and tested with regards to their capabilities
to introduce DNA double strand breaks (see figure 18). In this process it is to be noted that DNA
extracted from cells transfected with the gRNAs in question and not heterodimerised with wild-
type extracts showed respective fragments of the heterodimerised samples after treatment with
the surveyor nuclease. This is explained by the fact that the transfection reagent Fugene does
not have a 100% transfection efficiency in HeLa cells and therefore there will always be a mixture
between cells transfected and cells corresponding to the wild-type. After having all plasmids
ready (plasmid containing the gRNAs, the homology sequence containing the to be inserted tag,
the plasmid containing the human codon optimised Cas9), cells were transfected for 72 hours
and single cell clones were created by serial dilution into 96 well plates as described in [88]. Out
of 55 clones tested, 14 were determined to be heterozygous for tag insertion (25%), while two
clones (#76, #39) were homozygous (3.6%). This aligns with previously reported low efficiency of
homology directed repair (< below 10% of modified alleles) integration of genomic material[112].
Additionally, it is to be noted that in over 60 years of propagation of HeLa cells a lot of gen-
omic variations did occur and the copy number of the majority of the loci is 3 or higher[113].
Therefore, the generation of two homozygous clones can be seen as a good achievement con-
sidering the methodology used. Maybe an increase in transfection efficiency by reducing the
amount of plasmids to two (gRNAs/Cas9 on the same plasmid) or even to one (gRNA, homology
sequence, Cas9 on the same plasmid) plasmid might be helpful. Furthermore, reduction of off-
targets could be achieved by switching to a Cas9 nickase system[114]. For further experiments,
the clone HeLaDS1PL#76was selected as it contained only a one nucleotidemismatch in the 3’UTR
region, compared to a deletion of 9 nucleotides in the 3’UTR of HeLaDS1PL#39 (see figure 19). It
might be noted, that this genomic alteration could potentially influence the localisation/expres-
sion levels of GPAA1 [115; 116], but for the purpose of this project and the projection of 27/146
off-targets being located in genes (see figure 31) it seemed reasonable to only test for the integrity
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of the transamidase complex and its functionality.
The arrival of the GPI-anchor protein CD59 at the plasmamembranewas used previous as amodel
to determine transamidase complex activity[117]. Therefore, a comparison between HeLaDS1PL
and HeLaDS1PL#76 was conducted to assess the function of the transamidase complex (see fig-
ure 20C-E). No difference in the cell surface arrival of basal and transient expressed CD59 was
observed, thus indicating no substantial interference of the C-terminal tag with the function of
GPAA1 and the transamidase complex. Having verified the non-interference of the introduced
3xFLAG and 2xStrep-tag, the suitability to enrich the transamidase complex was successfully as-
sessed via FLAG- (see figure 20A and figure 24B-E) and streptactin-beads (see figure 20B). Further-
more, the complex constituted out of PIGK/T/S and GPAA1 (see figure 20A/B) and thus showed a
result comparable to the outcome of transient transfection (see figure 9B and [47]) and endogen-
ous IP (see figure 15A). While in the transient expression experiment it was not possible to Co-IP
or express PIG-U (see section 6.1.1), the use of SMA to extract endogenous tagged GPAA1 within
its native lipid environment showed a faint Western signal of PIG-U in the enriched fraction (see
figure 22A) located at the predicted height of around 50 kDa. This did not correspond to liter-
ature reported SDS-Page running behaviour of around 38 kDa[105], but was in agreement with
manufactures informations (a-PIGU antibody, see table 3). The experiment showing the 38 kDa
band of PIGU was based on Co-IP of whole cell extract of mammalian cells transiently transfected
with the yeast homologue of PIGK with a SDS sample buffer containing 6 M urea[105; 118]. The
addition of urea might have resulted in a more complete denaturation of PIGU[105], thus provid-
ing more opportunities for SDS to interact with the respective amino acids. This has been shown
to be specifically important for transmembrane containing proteins and might determine the
appearance or magnitude of ”gel shifting”, a term describing the fact that the formal molecular
weight might not correspond to the actual migration on the SDS-PAGE[119]. Therefore, the dis-
crepancy between results observed in this thesis and the literature might be due to the absence
of urea in the sample loading buffer, affecting the migration pattern of PIGU. This does not affect
the overall outcome, which is the ability to extract from the HeLaDS1PL GPAA1#76 cell line the
complete transamidase complex in its native lipid environment with SMA. In a proof-of-principle
experiment, it was ascertained that SMALP extracted from FLAG-beads mixed with a SMA whole
cell lysate of HeLaDS1PL GPAA1#76 cells allowed for detection of lipids viamass spectrometry (see
figure 23), but similar physiochemical properties of SMA and the endogenous lipids incorporated
in the SMALP nanodisc did not allow for a separation between SMA and the incorporated lipids,
thus indicating that further experiments are required to establish a lipid extraction method tak-
ing into account the characteristics of SMA. In the future, due to the 3xFLAG-Twin-Strep tag, this
systemmight also provide structural information via single particle cryo-electron microscopy as
it was already shown for other SMA extracted proteins[74]. This is of special interest, because
nowadays no structures are available depicting the whole complex and how all of the subunits
intervene in the process of GPI-anchor attachment.
Finally, HeLaDS1PL GPAA1#76 cells were assessed for their compatibility with different click-
reaction protocols (Alexa-N3 and biotin-N3 click reaction in whole cell lysate) and verified the
protein lipid interaction seen in the transient transfection experiments as described above.
Summarising, HeLaDS1PL GPAA1#76 contains the C-terminal 3xFLAG-Twin-Strep tag and GPAA1
can be purified over either of them. The knock-in did not influence the function of the transami-
dase complex as measured by CD59 cell surface expression levels and is compatible with different
click protocols.
= 80 =
6 DISCUSSION
6.2.3 Protein-Lipid interactions of the endogenous transamidase complex
To assess potential lipid interactions of the transamidase complex subunits, the model cell line
HeLaDS1PL GPAA1#76 was subjected to continuous labelling with the bifunctional lipids, pacChol
and pachSph and detection via biotin-N3.
6.2.3.1 Interactions of cholesterol with the endogenous transamidase complex Of the
subunits of the transamidase complex, only GPAA1 showed a strong labelling signal (see figure
25B). This matches with the two detected CARC binding motifs in the TMDs 5 and 6 of GPAA1 (see
table 13 and figure 26). Weak signals for PIGK/T/S (see figure 25B) were visible, but were not
reliable quantifiable. This does not match with the in silico predicted cholesterol binding motifs,
where PIGK/S/T/U seemed to contain either CRAC- or CARC-motifs or both. As seen in table 13,
the amount of cholesterol bindingmotifs inside of TMDs is much smaller than bindingmotifs loc-
ated outside of TMDs. It has been shown that proteins exist that use exposed cholesterol binding
motifs to interact with cholesterol containing liposomes[120]. As the transamidase complex is not
being thought of having interactions of such type, the focus was set on motifs which have at least
one amino acid inside of the TMD. Amass spectrometry–based profiling of sterol-binding proteins
in HeLa cells identified over 250 cholesterol-binding proteins and the follow up pathway analysis
identified the ”GPI-anchor synthesis” as one of the top 5 KEGG pathway matches and one of the
top 12 of biological function networks as assessed via the DAVID gene ontology server [121]. All
transamidase subunits in this experiment were seen to interact with cholesterol in the following
quantifiable order: GPAA1=PIGS=PIGT~PIGS>PIGU. This contradicts somehow the results of this
thesis, where the observed signal of GPAA1 clearly dominates over the weak signals for PIGK/T/S.
This discrepancy can be explained through themissing validation of the results and the high sens-
itivity of mass spectrometry in[121]. Especially the latter one might provide false positive results
for the members of the inner core complex PIGK/T/S, which are in close proximity to the cho-
lesterol binding protein GPAA1. This aligns well with a model where PIGK/T and GPAA1 are part
of a closely associated inner core complex inside of the transamidase complex[46]. This results
further indicate, that some sort of spatial arrangement into specific lipid domains occurs, where
specifically cholesterol surrounds the inner core complex. Lipid analysis of SMALPs containing
endogenous transamidase complex via mass spectrometry might provide the key to verify this
assumption and allow a closer look at the exact lipid environment surrounding the transamidase
complex inside the ER membrane.
6.2.3.2 Interactions of sphingolipids with the endogenous transamidase complex Of
the subunits of the endogenous transamidase complex, only GPAA1 showed a strong labelling
signal (see figure 25A/C) and aligns well with the results of transiently expression of GPAA1 in
HelaDS1PL cells, as presented in this thesis and in[16; 85]. In a proteomic profiling of protein-
sphingolipid complexes[85], endogenous GPAA1 has been identified as an interaction partner
for sphingolipids in MEFDS1PL cells[85]. Under the stringent criteria applied in this screen (4x
fold increase in spectral counts between treated and untreated cells) PIGK/PIGS/PIGT showed
no observable enrichment in any of the three biological replicates, while PIGU was not part of
the 2098 annotated hits[85]. As PIGU came up in the in silico screen with a partial sphingolipid
binding motif, this one is most likely a false positive as the last amino acid tryptophan (W) in the
binding motif is outside of the TMD and therefore lacks probably the properties to accommodate
the respective sphingolipid head group[15]. This characteristic of one or more amino acids being
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outside of the TMD, is generally seen in nearly all motifs (CRAC, CARC, sphingolipid) residing
in the TMDs of PIGU. When PIGU was discovered in 2003, it was suspected that PIGU might be
responsible for recognition of long-chain fatty acids in GPI[105]. 15 years later, this hypothesised
function was reaffirmed by a bioinformatic screen that found a membrane-embedded domain
conserved in the GPI-anchor synthesis pathway of the proteins PIGB/M/U/W/V/Z[122]. This
Bind-GPILA(“bind GPI lipid anchor) motif is consistently available throughout the GPI-anchor
synthesis pathway and comprises out of a stretch of 10 TMDs[122]. Comparing this with the
annotation retrieved from UniProt, which is also referenced as source data of the article, reveals
that only 9 TMDs are annotated for PIGU and it was suggested that a signal peptide sequence
was wrongly assigned and should have been a TMD in reality[122]. This might have resulted in
annotation of two more CARC motifs (see 6.2.3.1) in the hypothetical TMD1, but would not have
changed the outcome of the experimental results.
The subset of specific sphingolipid species interacting with the transamidase complex were
to be elucidated by selective inhibition of enzymes involved in the sphingolipid metabolism
(see figure 27A). Fumonisin B1 (FB1) inhibits ceramide synthases[123; 124] and was used to
investigate if sphingosine or one of its downstream metabolites are engaged in the interaction
with GPAA1. The decrease of labelling intensity (see figure 27B/D/F) indicates that the primary
interaction partner of GPAA1 is not a sphingosine. Mass spectrometry analysis of the actual lipid
composition of this experiment showed only a significant decrease in sphingomyelin levels and
a trend towards decreased hexosylceramides, while ceramides and lactosylceramides showed
no difference (see figure 28). Independent of the FB1 concentrations used and variations of
different pre-incubation and labelling times, it was never possible to achieve a nearly complete
reduction of ceramide levels as seen in MEFDS1PL cells[85]. The intriguing observation was,
that HeLaDS1PL GPAA1#76 cells treated with FB1 displayed a reduction of sphingomyelin and
ceramide containing long chain length fatty acids, comparable to the HeLaDS1PLDCerS2 cell
line[125], which is characterised by its knock-out of the ceramide synthase 2 (CerS2). CerS2 (next
to CerS4 and CerS3) is specifically involved in the synthesis of ceramides containing fatty acid
chain lengths (C20-C26), while CerS6 (next to CerS5) is required for generation of ceramides
containing short chained fatty acids (C14-C16)[126]. During the generation of the HeLaDS1PL
cell line, a slight, but not significant increase of sphingolipids containing short chain fatty
acids and a significant decrease in long chain fatty acids was reported [18]. CerS6 came up as a
differentially regulated protein during a proteomic comparison between HeLa and HeLaDS1PL,
but was classified as a false-positive hit based on western blot expression levels[18]. An in-depth
analysis of the influence of FB1 on fatty acid chain length in HeLaDS1PL GPAA1#76 cell line
treated with FB1 compared to untreated cells (not shown) demonstrated a nearly 50% decrease
of ceramide 42:2,2 (two-sided t-test, p=0.0006) and a trend for an increase of ceramide 34:1,2. The
latter one might be due to high variability of drug efficacy and low sample number (n=3). This
would indicate either a difference in the set of ceramide synthases active in the HeLaDS1PL based
cell line HeLaDS1PL GPAA1#76 or a difference in expression levels of specific ceramide synthases
with a respective interference on FB1 activity, as literature reports indicate that in some cases of
increased levels of ceramide synthases FB1 might not display its inhibitory effect and even result
in elevated ceramide levels [127]. Additionally, there might be an unkown specificity of FB1 to
respective ceramide synthases, but this has not been investigated so far. In summary, the FB1
experiment indicates that the specific interaction partner of GPAA1 is not sphingosine, but one
of its downstreammetabolites and probably one containing long chain fatty acids. To verify this,
there might be additional experiments required, employing different specific CerS inhibitors in
combination with additional inhibitors downstream of the sphingosine metabolite ceramide.
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The second inhibitor investigated was PPMP which acts on the glucosylceramide synthase. Here,
no interference with GPAA1 labelling was observed (see figure 27E/G). This might be due to no
significant changes in the lipid profile (see figure 28B) as detected by mass spectrometry. The
low number (n=3) and intra experiment variability of the samples (two showing the same trend,
one the opposite) did not allow to attain statistical significance. When taking the TLC results
(see figure 27C) in consideration, PPMP showed a complete reduction of glucosylceramide and
therefore eliminates glucosylceramide as an interaction partner of GPAA1.
The third inhibitor assessed was D609, which has been shown in different literature sources to
inhibit sphingomyelin synthase (SMS)[128; 129; 130] in a dose dependent manner[131; 132]. D609
was proven to inhibit SMS1 with a two fold higher specificity than SMS2[130]. For example, in-
cubation times of two hours with 50 µM D609 were sufficient to block sphingomyelin synthesis in
HeLa cells[129]. Pre-incubation with 50 µM D609 for over 6-24 hours did not result in unbearable
cell toxicity[133]. Furthermore, HeLa cells with transfection stress and 4 hours of 200 µM D609
did not die due to cell toxicity[134]. 300 µM D609 over 16 hours of pre-incubation did not increase
mortality of mouse myoblasts[135]. The inhibition of SMS via D609 has been shown to increase
intracellular ceramide concentrations, to induce cell cycle arrest and apoptosis[136; 137]. In
this thesis, different concentrations of D609 (with/without pre-incubation time) together with
pacSph were assessed for their ability to inhibit SMS and to remove sphingomyelin as a potential
interaction partner of GPAA1. Unfortunately, none of the tested concentrations showed a
reproducible reductionof cellular SM levels. Either the cell toxicity was not tolerated by the
cells and up to 90% died (not shown), or there was no effect measurable on sphingomyelin levels
detected via TLC (see figure 28C). When using 375 µM for 4 hours with 0.5 µM pacSph without
pre-incubation time, a reduction of sphingomyelin was observed, but due to the overall low
intensity on TLC level due to low lipid quantities, this could not be used as a suitable experiment
for the biotin-N3 click reaction. A theoretical possibility for this behaviour could be, that the
increased level of intracellular ceramide due to reduced channelling into sphingomyelin and the
continuously inflow of ceramide through pacSph passed the threshold of intracellular ceramide
concentrations and activated the pro-apoptotic signalling of ceramide[138].
In the future, the treatment of the generated HeLaDS1PL GPAA1 # 76 cell line with respective
inhibitors and mass spectrometric analysis of SMALPs containing the endogenous transamidase
complex would help to get insights into lipid interactions of the transamidase complex.
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8 Appendix
8.1 Sequences: GPAA1 genomic context
Genomic sequence of GPAA1 including exons, introns, start/stop codons and 3’UTR
>8 dna:chromosome chromosome:GRCh38:8:144082610:144086216:1 GTCTCTGGGACCGGAAGTGCGGGCGAG
CGCGGGTCCCCGGGTCTGACAGGAGCAGCCTGTGGGCACCGCGGCGGTAGTTGGAGGCGGGAGAGGGTCCGTAGCC
GCGCCGCCCTGCCCCGCC ATG GGCCTCCTGTCGGACCCGGTTCGCCGGCGCGCGCTCGCCCGCCTAGTGCTGCGCCT-
CAACGCGCCGTTGTG GTGAGGACAGGGCCCGGGGAGGCGGGGACCCGAGGGCCCTGGGCTCGCGCCGGCGGCCCCA
TGCGCGGTCCCCATCGAGGGCCGGGGCCGCTCCAGCTGCTCGCGCCCCTCCGGCTGCTCGCGCCCTTCCGCTCCTGCC
CTCTGGAAGCACTGAGGGTATCAGGCCCAGGCTTAGGGCTCGGGTCCGGCGTCCCGATGCAGGACTCCGGGTTTAG
GTCTCCCAGACCCGCGCGATCGACCCCGGGTGCGGAGGTTGTGGCCTCGGGTCGGCGTCTGAGGACCCGCTGACGCT
CCGGTGCCCCTCCGTCCTCTCTCACAG CGTGCTGAGCTACGTGGCGGGCATCGCCTGGTTCTTGGCGCTGGTTTTCC
CGCCGCTGACCCAGCGCACTTACATGTCGGAGAACGCCATGGGCTCCACCATGGTGGAGGAGCAGTTTGCGGGCGG
AGACCGTGCCCGGGCTTTTGCCCGGGACTTCGCCGCCCACCGCAAGAAGTCGGG GTGAGCGGCAGAGCAGGGCGTA
TGGGGCGAGCAGTGGTGGCTAAGGCCGGGGAGCTCTGCTCAGAGGCTCCCTTCGTGTCTGCAG GGCTCTGCCAGTG
GCCTGGCTTGAACGGACGATGCGGTCAGTAGGGCTGGAGGTCTACACGCAGAGTTTCTCCCGGAAACTGCCCTTCCC
AGATGAGACCCACGAGCGCTAT GTACTGGGGGAGTGGGGTGTGCCTGGGCCCAGAAAGCACCTTGGAGGGAGGGG
TCTGGGCTGGGTATCACCTTGCGGGGGTGTCATGGGGCCAGGAAGCTCAGTGGGAGGGAAATCCCTGGTGGGCACT
GGAGGGCTAGGAAAGTTGTGGGGGGCCCTTCAGCCCCCTACCACAAAGTTACACTGAGGCTCCCCCCACCGATGCTG
CATACAG ATGGTGTCGGGCACCAACGTGTACGGCATCCTGCGGGCCCCGCGTGCTGCCAGCACCGAGTCGCTTGTG
CTCACCGTGCCCTGTGGCTCTGACTCTACCAACAGCCAGGCTGTGGGGCTGCTGCTGGCACTGGCTGCCCACTTCCG
GG GTGAGTCTCAGGGCTGCTGGCCGTGGAGGGGTTTGGTCAGTGCCCCAGACCCTGCTGATCCTGCTTCTGGCCTCC
AG GGCAGATTTATTGGGCCAAAGATATCGTCTTCCTGGTAACAGAACATGACCTTCTGGGCACTGAGGCTTGGCTT
GAAGCCTACCACGATGTCAATGTCACTG GTAGGTTCTCTTGTCCTGCCTGCCCTGGTCCCCCTCTCAGGGTCACTGT
CCTCACCACGTCCTCCATTAGCACTCATTCACTTGCTCCTACAG GCATGCAGTCGTCTCCCCTGCAGGGCCGAGCTG
GGGCCATTCAGGCAGCCGTGGCCCTGGAGCTGAGCAGTGATGTGGTCACCAGCCTCGATGTGGCCGTGGAGGGGCT
TAACGGGCAGCTGCCCAACCTTGACCTGCTCAATCTCTTCCAGACCTTCTGCCAGAAAGGGGGCCTGTTGTGCACGC
TTCAGGGCAAG GTGGGGCTGCCTGCCTGCCTGAGGGCTGAAGGGCACAGGGTCTGTGGGAGGGGCTGTCTCATCCT
GTCCTGCACCTCTAAAG CTGCAGCCCGAGGACTGGACATCATTGGATGGACCGCTGCAGGGCCTGCAGACACTGCT
GCTCATGGTTCTGCGGCAGGCCTCCGGCCGCCCCCACGGCTCCCATGGCCTCTTCCTGCGCTACCGTGTGGAGGCCCT
AACCCTGCGTGGCATCAATAGCTTCCGCCAGTACAAGTATGACCTGGTGGCAGTGGGCAA GTAAGTAGTCTCTGGT
CCCCCCTTTCCATGCCCAGGATGGGGTCTAGCTGGAGCGGAGTGGGGGATGGCCTGGTGGCTCTGGCCAGCCGTGAA
CCTGCCCCACACCTGACAG GGCTTTGGAGGGCATGTTCCGCAAGCTCAACCACCTCCTGGAGCGCCTGCACCAGTCC
TTCTTCCTCTACTTGCTCCCCGGCCTCTCCCGCTTCGTCTCCATCGGCCTCTACATGCCCGCTGTCGGCTTCTTGCTC
CTGGTCCTTGGTCTCAAG ATATCCTCTGCCCCTTGCCATCTACCTGTGACCAGCCTCCAGTCTCCTCAACTCTAGGC
TGGGGAGAGTCTTCCATCCTGATGGGGGGTGGGGTACGGGGGTGAGCCCTGGGTCCCCCTCTGGGCAGATCCCGTTA
CACCTCTTGTTGGGGTCCTTGATTGGGCTAC GCTCTGGAACTGTGGATGCAGCTGCATGAGGCTGGAATGGGCCTT
GAGGAGCCCGGGGGTGCCCCTGGCCCCAGTGTACCCCTTCCCCCATCACAG GTGATGGCACCCCCTTCTGTTGTTGG
AATGGGCTTCTGGGGTCTGACTGGTGTTTAGTGTTGCAACTTAGCCTCAGCTGGTGGGATGGTGGTGGTCTTTGGG
GATCCCCTGGCCCCAGGGTCCATCTCCAAGAGCCTGTGTGCCCTGCAG GGTGTGGGGCTGGCCTCGCTCGTGGCACC
TCTGCTGATCTCACAGGCCATGGGACTGGCCCTCTATGTCCTGCCAGTGCTGGGCCAACACGTTGCCACCCAGCACT
TCCCAGTGGCAGAGGCTGAGGCTGTGGTGCTGACACTGCTGGCGATTTATGCAGCTGGCCTGGCCCTGCCCCACAAT
ACCCACCG GTAAGAGGCTGGGCTGGTTGTTGGGGGCAGGGGTAGAGGTCCCCTGGACATGCAGACAGCTTGTGGGT
TGCCTCTGAGTCCTTTGTCTTACAG GGTGGTAAGCACACAGGCCCCAGACAGGGGCTGGATGGCACTGAAGCTGGT
AGCCCTGATCTACCTAGCACTGCAGCTGGGCTGCATCGCCCTCACCAACTTCTCACTGGGCTTCCTGCTGGCCACCA
CCATGGTGCCCACTGCTGCGCTTGCCAAGCCTCATGGGCCCCG GTATGTATGGATCAGCCCCACTTCCCCCAATGCC
TGTGCCCTCATCACAGACCGCACCCTCATTCAGTAGCCCTTTCCCCCAACCTGGTGCCCATGCCCCCACCATGGAGCC
TACCTTGATGTTGCTTCTCCACCCAG GACCCTCTATGCTGCCCTGCTGGTGCTGACCAGCCCGGCAGCCACGCTCCT
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TGGCAGCCTGTTCCTGTGGCGGGAGCTGCAGGAGGCGCCACTGTCACTGGCCGAGGGCTGGCAGCTCTTCCTGGCAG
CGCTAGCCCAGGGTGTGCTGGAGCACCACACCTACGGCGCCCTGCTCTTCCCACTGCTGTCCCTGGGCCTCTACCCCT
GCTGGCTGCTTTTCTGGAATGTGCTCTTCTGGAAG TGA GATCTGCCTGTCCGGGCTGGGACAGAGACTCCCCAAGG
ACCCCATTCTGCCTCCTTCTGGGGAAATAAATGAGTGTCTGTTTCAGCAGCTA
8.2 GPAA1 RNA expression in different tissues
Figure 29: Overview of GPAA1 in the tissue-specific gene expression and regulation (TiGER) data-
base TiGER is a database developed by the Bioinformatics Lab at Wilmer Eye Institute of Johns Hopkins
University. The database contains tissue-specific gene expression profiles or expressed sequence tag (EST)
data, cis-regulatory module (CRM) data, and combinatorial gene regulation data. Legend adapted from
http://bioinfo.wilmer.jhu.edu/tiger/. Last publication for this database is from the year 2008[139].
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Figure 30: Tissue specific RNA expression overview of the Human Protein Atlas Project RNA ex-
pression overview shows RNA-data from three different sources: Human Protein Atlas (HPA) RNA-seq
data (https://www.proteinatlas.org/), RNA-seq data from the Genotype-Tissue Expression project (http:
//www.gtexportal.org/) and data from the Cap Analysis of Gene Expression project FANTOM5 (http:
//fantom.gsc.riken.jp/5/). TPM= transcripts per million, RPKM= reads per kilobase per million mapped
reads. Figure and figure legend adapted from HPA.
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8.3 gRNA Design
Figure 31: Detailed results for gRNA#1, Results derived from the gRNA prediction tool CRISPR Design
(http://crispr.mit.edu/) from the Zhang lab (MIT, USA) for the c-terminal part of GPAA1 exon 12 in its
genomic context. For the full sequence of the genomic context, see appendix 8.1. Overview of the results
are displayed in figure 17.
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Figure 32: Detailed results for gRNA#2, Results derived from the gRNA prediction tool CRISPR Design
(http://crispr.mit.edu/) from the Zhang lab (MIT, USA) for the c-terminal part of GPAA1 exon 12 in its
genomic context. For the full sequence of the genomic context, see appendix 8.1. Overview of the results
are displayed in figure 17.
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Figure 33: Detailed results for gRNA#3, Results derived from the gRNA prediction tool CRISPR Design
(http://crispr.mit.edu/) from the Zhang lab (MIT, USA) for the c-terminal part of GPAA1 exon 12 in its
genomic context. For the full sequence of the genomic context, see appendix 8.1. Overview of the results
are displayed in figure 17.
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8.4 Sequences: Homology Arms
Left Homology Arm: poly(A) for restriction enzyme binding 5’-NdeI/3’-NgoMIV
AAAAAAAACATATGCACGTTGCCACCCAGCACTTCCCAGTGGCAGAGGCTGAGGCTGTGGTGCTGACACTGCTGGC
GATTTATGCAGCTGGCCTGGCCCTGCCCCACAATACCCACCGGTAAGAGGCTGGGCTGGTTGTTGGGGGCAGGGGT
AGAGGTCCCCTGGACATGCAGACAGCTTGTGGGTTGCCTCTGAGTCCTTTGTCTTACAGGGTGGTAAGCACACAGG
CCCCAGACAGGGGCTGGATGGCACTGAAGCTGGTAGCCCTGATCTACCTAGCACTGCAGCTGGGCTGCATCGCCCT
CACCAACTTCTCACTGGGCTTCCTGCTGGCCACCACCATGGTGCCCACTGCTGCGCTTGCCAAGCCTCATGGGCCCC
GGTATGTATGGATCAGCCCCACTTCCCCCAATGCCTGTGCCCTCATCACAGACCGCACCCTCATTCAGTAGCCCTTT
CCCCCAACCTGGTGCCCATGCCCCCACCATGGAGCCTACCTTGATGTTGCTTCTCCACCCAGGACCCTCTATGCTGC
CCTGCTGGTGCTGACCAGCCCGGCAGCCACGCTCCTTGGCAGCCTGTTCCTGTGGCGGGAGCTGCAGGAGGCGCCAC
TGTCACTGGCCGAGGGCTGGCAGCTCTTCCTGGCAGCGCTAGCCCAGGGTGTGCTGGAGCACCACACCTACGGCGCC
CTGCTCTTCCCACTGCTGTCCCTGGGCCTCTACCCCTGCTGGCTGCTTTTCTGGAATGTGCTCTTCTGGAAGGGATC
CGCCGGCAAAAAAAA
Right Homology Arm: poly(A) for restriction enzyme binding 5’-BstBI/3’-EcoRI necessary for in
frame insertion of thr strep tag and second STOP codon
TTCGAAAAGTGATAAGATCTGCCTGTCCGGGCTGGGACAGAGACTCCCCAAGGACCCCATTCTGCCTCCTTCTGGGG
AAATAAATGAGTGTCTGTTTCAGCAGCTATTTGAGCTCCTGGCCCGCTGTCCGTGTAGGGCCCCAGGGCATGGGGG
TGAGAAGCCTCTGTCTGCAGGGCTTGGCATTCCTCACACCTCCTCCCTGGCAAGGGCTGCTGTAGTCCACTTACTGG
GTAGCATTCCTGCCGACCAGGGCTCTGCTGCTGCATCAGGTGCACTCTCAGCCCTGGCGGGTGCCATGCAGGCTCAG
AGGGCTGTGTGCATTGCTCTGTGGTACTGTGCCAGGAGCGGTGCTGGGAAGGAGAATACACCATAGCCATGGTTTG
AGGGCCTGCCAGGAGCTGAGGCACCCAGAAACCACCTAACACCATCTTTACTGCTAGGACTGAGGCTGGAGCTGGA
GCCCTGCAGAGGAGGCCCAGGGTGCATGGCATGGGGCCCAGGCAAGGCCATCGCCTTGGTGTGGGATTGGGATGGA
GCAGGGAGGAGCACCCGGCCTGGCTTCCTCAGAGTTGAGTCAGCCCAGGTGAGATGCCCACGAGGGGCTGGGCAGG
CAACACAGTGGAGCCAGGACCCAGGGGCAGGCGGGGCACGGGGACAAGAGCCCCACGGGAGAGGGCACTGACAGGC
CAGCAAGGAGAGAAGCAGGCTGTTATACTAGGACTCTGAAAGGAACTGGGAAGACCACTGTCTGTTCCAAAAGAA
AGGAAAAACCTGTGGCCTTTAGGGAATTCAAAAAAAA
8.5 Sequences: Transamidase subunits UniProt
Sequences were retrieved July 2018
>sp|Q92643|PIGK_HUMAN GPI-anchor transamidase OS=Homo sapiens GN=PIGK PE=1 SV=2 MAVTDS
LSRAATVLATVLLLSFGSVAASHIEDQAEQFFRSGHTNNWAVLVCTSRFWFNYRHVANTLSVYRSVKRLGIPDSHIV
LMLADDMACNPRNPKPATVFSHKNMELNVYGDDVEVDYRSYEVTVENFLRVLTGRIPPSTPRSKRLLSDDRSNILIY
MTGHGGNGFLKFQDSEEITNIELADAFEQMWQKRRYNELLFIIDTCQGASMYERFYSPNIMALASSQVGEDSLSHQPD
PAIGVHLMDRYTFYVLEFLEEINPASQTNMNDLFQVCPKSLCVSTPGHRTDLFQRDPKNVLITDFFGSVRKVEITTETI
KLQQDSEIMESSYKEDQMDEKLMEPLKYAEQLPVAQIIHQKPKLKDWHPPGGFILGLWALIIMVFFKTYGIKHMKFIF
>sp|Q96S52|PIGS_HUMAN GPI transamidase component PIG-S OS=Homo sapiens GN=PIGS PE=1 SV=3
MAAAGAAATHLEVARGKRAALFFAAVAIVLGLPLWWKTTETYRASLPYSQISGLNALQLRLMVPVTVVFTRESVPL
DDQEKLPFTVVHEREIPLKYKMKIKCRFQKAYRRALDHEEEALSSGSVQEAEAMLDEPQEQAEGSLTVYVISEHSSLLP
QDMMSYIGPKRTAVVRGIMHREAFNIIGRRIVQVAQAMSLTEDVLAAALADHLPEDKWSAEKRRPLKSSLGYEITFSL
LNPDPKSHDVYWDIEGAVRRYVQPFLNALGAAGNFSVDSQILYYAMLGVNPRFDSASSSYYLDMHSLPHVINPVESR
LGSSAASLYPVLNFLLYVPELAHSPLYIQDKDGAPVATNAFHSPRWGGIMVYNVDSKTYNASVLPVRVEVDMVRV
MEVFLAQLRLLFGIAQPQLPPKCLLSGPTSEGLMTWELDRLLWARSVENLATATTTLTSLAQLLGKISNIVIKDDVASE
VYKAVAAVQKSAEELASGHLASAFVASQEAVTSSELAFFDPSLLHLLYFPDDQKFAIYIPLFLPMAVPILLSLVKIFLET
RKSWRKPEKTD
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>sp|Q969N2|PIGT_HUMAN GPI transamidase component PIG-T OS=Homo sapiens GN=PIGT PE=1 SV=1
MAAAMPLALLVLLLLGPGGWCLAEPPRDSLREELVITPLPSGDVAATFQFRTRWDSELQREGVSHYRLFPKALGQLIS
KYSLRELHLSFTQGFWRTRYWGPPFLQAPSGAELWVWFQDTVTDVDKSWKELSNVLSGIFCASLNFIDSTNTVTPTA
SFKPLGLANDTDHYFLRYAVLPREVVCTENLTPWKKLLPCSSKAGLSVLLKADRLFHTSYHSQAVHIRPVCRNARCTS
ISWELRQTLSVVFDAFITGQGKKDWSLFRMFSRTLTEPCPLASESRVYVDITTYNQDNETLEVHPPPTTTYQDVILGT
RKTYAIYDLLDTAMINNSRNLNIQLKWKRPPENEAPPVPFLHAQRYVSGYGLQKGELSTLLYNTHPYRAFPVLLLDTV
PWYLRLYVHTLTITSKGKENKPSYIHYQPAQDRLQPHLLEMLIQLPANSVTKVSIQFERALLKWTEYTPDPNHGFYVS
PSVLSALVPSMVAAKPVDWEESPLFNSLFPVSDGSNYFVRLYTEPLLVNLPTPDFSMPYNVICLTCTVVAVCYGSFY
NLLTRTFHIEEPRTGGLAKRLANLIRRARGVPPL
>sp|Q9H490|PIGU_HUMAN Phosphatidylinositol glycan anchor biosynthesis class U protein
OS=Homo sapiens GN=PIGU PE=1 SV=3 MAAPLVLVLVVAVTVRAALFRSSLAEFISERVEVVSPLSSWKRVVEG
LSLLDLGVSPYSGAVFHETPLIIYLFHFLIDYAELVFMITDALTAIALYFAIQDFNKVVFKKQKLLLELDQYAPDVAELIR
TPMEMRYIPLKVALFYLLNPYTILSCVAKSTCAINNTLIAFFILTTIKGSAFLSAIFLALATYQSLYPLTLFVPGLLYLLQR
QYIPVKMKSKAFWIFSWEYAMMYVGSLVVIICLSFFLLSSWDFIPAVYGFILSVPDLTPNIGLFWYFFAEMFEHFSLFF
VCVFQINVFFYTIPLAIKLKEHPIFFMFIQIAVIAIFKSYPTVGDVALYMAFFPVWNHLYRFLRNIFVLTCIIIVCSLLFPV
LWHLWIYAGSANSNFFYAITLTFNVGQILLISDYFYAFLRREYYLTHGLYLTAKDGTEAMLVLK
>sp|O43292|GPAA1_HUMAN Glycosylphosphatidylinositol anchor attachment 1 protein OS=Homo
sapiens GN=GPAA1 PE=1 SV=3MGLLSDPVRRRALARLVLRLNAPLCVLSYVAGIAWFLALVFPPLTQRTYMSENA
MGSTMVEEQFAGGDRARAFARDFAAHRKKSGALPVAWLERTMRSVGLEVYTQSFSRKLPFPDETHERYMVSGTNV
YGILRAPRAASTESLVLTVPCGSDSTNSQAVGLLLALAAHFRGQIYWAKDIVFLVTEHDLLGTEAWLEAYHDVNVTG
MQSSPLQGRAGAIQAAVALELSSDVVTSLDVAVEGLNGQLPNLDLLNLFQTFCQKGGLLCTLQGKLQPEDWTSLDGPL
QGLQTLLLMVLRQASGRPHGSHGLFLRYRVEALTLRGINSFRQYKYDLVAVGKALEGMFRKLNHLLERLHQSFFLYLL
PGLSRFVSIGLYMPAVGFLLLVLGLKALELWMQLHEAGMGLEEPGGAPGPSVPLPPSQGVGLASLVAPLLISQAMGLA
LYVLPVLGQHVATQHFPVAEAEAVVLTLLAIYAAGLALPHNTHRVVSTQAPDRGWMALKLVALIYLALQLGCIALTN
FSLGFLLATTMVPTAALAKPHGPRTLYAALLVLTSPAATLLGSLFLWRELQEAPLSLAEGWQLFLAALAQGVLEHHTY
GALLFPLLSLGLYPCWLLFWNVLFWK
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9 Abbrevations
BZH Heidelberg University Biochemistry Center
Cas9 CRISPR associated protein 9
Chol cholesterol
COPI coatomer protein I
COPII coatomer protein II
CRISPR clustered regularly interspaced short palindromic repeats
CuAAC copper-catalysed azide-alkyne cycloaddition
CNBr cyanogen bromide
DNA deoxyribonucleic acid
ER endoplasmic reticulum
ERES ER-exit sites
EtNP ethanolaminephosphate
ERAD ER-associated degradation
FBS fetal bovine serum
GlcN glucosamine
GPAA1 GPI attachment 1 protein
GPI glycosylphosphatidylinositol
GPI-AP GPI-anchored protein
GPL glycerophospholipid
GRAVY grand average hydropathy
GM3 monosialodihexosylganglioside
IP immunoprecipitation
LB medium Luria-Bertani medium
m/z mass-to-charge ratio
Man mannose
MPD mannose-P-dolichol
MSP membrane scaffold protein
NCBI national center for biotechnology information
HDR homology directed repair
NHEJ non-homologous end joining
NHS N-hydroxysuccinimide
pac photoactivatable and clickable
PA Phosphatidic acid
PBS phosphate-buffered saline
PC phosphatidylcholine
PE phosphatidylethanolamine
PGAP GPI inositol-deacylase
PS phosphatidylserine
PI Phosphatidylinositol
PIG PI-glycan biosynthesis class protein
RG research group
(g)RNA (genomic) ribonucleic acid
RT room temperature
S1PL sphingosine-1-phosphate lyase
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
SMA styrene-maleic acid
SMALP SMA lipid particles
SP sphingolipids
Sph sphingosine
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ST sterols
TMD transmembrane domain
UTR untranslated region
UV ultraviolet
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